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ABSTRACT 
Osteoporosis (OP) is a chronic, progressive disease of the skeleton 
characterized by bone fragility due to a reduction in hone mass and possible 
alterations in bone architecture which lead to a propensity for fractures with minimum 
trauma. Bone formation is related to osteoblastic proliferation, alkaline phosphatase 
(ALP) activity, and osteocalcin and collage synthesis. Bone resorption is associated 
with osteoclast formation and differentiation, and tartrate-resistant acid phosphatase 
activity (TRAP). It's a well established fact that osteoporosis and associated fractures 
constitute a major public health issue together representing an important cause of 
mortality and morbidity with annual incidence of fracture rates exceeding the 
combined incidence of breast cancer, stroke and heart attacks in postmenopausal 
women (PMW). Emergence of osteoporosis as a global bone health concern is 
reflected in the occurrence of 1.6 million hip fractures annually worldwide and the 
number projected to go up four times by 2050-2055. Osteoporosis affects both men 
and women; however the later are more susceptible targets of this crippling disorder 
of bone. 
Oxidative stress is caused by an imbalance between the generation of reactive 
oxygen species (ROS) and the activity of antioxidant defense. Severe oxidative stress 
has been implicated in many chronic and degenerative diseases, including 
osteoporosis, cancer, ageing, and neurodegenerative diseases such as Alzheimer's 
disease. Parkinson's disease and amyotrophic lateral sclerosis. Several medications 
such as calcitonin (CT), calcium products, estrogen, bisphosphonates, ipriflavone and 
anabolic steroids have been reported to be effective for curing osteoporosis. However, 
these medications may have serious side effects, may not improve bone quality, or 
may not reduce susceptibility to fracture. Recently. oriental traditional medicines have 
been re-evaluated by clinicians because these medicines have fewer side effects and 
are more suitable for long-term use compared with chemically synthesized medicines. 
Some natural flavonoids with potent antioxidant activity including scopoletin, 
resveratrol, and baicalein have found to exert anti-osteoporotic activities through 
suppressing osteoclast formation and TRAP. Accordingly, natural antioxidants have 
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become a topic of increasing interest as they could provide a safe, economical and 
valuable tool in combating such diseases. 
It has been well recognized that infection and inflammation as well as 
autoimmune diseases are associated with systemic and local bone loss. Recent studies 
show that that T lymphocytes and their product have also been recognized as key 
regulators of bone cell formation, lifespan and activity. Numerous proinflammatory 
cytokines are reported to be activated in osteoporosis. However, the autocrine 
cytokine namely TNF-a is probably the most dominant cytokine, which promotes 
osteoclastogenesis by augmenting the production of RANKL, the non-redundant 
cytokine responsible for osteoclast development. Such a capability of TNF-a is solely 
due to synergistic interactions at the level of NF-KB and activator protein-1 (AP-1) 
signaling. In addition to the above, TNF stimulates osteoclast (OC) activity and 
inhibits osteoblastogenesis thus further driving an imbalance between bone formation 
and bone resorption. 	With ever increasing number of elderly people in the 
population, improved survival and an increase in the age-specific fracture rates, there 
is an immediate need to develop new cost-effective therapeutic strategies against 
osteoporosis. Thus, in the present study, resveratrol, curcumin as well as allicin from 
garlic were employed as valuable natural antioxidants / natural tools in order to 
investigate the above. 
Allicin from garlic is the major biologically active thiosulfinate compound of 
freshly crushed garlic. It has been reported to possess potent antibacterial properties 
besides showing broad range antimicrobial and antifungal activities. Besides, allicin 
has radical scavenging properties in activated granulocytes and may also inhibit iNOS 
expression in activated macrophages. 
In view of reactive oxygen species (ROS) and reactive nitrogen species (RN!) 
playing an important role in both estrogens related and unrelated osteoporosis, thus, 
greater emphasis now being laid on development of compounds from natural sources 
having antioxidant and anti-inflammatory properties in combating osteoporosis. 
Earlier work in our laboratory has proved the antioxidant and anti-inflammatory 
effects of allicin from garlic in other diseases. Allicin, resveratrol and curcumin are 
one of the most versatile medicinal compounds natural antioxidants having a wide 
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spectrum of biological activity, where allicin have been reported to have multiple 
properties some of which include anti-inflammatory. hnmunostimulatory, anti-
malarial, anti-mycohacterial, antipyretic. anti-carcinogenic, anti-oxidant and analgesic 
activities. In view of the above, thus, we studied the incorporation of such natural 
antioxidants r compounds in the management for bone loss. 
In the first phase of the present study, an attempt was made to carry out a 
detailed characterization of sera and monocytes of osteoporosis patients in order to 
assess the activity of predominant antioxidant enzyme, GPx as well as to measure the 
intramonocyte (GSH) levels. Glutathione (GSH) directly reacts with ROS, and 
glutathione peroxidase (GPx) catalyses the removal of hydrogen peroxide. Our 
ELISA results exhibited nearly less than half the activity of enzyme both in sera and 
monocytes of osteoporosis patients as compared to healthy individuals. Decrease in 
GPx activity indicates impairment of hydrogen peroxide-neutralizing mechanism. 
Similarly. suppression in intramonocyte GSH levels was also observed in these 
patients, which in turn, were indicative of weak antioxidant power. Furthermore, 
elevated free radicals in osteoporosis patients were also substantiated by MDA 
determination. 
Thereafter, further study showed that the levels of by-product of lipid 
peroxidation namely malondialdehyde (NIDA), to be appreciably high both in sera 
and monocyte cultures of osteoporosis patients, thereby, further pointing to the 
augmented / increased oxidant stress in such patients. Subsequent increase in 
hydrogen peroxide levels due to depressed GSH levels and GPx activity in 
osteoporosis patients might have induced the peroxidation of polyunsaturated fatty 
acids, thereby leading to the formation of high MDA levels. Moreover, due to high 
reactivity of MDA towards amino groups may also lead to deactivation of enzymes. 
Allicin, resveratrol and curcumin dose-dependently down-regulated the excess levels 
of MDA in monocyte cultures of osteoporosis patients. 
A wide spectrum of studies show established evidences which suggest that 
estrogen prevents bone loss by blocking the production of proinflammatory cytokines 
by bone marrow stromal and bone cells. The most prominent cytokines that are 
regulateJ by estrogen are IL-l. IL-6 and TNF a. In the present study also, probe by 
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ELISA exhibited an appreciable secretion of TNF-a and IL-l13 in the s-ra and 
monocytes of osteoporosis patients. Infect. IL-I is a potent stimulator of bone 
resorption together with TNF, and both are well-recognized inhibitors of bone 
formation. IL-1 and TNF are also powerful inducers of other cytokines such as IL-6, 
M-CSF and GM-CSF, which potentiate the effect of IL-I on osteoclastogenesis. 
Thereafter, monocytes from osteoporosis patients were also characterized with 
respect to TNF-a and osteoprotegerin (OPG). wherein monocytes from these patients 
evaluated by real-time RT-PCR revealed appreciably high basal levels of both TNF-a 
and OPG mRNA expressions in comparison to healthy controls. 
The role of OPG in the pathogenesis of osteoporosis has not been clear since 
OPG levels are not consistently altered. In humans, OPG levels increasing with age 
are understood as a homeostatic response to limit the bone loss that occurs with an 
increase in other bone resorting factors. Thus, in the present study, we attempted to 
probe the expression level of OPG and RANKL together with TNF a and the 
regulation of RANKL by natural antioxidants like allicin. resveratrol and curcumin in 
osteoporosis. 
In order to probe the above, in the present study, a real-time RT-PCR was 
carried out, where the data exhibited that all the three natural antioxidants namely 
allicin, resveratrol and curcumin down-regulated the expression of TNF-u mRNA in 
PBMC's of osteoporosis patients in a dose-dependent manner. Concentrations of 250 
and 500 ngs/ml of allicin and that of 25 tg/ml of resveratrol and curcumin 
respectively were found to suppress the appreciably high basal levels of TNF 
mRNA's by an appreciable degree. It is to be pointed out that previous reports 
indicated higher doses of allicin were toxic to human cells. However, our laboratory 
has shown lower doses of allicin (0-500 ng/ml) to be non-toxic and proved to be 
potent anti-inflammatory agent in other disease conditions such as tuberculosis. From 
our data, it is evident that whereas low concentrations of allicin, resveratrol and 
curcumin used in this study appreciably down-regulate the mRNA expression of TNF 
a, at the same time show no significant effect on the expression of human 
housekeeping gene R 18. Thus, low dose of allicin, resveratrol and curcumin used in 
the study was non-toxic. 
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Osteoprotegerin (OPG) is produced in many tissues, but bone derived OPG 
may be released into circulation, thereby reflecting the situation locally in bone. Our 
data exhibiting appreciably augmented OPG mRNA expression in the osteoporosis 
patient PBMMC's therefore may indicate a compensatory response to increased 
osteoclastic bone resorption and the resultant bone loss caused by estrogen deficiency; 
this considering the fact that OPG has bone sparing activity. In the present study. the 
expression of OPG mRNA correlated positively with that of TNF u mRNA 
expression. Thus. OPG. a soluble member of TN FR super family of proteins plays an 
important role in the negative regulation of osteoclastic bone resorption. 
In case of osteoporosis patients, sRANKL secretion dose-dependently 
decreased from 33.16 pg ml at through 27.54. 20.33, 12.98 and 3.02 pg!ml with 50. 
100, 250 and 500 ng allicin respectively. On the contrary, healthy controls exhibited 
in between 1.33 - 3.12 pg'ml of RANKL. Next, after dose response evaluation, an 
attempt was also made to re-check the data by co-culturing with the maximum dose of 
allicin (500 ng/ml) selected in the study. and that, similar results were observed to the 
one's observed above in dose response experiments at the maximum dose. 
Computation of the data exhibited that allicin suppressed the secretion of sRANKL by 
around 16.94%, 38.69%. 60.85% and 90.89% with 50, 100, 250 and 500 ng allicin 
respectively. The IC ) was computed out to be in between 100 -135 ng ml. 
Thereafter, monocytes of study groups were co-cultured separately with 
varying concentrations of resveratrol and curcumin (0, 2, 5, 10, 15 20 and 25 µg/ml). 
In case of osteoporosis patients, sRANKL secretion was found to dose-dependently 
decrease from 35.16 pg ml at through 29.11, 24.26, 15.16, 11.33, 9.16 and 8.89 pg~ml 
with 0, 2, 5. 10, 15 20 and 25 pg resveratrol respectively. On the contrary. healthy 
controls exhibited in between 1.3 - 3.2 pg ml of RANKL. 
Next, the effect of varying doses of curcumin on RANKL in 5 days monocyte 
cultures was also analyzed. Co-culturing of patient monocytes with curcumin 
exhibited a dose-dependent down-regulation of sRANKL., which was of the order of 
32.65, 27.81, 22.45, 17.29, 13.07, 9.44 and 9.23 pg/ml with 0, 2. 5, 10, 15, 20 and 25 
pg/ml of curcumin respectively. ICS„ was computed out to be - 9 tg ml. Next, 
computational analysis of the data revealed that curcumin down regulated the 
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secretion ot'sRANKL by around 15%, 31%, 46%, 60%, 70% and 73% with 2, 5. 10, 
15 20 and 25 µg curcurnin respectively. 
Bone marker study involving TRAP assay data revealed that healthy control 
monoeyte cultures did not show any multinucleated cells/osteoclasts, whereas those 
from osteoporosis patient exhibited appreciable number of multinucleated 
cells//osteoclasts. However, there was no/negligible appearance of osteoclast 
precursors after 24 hr (I day) of culture. The number of multinucleated preosteoclasts, 
arising from PBMCs isolated from the blood of normal healthy individual (data not 
shown) and osteoporotic patients were counted by TRAP staining. Interestingly, we 
observed an individual variation in osteoclast generation from different donors as 
depicted by different number of multinucleated cells. Interestingly, we observed that 
co-culturing of PBMCs from osteoporosis patients with allicin, resveratrol and 
curcumin in osteoclastogenic medium for 3 days resulted in an appreciable amount of 
reduction in appearance of multinucleated osteoclast precursors. Hence. this reflects 
the potential of allicin, resveratrol and curcumin to exert regulatory effect in 
osteoclast generation and differentiation. The above doses of allicin, resveratrol and 
curcumin were selected after performing dose response experiment, where TRAP 
assay revealed a linear suppression in the formation of multinucleated cells was 
observed. The data in the present study shows nearly 20-30% suppression in 
appearance of multinucleated cells in cultures separately resveratrol (25 tg/ml)  or 
curcumin (25 pg/ml) respectively receiving relative to control devoid of any 
supplement. Interestingly, around 35-40 Vu suppression in appearance of 
multinucleated cells was observed in cultures receiving 500 ng/ml of allicin relative to 
control cultures devoid of any allicin.  
Next, the presence of human osteopontin (OPN) was probed both in sera of 
healthy controls and osteoporosis patients, where healthy controls showed negligible 
levels of OPN (range: 2.07 ng/ml to 324 nghnl), while sera of osteoporosis patients 
exhibited appreciable levels of OPN, which was in the range of 15.98 nghnl to 28.35 
ng/ml. Thus, in comparison to healthy controls, around an 8-fold OPN levels were 
recorded in osteoporosis patients. Also, in the present study also shows no or 
negligible levels of OPN in 24 hours culture supernatants of monocytes obtained from 
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healthy controls. Around 12 fold levels of OPN was detected in osteoporotic patients 
in comparison to healthy controls. 
Modulation study on monocytes from osteoporosis patients that were cultured 
for 3 days in osteoclastogenic medium with and without I ng/ml of calcitonin (CT), 
exhibited that those culture wells receiving CT exhibited an augmentation/increase by 
around I.4-folds in OPN levels thereby substantiating that CT was a positive 
modulator of OPN. Next, upon comparison of the data, it was observed that allicin 
proved to be the most potent suppressor of OPN followed by resveratrol, and in turn, 
followed by curcumin. Thereafter, the effect of known negative modulator, namely 
Denosumab (Prolia) of OPN and osteoclasts was probed. The data in the present study 
show that monocyte cultures of osteoporosis patients receiving denosumab (Prolia) 
for 3 days in osteoclastogenic medium exhibited remarkably suppressed / down-
regulated levels of OPN in comparison to cultures devoid of any supplements. 
Furthermore, on comparative analysis, it was observed that the degree of suppression/ 
down-regulation of OPN was nearly similav same with natural antioxidant allicin and 
monoclonal antibody namely denosumab (Prolia). 
Thereafter, the cytokine IL-1(i secretions as well as generation of ROS, as 
reflected by suppressed GPx activity and GSH levels in osteoporosis patients, were 
mediated through activation of NFKB. This fact was evidenced by their suppression in 
monncyte cultures in the presence of SN50, an inhibitor of NFKB while SN50/M, an 
inactive analogue of SNSO, failed to show any such effect. Apart from the above, 
NAC, a precursor of in vivo antioxidant glutathione, exhibited down-regulation / 
suppression of IL-1 secretion and exhibited enhancement 	amelioration of 
intramonocyte GSH levels. Interestingly, allicin and resveratrol showed a higher 
degree of inhibition of cytokine secretion and enhanced antioxidant effect in 
comparison to NAC, thereby, proving them as effective natural antagonists of 
pathogenesis / management of osteoporosis- 
Since higher doses of both allicin have previously proven to be toxic by 
various investigators, our present study employed lower concentrations (0-500 ng/ml) 
of allicin as well as that of resveratrol and curcumin (0-20jig/rill), both of which in 
their respective range of doses, failed to show any toxic effect on human monocyles 
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as revealed by MIT assay. Also no effect was observed on human housekeeping gene 
RIS as revealed by real-time RT-PCR, thereby indicating that allicin, resveratrol and 
curcumin did not non-specifically affect TNF a transcription in patient monocytes nor 
cause cellular death. 
Furthermore, the present study also revealed all the three natural antioxidants 
namely, allicin, resveratrol and curcumin augmented i up-regulated / ameliorated the 
activity of GPx in the monocyte cultures of osteoporosis patients in a dose-dependent 
manner. Our data indicate an appreciable degree of amelioration in GPx activity at 
500 ng/ml allicin and at 20 %g/ml resveratrol and eurcumin. It's an established fact 
that significant amelioration of GPx activity in osteoporosis patient monocyte cultures 
indicates reversal of impaired neutralizing mechanisms. Furthermore, allicin, 
resveratrol and curcumin were also found to appreciably augment / up-regulate the 
intramonocyte GSH levels in patients with osteoporosis in a dose-dependent manner. 
Interestingly, in comparison to NAC and SN50. allicin and resveratrol, both exerted 
more efficient restoration of decreased antioxidant power whereas curcumin exerting 
somewhat equal restoration of decreased antioxidant power as said above, thereby 
indicating that these compounds I natural antioxidants to be effective herbal 
antioxidants combating ROS, generated as a consequence of excess cellular activation 
in monocytes of osteoporosis patients. 
Next, it's well established that the Intraccl!ular signaling pathways, especially 
NFicB. are known to be ROS sensitive. Our results indicate that the increased 
secretion of TNF-a, sRANKL and IL-1(i at protein levels as well as TNF-a and OPG 
at the gene i. e. mRNA levels, and excess ROS generation as mirrored by decreased 
GPx activity and OSH levels, are interconnected and involve cellular activation of 
NFxB. This fact is evidenced by the suppression of TNF-a and IL-I (f expressions at 
the gene and protein levels and augmentation / up-regulation of GSH levels in the 
presence of SN50, an inhibitor of NFKB. SN50/M, an inactive analogue of SN50. did 
not show any such effect. In light of the above, our study demonstrates that this effect 
involved inhibition of NFKB pathway induced by allicin, resveratrol and eureumin, 
probably by inhibiting the degradation of IKBa. As a matter of fact, since numerous 
genes involved in inflammatory responses are regulated by NFKB pathway, thus a 
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high magnitude suppression / down-regulation of this pathway by allicin, resveratrol 
and curcumin would predictably minimize % reduce the elaboration of NFKB-mediated 
OPN, TNF-a. sRANKL, and IL-1(3 expressions and generation of ROS. 
In conclusion, the presence of high levels of proinflammatory cytokines such 
as lL-1p, TNF a, sRANKL and a related TNFR super family member OPO as well as 
OPN together with antioxidant deficiency in terns of both low GPx activity and GSH 
levels and a simultaneous increase in MDA levels add to the severity of estrogen 
deficiency bone loss. Our study shows appreciable reversal of impaired neutralizing 
mechanisms by resveratrol, allicin and curcumin which correlates inversely with the 
down-regulation of OPN, TNF a, sRANKL and IL-Ill expressions in monocytes of 
osteoporotic patients. Thus, allicin, followed by resveratrol followed by curcumin. 
probably may prove to be valuable natural antioxidant and anti-inflammatory agents 
in the management of osteoporosis and, therefore, be useful adjuncts in the treatment 
of bone loss. 
Therefore, 	these 	observations strengthen 	the 	idea 	that 	these natural 
antioxidants namely allicin, resveratrol and curcumin can be subjected to in-depth 
investigation 	in 	in 	,'ho 	models to evaluate their therapeutic 	potential in 	the 
pathogenesis / management of osteoporosis. 
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INTRODUCTION 
1.1 Bone: An Architectural Masterpiece 
Bone is a vital, dynamic and complex connective tissue that provides form/shape to 
the body, supporting its weight. Bone has multiple functions in vertebrates, including 
protection of vital organs and the environment and niches required for 
haematopoiesis. mechanical and structural support for muscles and joints, and a 
mineral reservoir that is essential for calcium homeostasis, and of growth factors 
stored in the matrix [Lacey etal.. 2012; Rouhi. 2012; Boyce and Xing, 2008; Morgan 
etal., 2008]. 
1.1.1 Bone Structure 
Bone is not a uniformly solid material, but rather has some spaces between its hard 
elements. 
(a) Compact (Cortical) bone 
(h) Trabecular (Cancellous or Sp ngy) hone 
Compact Boot & Spoagy (Cancellous Bout) 
Lacunae containing c' teoC'tes 	 Cisteon of compact bone 
Lamellae Trabeculae of sporgy 
Canaliculi 	 .y 	 bone 
Csteon 
PenosteL 
Haversian 
Volkmann's canal 
Figure 1: Compact Bone and Spongy Bone, Source: U.S. National Cancer 
Institute's surveillance, Epidemiology and End Results (SEER) 
(http://training.seer.cancer. gov/index.html). 
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1.1.1.1 Compact (Cortical) Bone 
Cortical bone makes up the hard, dense outer shell of the skeleton [Riggs er al., 2002]. 
Cortical hone constitutes approximately 80% of the skeletal mass. It has minimal gaps 
and spaces. Its porosity is 5-30% [Hall, 2007]. 
1.1.1.2 Trabecular (Cancellous or Spongy) Bone 
Trabecular bone fills the ends of the limb bones and the vertebral bodies in the spine, 
the sites of most osteoporotic fractures [Riggs et al., 20021. Trabccular bone 
constitutes approximately 20% of the skeletal mass. Filling the interior of the bone is 
the trabecular bone tissue which is composed of a network of rod- and plate-like 
elements that make the overall organ lighter mid allow room for blood vessels and 
marrow. It has nearly ten times the surface area of compact bone. Its porosity is 30-
90% [Hall, 2007]. 
1.1.2 Bone Major Functions 
Bone has two major functions: 
(a) Provision of mechanical integrity for locomotion and protection, and 
(b) Involvement in the metabolic pathways associated with mineral homeostasis. 
The structure and composition of this tissue reflect a balance between these two major 
functions. Besides this, bone is also the primary site of hematopoicsis. There is a 
complex interplay between the bone organ system and the immune system [Bab and 
Einhom, 1994; Horowitz and Jilka, 1992: Vein et al., 2005; Boyce and Xing, 2007; 
Morgan et al., 2008]. 
1.1.3 The Structure-Function Relationship 
Galileo, in 1638, proposed an early hypothesis about the dependence of the structure 
and form of bone,, and the mechanical loads they carry [Ascenzi, 1993; Rouhi, 2012]. 
Wolff in 1892 described this concept in a semi quantitative manner [Wolff. 1986; 
Rouhi, 2012]. The structure-function relationships observed in hone under normal 
physiological conditions, coupled with its role in maintaining mineral homeostasis, 
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strongly suggest that it is an organ of optimum structural design [Rouhi. 2012]. In 
maintaining the structure—function relationship, bone tissue is constantly being broken 
down and rebuilt in a process called remodeling [Rucei, 2008]. Bone has the potential 
to adapt its architecture, shape, and mechanical properties via a continuous process 
termed adaptation in response to altered loading conditions [Burr et al., 2002; 
Forwood and Turner, 1995; Hsieh and Turner. 20011. The regulation of bone mass in 
mammals is governed by a complex interplay between bone-forming cells termed 
osteoblasts (OBs) and bone-resorbing cells termed osteoclasts (OCs), and is guided 
physiologically by a diverse set of hormones. cytokines and growth factors. The 
balance between these processes changes over time, causing an elevated risk of 
fractures with age [Lacey ei al., 2012J. With age, remodeling tends to result in a 
negative bone balance due to decrease in the number of osteoblasts, in that at each 
remodeling site slightly less bone is deposited than is resorbed. This negative balance 
leads to osteopenia and osteoporosis (OP), thus predisposing the bone to fracture 
during even minimal trauma [D'ippolito et al., 1999: Morgan et al., 20081. 
1.2 Bone Composition 
Bone is a composite material consisting of two phases: 
(a) Inorganic phase. 
(b) Organic phase. 
By weight, approximately 60-70% of the tissue is inorganic matter, 8 -10% is water, 
and the remainder is organic matter [Gong et al.. 19641. By volume, these proportions 
are approximately 40%, 25%, and 35%, respectively [Morgan et al., 2008J. 
Inorganic (mineral): 
hydrQxyapatMe 
Watar  
Collagen (type 1) 
85% 
8516 
Noncollagenous 
proteins 	 Extracellular 	Cellular protein 
Figure 11: Bone Composition, Source: Atlas of Postmenopausal Osteoporosis, 
Third Edition. 
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Table 1: Bone Composition 
Components 	 By Weight (%) 	By Volume (%) 
Inorganic Matter 	 60-70% 	 40% 
Water 	 i 8-10% 	 25% 
Organic Matter 	 ~ 22-32% 	 1 35% 
1.2.1 Organic Phase 
The organic phase is composed of three components [Clarke, 2008]. 
(a) Type I collagen, 
(b) A variety of non-collagenous proteins (NCPs), 
(c) Cells. 
Type I collagen and variety of noncollagenous proteins constitute 98% by weight, of 
organic phase and cells make up the remaining 2% of this phase [Einhom, 1994; 
Morgan etal., 2008]. 
1.2.1.1 Role of the Organic Phase 
The organic phase of bone plays a wide variety of roles: 
(a) It influences the structure of the bone. 
(b) It also influences the mechanical and biochemical properties of the tissue also. 
(c) Growth factors, cytokines and extra cellular matrix (ECM) proteins such as 
osteonectin, osteopontin, bone sialoprotein. ostecealcin, prcteoglycans, and 
other phosphoprotcins and proteolipids, make major contributions to biologic 
function of bone [Morgan et al., 2008]. 
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1.2.1.2 Type I Collagen 
Properties 
(a) It is a ubiquitous protein of extremely low solubility. 
(b) The major structural component of the hone matrix. 
(c) Its molecule consists of three polypeptide chains composed of approximately 
1000 amino acids each. 
(d) These chains take the form of a triple helix of two identical 1(I) chains and 
one unique 2(1) chain cross-linked by hydrogen bonding between 
hydroxyprolinc and other charged residues. 
(e) This produces a very rigid linear molecule that is approximately 300 nm in 
length. 
(t) 	Each molecule is aligned with the next in a parallel fashion and in a quarter- 
staggered array to produce a collagen fibril. 
(g) The collagen fibrils are then grouped in bundles to form the collagen fiber. 
(h) Within the collagen fihril, gaps known as "hole zones" are present between the 
ends of the molecules. 
(i) Pores exist between the sides of parallel molecules. 
(j) Noncollagenous proteins or mineral deposits can be found within these spaces, 
and mineralization of the matrix is thought to be initiated in the hole zones 
[Morgan etal., 2008]. 
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(a) 	 (b) 
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Figure III (a) The scanning electron image shows bone collagen fibrils in both 
longitudinal and cross sections. (b) A back-scattered electron image of the 
regular patterns of collagen in layers in normal, or lamellar, bone. Source: Atlas 
of Postmenopausal Osteoporosis, Third Edition. 
1.2.1.3 Non-Collagenous Proteins (NCPs) of the Extracellular Matrix 
There are three types of NCPs of ECM found: 
(a) Structural matrix proteins 
(b) Enzymatic Matrix Modifiers 
(c) Bone Morphogens 
1.2.1.3.1 Structural Matrix Proteins 
There are six Structural Matrix Proteins found in the organic phase of bone. 
(a) Osteocalcin (OCN) 
(b) Osteopontin (OPN) 
(c) Bone Sialoprotein (BSP) 
(d) Decorin 
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(eJ 	Bielycan 
(f) 	Osteonectin (ON) 
1.2.1.3.1.1 Osteocalcin (OCN) 
Properties 
(a) It is one of the most abundant noncollagenous proteins in bone [Morgan et al., 
2008]. 
(b) It has been recognised as a bone-derived hormone to regulate energy 
metabolism [Femdndez-Real and Rican, 20!!; Li etal., 2011; Zivna er al., 
2013]. 
(c) It is produced by active ostcoblasts [Duncan et al., 1998], and restricted to the 
osteoblast lineage only. 
(d) It is also called bone-carboxyglutamic acid-containing protein (bone Gla 
protein) [Morgan et al., 2008]. 
(e) It is a small protein (molecular weight is approximately 5.8 kDa) having three 
glutamic acid residues carboxylated as a result of a vitamin K dependent, post-
translational modification. 
(f) The carboxylation of these residues confers on this protein calcium and 
mineral binding properties. 
(g) It accounts for 10-20% of the noncollagenous protein content [Morgan et al., 
2008]. 
(h) It is closely associated with the mineral phase. 
(i) This bone-specific protein may regulate activities of osteoclasts and osteoclast 
precursors. 
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(j) 	Through characterization of the phenotype of osteocalcin-deficient mice, it 
was also found that osteocalcin has an important role in inhibiting bone 
formation and in mineral maturation [Boskey et al., 1998]. 
1.2.1.3.1.2 Osteopontin (OPN) 
Properties 
(a) Osteopontin is expressed by a variety of cells [Li et al., 2011]. 
(b) It is a member of the small integrin-binding ligand Winked glycoprotein 
family. 
(c) It is highly expressed in bone and inflammatory tissue. 
(d) It contains an arginine-glyeine-aspartie acid (RGD) sequence. 
(e) These amino acid sequences are the characteristic of cell-binding proteins. 
(1) 	These are recognized by a family of cell membrane proteins known as 
integrins. 
(g) The integrins span the cell membrane and provide a link between the 
extracellular matrix and the cyttoskeleton of the cell. 
(h) Integrins on osteoblasts, osteoclasts, and fibroblasts provide a means for 
anchoring these cells to the extraceltular matrix. 
(i) Once anchored, the cells are then enabled to express their phenotype and 
conduct the types of activities that characterize their functions [Ruoslahti, 
19911. 
(j) Thus, it supports osteoblast attachment to bone. 
(k) It binds and activates matrix metalloproteinase-3 (MMP-3) [Morgan et al., 
2009]. 
1.2.1.3.1.3 Bone Sialoprotein (BSP) 
Properties 
(a) BSP is a marker of terminally differentiated osteoblasts [Li e! al., 2011]. 
(b) BSP is selectively expressed in mineralizing tissues and, especially, at sites of 
de novo bone formation [Chen et al., 1994; Li et al., 2011]. 
(c) It is a member of the sihling family. 
(d) It may initiate mineralization. 
8 
Introduction 
(e) It supports cell attachment. 
(f) It binds Ca 2 with a high affinity. 
(g) It binds and activates matrix metalloproteinasc-2 (MMP-2) [Morgan et al., 
2008]. 
1.2.1.3.1.4 Decorin 
Properties 
(a) Decorin is also known as chondroitin sulphate proteoglycan I. 
(b) It regulates collagen tibrillogenesis and transforming growth factor (f t 
(TGF(3]) activity. 
(c) It binds to fibrinogen [Morgan et at, 2008]. 
1.2.1.3.1.5 Biglycan 
Properties 
(a) Biglycan is also known as ehondroitin sulphate protcoglycan II. 
(b) It is involved in the regulation of fibrillogenesis. 
(c) It modulates bone morphogenic protein-2 (BMP-2) induced osteogenesis 
[Morgan et al., 2008]. 
1.2.1.3.1.6 Osteonectin (ONV) 
Properties 
(a) Osteonectin is expressed in a variety of connective tissues. 
(b) It has strong affinity for Ca*2. 
(c) It may play a role in matrix mineralization [Morgan et al., 2008]. 
1.2.1.3.2 Enzymatic Matrix Modifiers 
There are four Enzymatic Matrix Modifiers 
(a) Matrix metalloprotcinases (MMPs) 
(b) Tissue inhibitors of MMPs (TIMPs) 
(c) Lysyl Oxidasc 
(d) Stromelysin 
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1.2.1.3.2.1 MatrLv nretalloproteinases (MMPs) 
Properties 
(a) These include collagenases (MMP-1 and -13) and gelatinases (MMP-2 and - 
9). 
(b) MMPs are required for collagen degradation. 
(c) Most of them are expressed in mature chondrocytes and osteoblasts [Morgan 
et al., 2008]. 
1.2.1.3.2.2 Tissue inhibitors of MMPs (TIMP3) 
These are the inhibitors of MMP activity Morgan et al., 2008]. 
1.2.1.3.2.3 Lysyl Oxidase 
Lysyl Oxidase is a copper-dependent extracellular enzyme that catalyzes oxidative 
deamination of c1 tin and collagen precursors leading to the formation of a mature 
ECM [Morgan el al., 2008]. 
1.2.1.3.2.4 Stromelysin 
Properties 
(a) Stromelysin is a member of the MMP family (MMP-3). 
(b) It degrades most components of the ECM. 
(c) It activates other MMPs [Morgan etal., 20083. 
1.2.1.3.3 Bone Morplmgens 
There are three types of Bone Morphogens. 
(a) TGF(i Super Family 
(b) Fibroblast growth factors (FGFs) 
(c) Platelet-derived growth factors (PDGFs) 
1.2.1.3.3.1 Transforminggron,th factor/! (TGF#) super family of morphogens 
Properties 
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(a) These include TGF[31-3, the bone morphogenic proteins (BMPs) and the 
growth and differentiation factors (GDFs). 
(b) This family of morphogens regulates most steps in chondrogenic, osteogenic, 
and osteoclastogenic cellular differentiation [Morgan et al., 2008]. 
1.2.1.3.3.2 Fibroblast growth factors (FGFsf 
Properties 
(a) FGFs I and 2 have angiogenic properties. 
(b) FGFs promote cellular proliferation [Morgan et al, 2008]. 
1.2.1.3.3.3 Platelet-derived grorvtiz factors (PDGFs) 
Properties 
(a) These exist in three forms (AA, AB and BB). 
(b) PDGFs are associated with mesenchytnal cell chemotaxis and proliferation 
[Morgan etal.. 20081. 
1.2.2 Inorganic Phase 
Properties 
(a) It is an impure form of hydroxyapatite (CaJQ[PO4]6[OH]2). 
(b) It is a naturally occurring calcium phosphate. 
(c) The small plate-shaped apatite crystals contain impurities, most notably 
carbonate in place of the phosphate groups. 
(d) The concentration of carbonate (4-6%) makes bone mineral similar to a 
carbonate apatite known as dahllite. 
(e) Potassium, magnesium, strontium, and sodium in place of the calcium ions 
and chloride and fluoride in place of the hydroxyl groups arc also found 
[McConnell, 1962]. 
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(t) 	These impurities reduce the crystallinity of the apatite [Ou-Yang et al., 2001], 
and in doing so may alter certain properties such as solubility [Kaplan et al., 
1994]. 
(g) The solubility of bone mineral is critical for mineral homeostasis and bone 
adaptation. 
(h) In Paget s disease [Sins, 1998] and diabetes [Einhom et al., 1988], crystal size 
is reported to be decreased, 
(i) In osteopetrotic individuals [Boskey and Marks, 1985] and with 
bisphosphonate treatment [Fratzl etal., 1996; Morgan et al., 2008], the crystal 
size is found to be increased. 
1.3 Bone Cellular Components 
1.3.1 Bone Cell Types 
There are three cell types typically associated with bone homeostasis. 
(a) Ostcoblasts ("bone builders") 
(b) Osteocytes (`bone maintainers", "bone controllers") 
(c) Osteoclasts ("bone resorbers", "bone breakers', "bone carvers") 
These three cell types are derived from two separate stem cell lineages— the 
mesenchymal lineage and the hematopoietic lineage [Morgan et al., 2008]. 
1.3.1,1 Mesencltyntal Lineage Celts 
1.3.1.1.1 Osteoblast 
Properties 
(a) Osteoblasts ("bone builders") commonly called bone-forming cells which 
derived from the osteoblast progenitor cells, participate in mineralization and 
are unable to multiply [Clarke, 20081. 
(b) These are the specialized fibroblasts that in addition to fibroblastic products, 
express BSP and osteocalcin [Salentijn, 2007]. 
12 
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(c) 	Both embryonic and postnatal hone formation is carried out by the 
mesenchymal lineage osteoblast. 
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Figure IV: Osteoblasts (blue) rimming a bony spicule (pink-on diagonal of 
image), Source:http://en.wwikipedia.org/w- iki/File:Bone_hypercaleemia_-_cropped 
_-_very _high_mag. jpg 
(d) Osteoblasts produce the protein matrix of bone made up of type I collagen and 
several noncollagenous proteins. 
(e) This protein matrix is referred to as the osteoid which creates a template for 
mineralization and production of they mature bone. 
(f) Zinc, copper and sodium are some of the minerals required in this process 
[D'ippolito etal.. 1999]. 
(g) Osteoblasts also assist with the initiation of bone resorption by secreting 
factors macrophage-colony stimulating factor (M-CSF) [Buckley et al.. 20051. 
receptor activator for nuclear factor kappa b ligand (RANKL) and 
osteoprotegerin (OPG) that recruit and promote the differentiation of 
monocytic lineage cells into mature osteoclasts and also by producing neutral 
proteases that degrade the osteoid and prepare the bone surface for osteoclast-
mediated remodeling [Wada etal.. 2006]. 
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(h) Mesenchymal stem cells (MSCs) are the pluripotent cells that can differentiate 
into a variety of cell types including myoblasts, adipocytes, chondrocytes, 
osteoblasts. and osteocytes in bone marrow [Kamon el al., 2010; Rayalam et 
al., 2011]. 
(i) Osteoblasts differentiate from the mesenchymal stem cell under the 
stimulation of BMPs [Katagiri and Takahashi, 2002]. 
(j) The specific lineage selection of an individual mesenchymal stem cell 
involves a number of coordinated lineage selection steps and the actions of a 
number of transcriptional regulators, in particular the BMPs [Agata et al., 
2007]. 
(k) RMP4 and FGF2 have been experimentally shown to increase osteoblast 
differentiation [Lee et al., 2013]. 
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Figure V: Osteoblast Organization and Mineralization of Bone, Source:http://en. 
wikipedia.org/wiki/File:Osteob last Organization.jpg 
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1.3.1.1. LI Osteoblast Formation and Differentiation 
[Kobayashi and Kronenberg. 2005] reported that there are two transcription factors 
which have been demonstrated to he required for osteoblast formation and 
differentiation: 
(a) RUNX2 
(b) Osterix 
1.3.1.1.1.1.1 Runt-Related Transcription Factor 2 (RUNX2) 
Properties 
(a) R1TNX2 is best known as an essential master transcription factor in osteoblast 
differentiation and bone development [Li et al., 2011; Ferrari et at, 2013; 
Yoon etal., 2013]. 
(b) RUNX2 also known as core-binding factor subunit alpha-I (CBF-a-1) is 
a protein that in humans is encoded by the Runx2 gene. 
(c) RUNX2 is a member of the runt homology domain transcription factors 
[Morgan et at, 2008]. 
(d) It acts as a scaffolding protein organizing nuclear complexes at discrete sites 
on the nuclear matrix associated with active gene transcription. 
(e) The differentiation of osteoblasts is led by the induction of expression of 
alkaline phosphatase (ALP) or bone matrix proteins such as type I collagen, 
OCN and OPN, under the action of the transcription factors Runx2 and 
Osterix [Nakashima et al., 2002; Komori, 2005].  
(f) The repression of the differentiation factor to muscle cell and adipocyte also 
leads to the differentiation to osteublasts [Nakashima et al., 2002; Komori, 
2005]. 
(g) Thus, RUNX2 is indispensable for mature osteoblast differentiation and 
function [Meyer et al., 2014]. 
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(h) 	Differentiation leads to a restricted RUNX2 cistrome that correlates with 
changes in gene expression [Meyer ei al., 2014]. 
1.3.1.1. L 7.3 Osteric (Osx4 
Properties 
(a) Osterix is a novel zinc finger—containing transcription factor that is essential 
for osteoblast differentiation and bone formation [Cao et al., 2005; Li et al., 
201!]. 
(b) The Osterix knockouts also lack embryonic bone formation and osteoblast 
differentiation [Nakashima eta)., 2002]. 
(c) Osterix functions downstream of RUNX2 activity as RUNX2 1- cells express 
no Osterix. 
(d) In the Osterix knockout mice, the pool of RUNX2- expressing pre-osteoblasts 
express several genes associated with chondrogenesis, suggesting Osterix 
plays a role in stabilizing osteogenic commitment and osteoblast maturation. 
(e) The relative expression and activity of RUNX2 and Osterix are regulated by 
the local microenvironment and the locally produced morphogens to which the 
cells are exposed. 
(f) Growth factors including members of insulin-like growth factors (IGFs), 
FGFs, TGF-(1, BMPs, and Wnts have all been demonstrated to play important 
roles in regulating embryonic osteoblast differentiation. 
(g) Once osteoprogenitor start to differentiate into osteoblasts, they begin to 
express a range of genetic markers including collagen I (Coll), ostcrix, BSP, 
M-CSF, ALP, OC, OPN and ON [Ringc et al., 2008; Szutc et al., 2005]_ 
(h) These cells are also characterized by the expression of different markers such 
as RANKL, OPG [Wauquier et ad., 2009; Wada et al., 2006]. 
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1.3.1.1.1.2 Regulation of Osteoblast Differentiation 
Osteoblast differentiation and bone formation are regulated by transcriptional and 
post-transcriptional mechanisms [Chen et al., 2014]. More recently, micro RNAs 
(miRNAs) were identified as novel key regulators of human stromal (skeletal, 
tnesenchymal) stem cells (hMSC) differentiation [('hen et al., 2014]. Osteoblast 
differentiation from \ISCs is also tightly regulated. An insufficiency of peroxisome 
proliferator activated receptor y (PPAR f), promotes osteoblast formation. PPAR', a 
key transcription factor, is considered a master regulator of adipogenesis and is 
implicated in lipid metabolism [Pei and Tontonoz, 2004]. Deletion of PPARy resulted 
in an increased expression of key molecules for osteoblastic differentiation like 
Runx2 and osterix. Wnt signaling also diverts MSCs towards osteogenic lineage. 
While osteoblast precursors enhance bone resorption by stimulating RAN KL-induced 
osteoclast activation, mature osteoblasts block RANKL-induced osteoclastogenesis by 
increasing osteoprotegerin expression [Goldring and Goldring, 2007]. The activation 
of sirtuin 1(Sirt l) promoted osteoblast differentiation in hone marrow stromal cells 
and MSCs [Backesjo et al., 2009; Backesjo et al., 2006]. 
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Figure V'1: Adipocytes and osteoblast life cycle [Rayalam et al., 20111. 
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1.3.1.1.1.3 Morphology  
Properties 
(a) An active ostcoblast has a prominent Golgi apparatus that appears 
histologically as a clear zone adjacent to the nucleus. 
(b) The nucleus is spherical and large. 
(c) The cytoplasm of osteoblasts is basophilic due to the presence of a large 
amount of rough endoplasmic reticulum (RER) as revealed by haematoxylin 
and eosin staining (H&E staining). 
(d) Active osteoblasts synthesize and stain positively for Coll and ALP [Clover et 
al., 1992]. 
1.3.1.1.1.4 Osteoblusts-O.steocytes Relationship 
During bone formation and remodeling, osteoblasts get embedded into the matrix they 
deposit and differentiate to osteccytes [Kerschnitzki et at., 2013]. They cease to 
generate osteoid and mineralized matrix, and instead act in a paracrine manner on 
active osteoblasts. They are believed to respond to meehanusensory stimuli [Ehrlich 
and Lanyon, 2002; You et al., 20001. 
1.3.1.1.2 Osteocyte 
Properties 
(a) Osteocytes (bone maintainers", `'bone controllers") are mature osteoblast 
which no longer secretes matrix, participates in nutrient/ waste exchange via 
blood and unable to divide [Clarke, 2008]. 
(b) Osteocytes are a type of ostcoblast and thus differentiate from the same 
mesenchymal lineage under the regulation of the same transcription factors 
discussed previously [Tate et al., 2004; Franz-Odendaal et a[, 2006]. 
(c) Osteocytes, escape apoptosis, reduce their production of matrix molecules, and 
eventually end up encapsulated in the hone matrix. 
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(d) In the bone they are characterized by their long processes that extend through 
the lacunocanalicular system of the bone. 
(e) Osteocytes are in fact the most abundant cellular component of mammalian 
bones, making up 95% of all bone cells. 
(f) Osteocytes must survive for decades within the bone matrix, making them one 
of the longest lived cells in the body [Dallas et aL, 2013]. 
(g) Osteocytes are long lived, relative to the other bone cells, with estimates 
running as high as 25 years, as compared to osteoblasts, which are estimated 
in humans to live approximately an average of 3 months [Tate et aL, 2004]. 
(h) These cells form a dense network throughout the entire bone material 
[Kcrschnitzki et at, 2013]. 
1.3.1.1.2.1 Functions 
(a) Osteocytes are known to orchestrate bone remodeling [Kerschnitzki et at, 
2013}. 
(b) Osteocytes encased within mineralized bone matrix are actually 
multifunctional cells with many key regulatory roles in bone and mineral 
homeostasis [Dallas et at., 2013]. 
(c) Osteocytes are mechanosensory cells that coordinate adaptive responses of the 
skeleton to mechanical loading, and also serve as a manager of the bone's 
reservoir of calcium. 
(d) The pericellular matrix (PCM), a thin coating surrounding nearly all 
mammalian cells, plays a critical role in many cell-surface phenomena [\Nang 
et aL, 2014]. 
(e) In osteocytes, the PCM is believed to control both "outside-in" 
(mcchanosensing) and "inside-out" (signaling molecule transport) processes 
(Wang et aL, 2014]. 
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(t) 	Osteocytes create an interconnected network in bone allowing for intercellular 
communications between both neighboring osteocytes and the surface-lining 
osteoblasts. 
(g) 	The osteocyte network provides access to a huge mineral reservoir in bone due 
to its dense organization [Kerschnitzki et al., 2013]. 
.i 	'.~,z 	~~ /., ,` •f ,~ `-* - ail! ~t 
-'iq 	 : 	
If 
	: r 
Figure VII: Structure of osteocyte, 
source: http://en.wikiped ia.org/wiki/File:Osteocyte_2. j pg 
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(h) This interconnection between osteocytes allows for the transmission of 
mechanical and chemical signals across the network through direct 
transmission of mechanical forces either through the triggering of integrin 
force receptors, changes in membrane conformation, chemical signals via the 
gap junctions, or secreted factors that travel through the extracellular fluid of 
the lacunocanalicular system [Tate et al., 2004]. 
(i) Osteocytes interact with their mineralized vicinity and thus, participate in bone 
mineral homeostasis [Kerschnitzki et al., 2013]. 
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1.3.1.2 The Hematopoietic Cell Lineage 
1.3.1.2.1 Osteoclasts (OO) 
Properties 
(a) Osteoclasts ("bone resorbers", "bone breakers'. "bone carvers") were 
discovered by Kolliker in 1873 [Nijweidi and Feyen, 1986]. 
(b) Osteoclasts are capable of resorbing mineralized bone and excessive bone 
resorption by osteoclasts causes bone loss related diseases [Moon etal., 2012). 
(c) Osteoclastic bone resorption depends upon the cell's ability to organize its 
cytoskeleton [Fukunaga et al., 2014]. 
(d) Osteoclasts are bone-resorbing cells derived from hematopoietic precursors of 
the monocyte-macrophage lineage and participate in bone resorption [Kanzaki 
et a]., 2014; Zaidi plot., 2003; Quinn and Gillespie, 2005; Failure el al., 2008; 
Clarke, 2009; Wauquier et al., 2009; Lampropoulos et al., 2012]. 
(e) They are formed by the fusion of precursors that are derived from the 
pluripotent hematopoictic stem cell [Faust et a(., 1999; Netter, 1987; Suda et 
al., 1992] and circulate in the monocyte fraction [Udagawa et al., 1990; 
Fujikawa et al., 1996]. 
(f) Osteoclasts are unique multinucleated cells which show the ability to destroy 
the bone extracellular matrix through the dissolution of hydroxyapatite and the 
degradation of the organic matrix components [lcitelbaum, 2007; Suda et al., 
1992; Wada et al., 2006; Wauquier et al., 2009; Ha et al., 2013]. 
(g) To do so, osteoclasts must undergo a series of changes which imply massive 
cytoskeletal remodeling, polarization of plasma membrane, redistribution of 
transporters and organelles, as well as prominent endosomal trafficking 
[1-eitelbaum, 2007]. 
(h) Osteoclasts are characterized by high expression of tartrate resistant acid 
phosphatase (TRAP), cathepsin K (CTSK), receptor activator for nuclear 
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factor kappa B (RANK) and calcitonin receptor (CTR) expression [Wauquier 
et al., 2009]. 
(i) They are post-mitotic cells with a pre-definite life span which varies among 
species from days to weeks [Tanaka et al., 2006]. 
(j) Osteoclast number must he kept tightly controlled to maintain physiological 
remodeling and prevent excess of bone resorption leading to pathological bone 
loss [Bruzzaniti and Baron, 2006]. 
(k) Inflammatory cytokines play a major role in osteoclastogenesis, leading to the 
bone resorption that is frequently associated with cancers and other diseases 
[Bharti et al., 2004]. 
(1) 	Besides the well known RANK, RANKL and OPG axis, a variety of factors 
tightly regulate osteoclast fbnnation, adhesion, polarization, motility, 
resorbing activity and life span, maintaining bone resorption within 
physiological ranges [Fattore et at. 2008]. 
(m) Nuclear receptors, cell surface receptors, integin receptors and cell death 
receptors work together to control osteoclast activity and prevent both reduced 
and increased bone resorption [Fattore etal., 2008]. 
(n) Osteoclasts play a role in balancing calcium homeostasis with skeletal 
remodeling. 
(o) These cells are found at the apex of the classical "cutting cones" in cortical 
bone and in the resorptive cavities known as Howship's lacunae on trabecular 
bone surfaces undergoing active remodeling. 
1.3.1.2. L I Morphology 
Properties 
(a) 	An osteoclast is a large cell (approximately 40 am in diameter) containing 
around 15-20 closely packed oval-shaped nuclei in a cytoplasm with a 
homogeneous, "foamy" appearance. 
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(b) Foamy appearance is due to a high concentration of vesicles and vacuoles. 
(c) These vacuoles are lysosomes tilled with acid phosphatase. 
(d) In osteoclast, Golgi complexes are found in large area of cytoplasm and RER 
are scattered. [Standring, 2005: Holtrop and King, 1977; Vaananen cat al., 
2000]. 
WI 	I 
Figure VIII: Osteoclast cell with multiple nuclei. Source: 
http://upload.wikiniedia.org /wikipedia/commons/l/l a/Osteoclast.jpg 
1.3.1.2.1.2 Ruffled border formation 
At the active bone resorption site, the osteoclast forms a specialized cell membrane 
called ruffled border that touches the surface of the bone tissue [Netter, 1987]. 
Properties 
(a) This ruffled border facilitates removal of the bony matrix. 
(b) Ruffled border is a morphologic characteristic of an osteoclast that is actively 
resorbing hone. 
(c) The ruffled border increases surface area interface for bone resorption. 
Calcium and phosphate ions are the main components of the mineral portion of the 
matrix. These ions are absorbed into small vesicles, which move across the eel! and 
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eventually are released into the extracellular fluid, thus increasing levels of the ions in 
the blood [Morgan er al., 2003]. 
1.3.1.2.1.3 Bone Resorption Mechanism 
An osteoclast is a member of the mononuclear phagocyte series and may be thought 
of as a specialized type of macrophage [Quinn and Gillespie, 2005]. 
Steps 
(a) In order to remove bone, newly formed osteoclasts become polarized. 
(b) Then they form a raffled membrane. 
(o) 	Then adhere tightly to the bone matrix via an u431 integrin mediated binding to 
the bone surface to form the "scaling zone." 
(d) The osteoclast then secretes acid via H'-adenosine triphosphatases (ATPase) 
and proteases including CTSK into this closed micro compartment along the 
bone surface referred to as the hemi vacuole thereby removing the underlying 
bone. 
(e) H4-ATPase is used for hydroxyapatite dissolution. 
(f) 	CTSK is used for matrix protein digestion. 
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Figure IX: Illustrated cross-section of an activated osteoclast, Source: 
http://upload. wikimedia.org/wikipedia/en/d/d5/Osteoclast.jpg 
By focusing the secretion of these acids and enzymes, osteoclasts are able to move 
along a bone surface or into a cutting cone slowly solubilising bone in a defined area 
without disrupting the surrounding local microenvironment [Morgan et al., 20081. 
1.3.1.2.1.4 Osteoclasts Activation by ROS 
Reactive oxygen species (ROS) act as intracellular signaling molecules in the 
regulation of receptor activator of nuclear factor-KB ligand (RANKL)-dependent 
osteoclast differentiation, but they also have cytotoxic effects that include 
peroxidation of lipids and oxidative damage to proteins and DNA [Kanzaki et al., 
2014: He et al., 2010]. Osteoclasts have been shown to be activated by ROS [Bax et 
al., 1992: Garrett et al., 1990]. Several signals essential for osteoclasts are sensitive to 
activation by ROS. including Nuclear Factor-Kappa B (NF-x13), c-Jun N-terminal 
kinase (JNK). phosphoinositide 3-kinase (P13K) and p38 mitogen-activated protein 
kinase (p38 MAPK) [Paolicchi cat al., 2002: Finkel and Holbrook. 2000]. Osteoclasts 
contain a nicotinamide adenine dinucleotide phosphate- reduced form (NADPH) 
Osteoclast 
Sealina 
25 
Introduction 
oxidase [Steinbeck et al., 1994], an enzyme that is capable of cytokine-regulated 
generation of ROS. ROS are also potent inducers in many cells of tumor necrosis 
factor-alpha (TNF-a) and other cytokines strongly implicated in the bone loss of 
estrogen deficiency. Thus, if estrogen increases oxidant defenses in bone, estrogen 
deficiency might directly or indirectly stimulate osteoclastic bone resorption. 
1.3.1.2.1.5 Osteoclast Differentiation 
During osteoclast differentiation, ROS act as secondary messengers on signal 
pathways [_Moon et al., 2012]. The early differcntiation stages of osteoclast formation 
depend on the transcription factor PU. I which regulates the cell-surface receptor c-
fms expression along with the transcription factor are Zaidi el al., 2003; Quinn and 
Gillespie, 2005]. The cell-surface receptor c-tins is M-CSF receptor. M-CSF is also 
called colony-stimulating factor-I (CSF-1). The expression of c-fms is a central 
component of early osteoclast formation as M-CSF responsiveness is required for 
both monocyte progenitor prolitemtion and the expression of RANK. Interleukin-1 
(IL-I) and RANKL itself have been demonstrated to play a role in enhancing 
osteoclast activity. IL-I, [L-6, M-CSF, TNF-u, lipopolysaccharides (LPS) prolong the 
life span of an ostcoclast [Zaidi etal., 2003; Quinn and Gillespie, 2005; Wada etal., 
2006]. Osteoclast maturation and function primarily depend on RANKL-mediated 
induction of nuclear factor of activated T cells cl (NFATcl), which is further 
activated via increased intracellular calcium ([Ca''];) oscillation [Kim et al., 2013]. 
1.3.1.2.1.6 Regulation 
Ostenclasts are regulated by several hormones including parathormone or parathyroid 
hormone PTH [Raisz, 200S], calcitonin (Cl) from the thyroid gland, and growth 
factor IL-6. Osteoclast activity is also mediated by the interaction of two molecules 
produced by osteohlasts, namely OPG and RANK!.. These molecules also regulate 
differentiation of the osteoclast [Schoppet et al., 2002]. Vinculin (VCL), an actin-
binding protein has been reported to regulate osteoclast function and participate in 
skeletal degradation [Fukunaga etal., 2014]. Recently, vinculin expression has been 
reported to regulate osteoclast function in a talin-dependent, nv[33 integrin 
independent manner [Fukunaga et al., 2014]. 
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1.4 Bone Homeostasis 
Bone homeostasis involves two important processes as 
(a) 	The constant remodeling process 
(h) 	The constant rebuilding process 
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Figure X: Illustrated diagram of Bone Homeostasis, source [Redlich and Smolen, 
2012J. 
This resultant process leads to the replacement of 4-10% of bone each year in 
humans. The bone formation side of the equation is carried out by the mesenchymal 
lineage-derived osteoblasts; the remodeling side of the homeostasis equation in bone 
is carried out by the hematopoictic lineage osteoclasts [Morgan et aL. 2008J. Bone 
formation is related to ostcoblastic proliferation. ALP activity, and osteocalcin and 
collage synthesis [Morgan et a/.. 20141. Bone resorption is associated with osteoclast 
formation and differentiation, and TRAP [Morgan et al., 2014J. Usually, the amount 
of bone remains constant. as bone homeostasis is maintained through a balance 
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between ostcoblastic bone formation and osteoclastic bone resorption [Yamaguchi et 
at, 2012], and the number and function of osteoclasts and osteoblasts are kept normal 
by the mutual interaction of these cells [Takahashi et al., 1988a: Jimi etal., 1996]. 
Bone loss is induced due to decreased osteohlastic hone formation and increased 
osteoclastic bone resorption with various pathologic states [Yamaguchi eral., 2012]. 
Circulating hormones together with locally produced cytokines and growth factors 
modulate the replication and differentiation of osteoclast and osteoblast progenitors 
[Jilka, 2003; Raisz, 2005]. 
1.4.1 Osteoblast-Osteoclast Coupling 
Osteoblasts influence osteoclast formation and activity, and likewise osteoclasts 
influence osteoblast differentiation and activity. This coordination is referred to as 
"coupling" [Cao, 2011]. New bone formation occurs at bone resorption sites in each 
cycle of bone remodeling to maintain the micro architecture required for hone's 
mechanical properties. 
L4.1.1 Cellular Communication Levels 
There are three main communication levels in osteoblast-osteoclast coupling: 
(a) In hone matrix, coupling of resorption and formation through TGF-(31 and 
IGF-1 [Negishi-Koga ei al., 2011]. 
(b) Osteoclast-osteublast communication through semaphorin-4D (Sema4D)- 
Plexin-BI (PLXN-Bl). 
(c) RANK-RANKL mediates communication to induce differentiation of 
osteoclast progenitors. 
m 
Introduction 
Osteoclast 	RANK RANKL Osteoclast progenitor—  
MSC and osteocyte 	progenitor ~c 
communication through  
RANK-RANKL 
Multinucleated 
osteoclast 
Osteodast-osteodast 
communication through 
Sema4D-Plexin-B1 
Osteoclast 
Coupling of resorption 
and formation through 
TGF-151 and IGF-1 
in the bone matrix 	Bow 
resorption 
MSC 
TGF-~i1 
p0 
0 
Os1eo- 
	
. ~— * 	progenitor 
Sema4D 	— 	0 
~eost C p 
y  IGF 1 Plexin•B1 	Bone  surface 
TGF-01  
Osleocyte 
Figure XI: The Coupling process between Bone Resorption and Bone Formation 
ICao, 2011j. 
1.4.1.2 Mechanism 
'l'he level of expression of the cytokines changes with the immature osteoblast 
producing the highest levels of M-CSF and RANKI. during osteoblast differentiation. 
Steps 
(a) When an osteoblast begins to mature into a matrix-producing bone cell, it 
signals to local osteoclast precursors with RANKI. to differentiate, thereby 
coupling the new bone formation with the recruitment of new osteoclasts for 
its subsequent remodeling. 
(b) By coordinating osteoclast differentiation with osteoblast differentiation, the 
system stays in balance. 
(c) Osteoclasts signal back to osteoblast progenitors through the release of BMPs 
and other growth factors that promote osteogenesis from the bone matrix as a 
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pan of the bone removal process completing the circle [Martin and Sims, 
2005]. 
1.4.1.3 Significance 
This coupling system has been evolutionarily adapted to provide a means of 
responding to more mechanical forces and systemic metabolic requirements. Bones 
adapt to the mechanical forces placed upon them. The interconnected osteocytes 
network is widely perceived to provide mechanosensory feedback that is 
communicated to the lining osteoblasts [Tate et al., 20041. Intracellular responses to 
mechanical input can include increased cyclic adenosine monophosphate (CAMP), 
inositol triphosphate (1P3), intracellular calcium, and activation of MAPK pathway 
[Rubin et al., 2006]. Bone remodeling plays an important role in systemic mineral 
homeostasis, with Ca{' being the primary mineral stored in bone. Systemic Ca 
levels are monitored by Ca 2 sensors in the parathyroid gland. As Ca Z levels drop, the 
parathyroid releases PTH. Systemic PTH leads to increased remodeling and the 
release of Ca'', bringing levels back up into the optimal range. PT!! achieves this 
increase in remodeling primarily through its actions on the osteoblast. PTH increases 
the expression of the Notch ligand Jaggedl (JAGI) in osteoblasts [Weber et al., 
2006]. 
7.4.1.4 Regulation 
Osteoblasts can regulate the expansion of the hematopoictic stem cell niche in bone 
marrow through a Notch-mediated mechanism. and by increasing JAGI expression on 
ostcoblasts. PTH leads to an expansion of the hematopoictic lineage from which the 
osteoclasts are derived. Osteoblasts respond to PTLI, as well as interleukin- 11 (IL-
11), prostaglandin E2 (PGE2), and 1,25(OH)1D, by increasing the expression of 
RANKL and other osteoclast regulatory cytokines leading to increased osteoclast 
differentiation and activity and decreased osteoclast apoplosis [Atkins er al., 2003]. 
PTH induces increased neutral protease expression by osteoblasts and causes 
osteoblasts to contract away from the bone surface, exposing the bone and providing 
the osteoclasts access to the surface. Systemic release of PTI I can induce increased 
bone resorption and Ca 2 release by enhancing osteoclast formation and activity, by 
increasing osteoblast- mediated preparation of the bone surface by neutral protease 
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secretion. and by providing the osteoclasts access to the bone surface by causing 
contraction of lining osteoblasts away from the bone. 
1.4.1.5 ROS modulation of signaling pathways in bone cells. 
(a) ROS promote bone loss by inhibiting osteoblast differentiation and enhancing 
osteoclastogenesis. 
(b) ROS induced bone resorption occurs directly or indirectly (increased RANKL 
expression) through the modulation of kinases and transcription factor activities in 
both osteoclasts and osteoblasts [Wauquier et al.. 2009]. 
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Figure Xll. ROS modulation of signaling pathways in bone cells [Wauquier et 
al., 20091. 
1.4.2 Bone Remodeling 
Bone remodeling is a surface phenomenon. It occurs on periosteal, endosteal. 
Haversian canal, and trabecular surfaces. Bone surfaces may be undergoing formation 
or resorption, or they may be inactive. These processes occur throughout life in both 
cortical and trabecular hone. In normal bone, matrix remodeling of bone is constant: 
up to 10% of all hone mass may be undergoing remodeling at any point in time. This 
process is called bone remodeling [Raisz. 20051. 
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Figure XIII. A photomicrograph of bone showing osteoblasts and osteoclasts 
together in one BMU, 
Source: http://courses.washinLton.edu/bonephys/Gallery/BMtJ2.epg 
1.4.2.1 Basic Multicellular Units or Bone Metabolic Units (BMUs) 
Bone remodeling is accomplished by assembly of osteoclasts and osteohlasts into 
discrete temporary anatomic structural units called basic multicellular units or bone 
metabolic units (BMUs) as first described by Frost in 1963 [Frost and Thomas, 1963: 
Kaplan et al.. 1994: Jilka, 2003]. 
Properties 
(a) At the level of BMU, bone resorption and bone formation are tightly coupled 
in time and space. 
(b) Bone mass is determined by two important factors, first by the balance 
between resorption and formation within a BMU and second by the number of 
BMUs active during a certain period of time in the given part of bone. 
(c) The lifespan of osteoclasts and osteoblasts is short compared to the lifespan of 
the BMU; therefore, they must be continually replenished for BMU 
progression to occur. 
(d) Bone loss and osteoporosis are determined by the imbalance between bone 
formation and resorption at the BMU and by the increased number of BMUs. 
(e) The quantity of bone lost at the level of one BMtJ is very small, bone loss is 
driven mainly by the number of BMUs [Morgan et al., 2008). 
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1.4.3 Bone remodeling and oxidative stress. 
(a) BMSCs. hematopoietic precursors differentiate into multinucleated osteoclasts 
in the presence of RANKL. expressed by osteoblasts. 
(b) RANKI_ binding to the receptor RANK at the surface of pre-osteoclasts 
stimulates cell fusion. 
(c) It activates resorption capabilities and enhances cell survival. 
(d) ()PG is a decoy receptor for RANKL and it prevents osteoclast differentiation. 
(e) By degrading bone, osteoclasts create lacunae that are tilled with newly 
synthesized matrices by osteoblasts. 
(f) As a result of oxidative stress this bone coupling is unbalanced, and bone 
formation by osteoblasts is reduced, whereas osteoclast differentiation and 
activities and subsequent hone resorption are enhanced directly or indirectly 
through an increased RANKL production [Wauquier el al., 20091. 
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33 
Introduction 
1.5 Defining Osteoporosis (OP) 
Osteoporosis (OP) is a chronic progressive metabolic bone-related disease that is 
characterized by low or decrease in bone mineral density (BMD) and micro 
architectural deformation of hone tissue that leads to an increased risk of bone 
fragility and fractures and electrolyte imbalance [Kanis, 2002; Kim et al., 2013; Jin et 
al., 2014; Morgan et al., 2(114]. Decrease in bone mass and deterioration of hone 
architecture are determined by bone turnover abnormalities. BMD is a medical term 
normally referring to the amount of mineral matter per square centimeter of bones, it 
is used in clinical medicine as an indirect indicator of osteoporosis. Osteoporosis has 
become an alarming health problem through the entire world and about 200 million 
people in the world are under the threat of this deleterious health problem 
[Lampropoulos et al., 2012; Roy, 20131. With the extension of life expectancy, 
osteoporosis is becoming a major public health problem severely affecting the life 
quality of the elderly [Jin et al.. 2014]. 
1.5.1 Definition 
Osteoporosis is defined by the World Health Organization (WHO) as a BMD of 
2.5 standard deviations or more below the mean peak bone mass (average of young, 
healthy adults) as measured by dual-energy X-ray absorptiometry (DEXA); the term 
"established osteoporosis" includes the presence of a fragility fracture [WHO, 1994]. 
1.5.2 Classification of Osteoporosis Disease 
The disease may he classified as primary type I, primary type 2, or secondary and 
that, their details are illustrated as under. 
1.5.2.1 Primary Osteoporosis 
Primary osteoporosis is mainly a disease of the elderly, the result of the cumulative 
impact of bone loss and deterioration of bone structure that occurs as people age 
[Seeman, 2003]. This form of osteoporosis is sometimes referred to as age-related 
osteoporosis. 
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1.5.2.1.1 Primary Type I Osteoporosis 
The form of osteoporosis most common in women after menopause is referred to as 
primary type I or postmenopausal osteoporosis (PMO) [Fraser et aL, 2011]. PMO is 
caused by an imbalance of bone metabolism induced by the promotion of bone 
resorption due to a lack of estrogen during menopause [Saika et al., 2001]. As much 
as 20% of bone mass can be lost in the first 5-7 years following menopause [Rayalam 
et al., 201 I]. In postmenopausal osteoporosis estrogen deficiencies lead to high bone 
turnover and bone loss [Wensel ei al., 2011]. 
1.5.2.1.2 Primary Type 2 Osteoporosis 
Primary type 2 osteoporosis or senile osteoporosis occurs after age 75 and is seen in 
both females and males at a ratio of 2:1 [Fraser eta(., 2011]. Women have two phases 
of age-related bone loss, which are as under: 
(a) Rapid phase that begins at menopause and lasts 4-8 years. It results in losses 
of 5-10 percent of cortical bone and 20-30 percent of trabecular bone. 
(b) Slower continuous phase that lasts throughout the rest of life [Riggs el al., 
2002]. It results in losses of 20-25 percent of cortical and trabecular bone in 
both men and women, but over a longer period of time [Riggs et al., 2002]. 
As a result, women typically lose more bone than do men. Men go through only the 
slow, continuous phase. Around the ages of 30-35, cancellous or trabecular bone loss 
begins. Women may lose as much as 50%, while men lose about 30%. 
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Representation. Source: Riggs et AL, 1998. 
1.5.2.2 Secondary Osteoporosis 
Secondary osteoporosis may arise at any age and affect men and women equally. This 
form results from chronic predisposing medical problems or disease, or prolonged use 
of medications such as glucocorticoids, when the disease is called steroid- induced 
osteoporosis (S[OP) or glucocorticoid-induced osteoporosis (GIOP) [Khosla et al., 
1994]. The majority of men with osteoporosis exhibit secondary causes of the disease 
[Oncull, 1998]. The occurrence of OP is prevalent among the aging women than the 
aging men although corticosteroid treatment, intake of excessive alcohol, cigarette 
smoking, low calcium intake and hypogonadism may be the secondary cause 
[Lampropou[os et al., 2012; Chen et al., 2013; Roy, 2013]. 
L.5.3 Sputptonts 
OP is often described as a silent disease because it is typically asymptomatic until a 
fracture occurs, the disease negatively and significantly impacts morbidity and 
mortality as it can lead to severe pain, deformity, disability, and death [Chen et al., 
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2013]. Osteoporotic fractures occur in situations where healthy people would not 
normally break a bone; they are therefore regarded as fragility fractures. The signs of 
OP are deterioration of the microstructure of hone specifically at trabecular sites 
including vertebrae, ribs and hips, culmination in fragility fractures, pain and 
disability [Chen et al., 2013; Wongdee and Charoenphandhu, 2011]. 
Vertebral Fractures 
Wrist Fractures 
Hip Fractures 
Figure XVI: Bone Fracture Areas in Osteoporosis. Source: NOF 2004. 
1.5..1 Osteoporotic Fractures 
Fractures are the most dangerous aspect of osteoporosis. Debilitating acute and 
chronic pain in the elderly is often attributed to fractures from osteoporosis and can 
lead to significant morbidity, deterioration of quality of life, and even mortality [Old 
and Calvert, 2004; \Variaghli ct al., 2010; Goel and Kar. 2010; 7_ivna et al., 20131. 
These fractures may also be asymptomatic. Multiple vertebral fractures lead to a 
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stooped posture, loss of height, and chronic pain with resultant reduction in mobility 
[Kim and Vaccaro, 2006]. Involvement of multiple vertebral bodies leads to kypltosis 
of the thoracic spine, leading to what is known as dowager's hump. Fracture risk 
calculators assess the risk of fracture based upon several criteria, including BMD, age, 
smoking, alcohol usage, weight, and gender. It is known that the risk of fracture 
strongly correlates with BMD and the best site for the hip fracture risk prediction is 
the measurement of the proximal femur BMD [Wariaghti etal., 2010; Zivna et al., 
2013]. Eighty percent of those diagnosed with osteoporosis are female, and in women 
the risk of hip fracture due to osteoporosis is equal to the combined risk of breast, 
uterine and ovarian cancer [U.S. Department of l{ealth and Human Services, 2004]. In 
2005, osteoporosis-related fractures were responsible for an estimated $19 billion in 
costs. By 2025, these costs are predicted to rise to approximately $25.3 billion, and 
over the next 50 years, the national cost may be as high as $240 billion [U.S. 
Department of Health and Human Services, 2004]. 
1.6 Pathogenesis of Disease 
Bone structural integrity is maintained by removal of old hone by osteoclasts and 
synthesis of new bone in its place by osteoblasts [Jilka, 2003]. Bone is resorbed 
by osteoclast cells, after which new bone is deposited by osteoblast cells. The 
underlying mechanism in all cases of osteoporosis is an imbalance between bone 
resorption and bone formation. 
1.6.1 Mechanism 
There are the three following main mechanisms by which osteoporosis develop 
(a) An inadequate peak bone mass 
(b) Excessive bone resorption 
(c) Inadequate formation of new bone during remodeling. 
It should be noted that an inadequate peak bone mass means that the skeleton 
develops insufficient mass and strength during growth. Interplay of these three 
mechanisms underlies the development of fragile bone tissue I Raisz, 2005J. 
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1.6.2 Role of Estrogen 
Hormonal factors strongly determine the rate of bone resorption. Lack of estrogen 
increases bone resorption, as well as decreasing the deposition of new bone that 
normally takes place in weight-bearing bones. It should be noted that lack of estrogen 
happens as a result of menopause. The amount of estrogen needed to suppress this 
process is lower than that normally needed to stimulate the uterus and breast gland. 
The a-font of the estrogen receptor appears to be the most important in regulating 
bone turnover [Raisz, 2005]. 
1.6.3 Role of Calcium Metabolism:, Vitamin D, Prostaglandin and Parathyroid 
Hormone 
The activated vitamin D3 (1, 25(OH)2 D3), prostaglandin E2 and the parathyroid 
hormone act on osteoblasts, and control the differentiation of osteoclasts through the 
expression of RANKL [Takahashi el al., 1988a; Suda et aL, 1999]. Calcium 
metabolism plays a significant role in bone turnover, and deficiency of calcium and 
vitamin D leads to impaired bone deposition. The parathyroid glands react to low 
calcium levels by secreting parathyroid hormone, which increases bone resorption to 
ensure sufficient calcium in the blood [Raisz, 2005]. 
1.6.4 OPG/RA.NKIJR9NK system 
The discovery of the molecular triad OPG/ RANK/ RANKL system in the mid 1990s 
for the regulation of bone resorption has led to major advances in our understanding 
of how bone modeling and remodeling are regulated [Boyce and Xing, 2008]. This 
system has helped in elucidating a key signaling pathway between stromal cells and 
osteoclasts [Wittmnt et al., 2004].This system is the dominant and final mediator of 
osteoclastogenesis. OPG. RANKL and RANK are the members of the tumor necrosis 
factor (TNF) super family of ligands and receptors. These three factors play a decisive 
role in regulating bone metabolism. This was demonstrated by the findings of 
extremes of skeletal phenotypes (osteoporosis vs. osteopetrosis) in mice with altered 
expression of those molecules [Khosla, 2001]. These TNF super family members also 
have important functions outside hone [Boyce and Xing, 2007]. 
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1.6.4.1 Osteoprotegerin (OPG) 
It is also known as osteoclastogenesis inhibitory factor (OCIF) or tumor necrosis 
factor receptor super family member 11 B (TNFRSFI I B). It is a protein that in 
humans is encoded by the TNFRSFI I B gene [Walla et al., 2006]. The initial cloning 
and characterization of OPG as a soluble, decoy receptor for RANKL belonging to the 
TNF receptor super family was the first step that eventually led to an unraveling of 
this system [Simonet et al., 1997; Khosla, 2001 ]. 
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Figure XVII: The Signaling Pathway for normal osteoclastogenesis [Boyce and 
Xing, 20071. 
Properties 
(a) 	OPG is a basic glycoprotein comprising 401 amino acid residues arranged into 
7 structural domains. 
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(b) OPG is found as either a 60-kDa monomer or 120-kDa dirner linked 
by disulfide bonds [Schoppet or al., 2002]. 
(c) RANKL activity can be blocked by the soluble decoy receptor OPG, resulting 
in prevention of bone resorption [Simonet et al., 1997]. 
(d) OPG, a recently described member of the TNF receptor super family, is 
produced by a lot of cell types, such as bone-marrow stromal cells and 
osteoblasts. 
(c) 	OPG protects bone from excessive resorption by binding to RANKL and 
preventing it from binding to RANK [Boyce and Xing, 2008]. 
(f) OPG blocks the fusionldifferentiation stage of osteoclast precursors, rather 
than the proliferation stage, by binding to RANKL. 
(g) Thus, the relative concentration of RANKI. and OPG in bone is a major 
determinant of bone mass and strength [Boyce and Xing, 2008]. 
(h) OPG 	can 	reduce 	the 	production 	of osteoclaSTs by 	inhibiting 
the differentiation of osteoclast precursors into osteoclasts and also regulates 
the resorption of osteoclasts in vitro and in vivo. 
(i) Thus, in this way, OPG protects the skeleton from excessive bone resorption 
by binding to RANKL and preventing it from binding to its receptor, RANK 
[Raisz, 2005; Boyce and Xing, 2007]. 
(j) By binding RANKL, OPG inhibits NF-KB which is a central and rapid acting 
transcription factor for immune-related genes, and a key regulator of 
inflammation, innate immunity, and cell survival and differentiation 
[Krakauer, 20081. 
(k) OPG levels are influenced by voltage-dependent calcium channels Cavl.2. 
(1) 	OPG also protects arteries from medial ealcifiealion I Boyce and Xing, 20071. 
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(m) Space shuttle flight STS-108 in 2001 tested the effects of OPG on mice in 
microgravity, fording that it did prevent increase in resorption and maintained 
mineralization [Bateman and Countryman, 2002]. 
(n) OPG production is stimulated in vivo by the female sex hormone estrogen as 
well as the osteoporosis drug, strontium ranelate [Khosla, 20011. 
1.6.4.2 Receptor activator of,NF-n'B ligand (k4NKL) 
RANKI. is the molecule which is blocked by OPG. It is also known as tumor necrosis 
factor ligand super family member I I (TNFSF11), TNF-related activation-induced 
cytokine (TRANCE), osteoprotegerin ligand (OPGL) and osteoclast differentiation 
factor (ODF) is a protein that in humans is encoded by the TNFSFI I gene [Wong et 
al., 1997; Anderson et al., 1997; Yasuda et af., 1998; Lacey et al., 1998]. 
Properties 
(a) RANKL is one of the critical mediators of osteoclastogenesis [Bharti et al., 
2004]. 
(b) RANKL is the most important locally produced pro-osteoclastogenic 
factor/cytokinc that, in combination with M-CSF, induces osteoclast formation 
in vitro [Wittrant et al., 2004]. 
(c) RANKL is expressed as a membrane-bound protein on the surface of 
osteoblasts, osteocytes and marrow stromal cells [Lacey et al., 1998]. 
(d) In addition, activated T cells secrete RANKL as a soluble molecule [Kong et 
al... 1999]. 
(e) Most osteotropic factors such as IL-1, IL-11, PGE2 and 1,25-(O1-I)1D3 induce 
osteoclast formation by binding to marrow stromal cells, which in turn express 
increased levels of soluble or membrane forms of RANKL [Wittrant et al„ 
'_0041. 
(f) It was identified as the key mediator of osteoctastogenesis in both a 
membrane- hound form expressed on preosteoblastic/stromal cells and T cells 
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as well as a soluble form [Suda et aL, 1999; Wong et at, 1999; Khosla, 2001; 
Theill et al., 2002]. 
(g) Under physiologic conditions, osteoblasts produce CSF-1 and the 
differentiation-inducing factor, RANKL [Yoshida et al., 1990; Amano er at, 
1998; Lacey et at, 1998; Yasuda et al., 1998]. 
(h) Osteoclastic activity is triggered via the osteoblasts surface-bound RANKL 
activating the osteoclasts' surface-bound RANK. 
(i) The binding of RANKL to the RANK receptor activates NF-KB signaling 
leading to the formation of mature multinucleated osteoclasts [Wada et al., 
2006]_ 
(j) The activity of RANKL is balanced by the level of expression of its inhibitor 
osteoprotegerin OPG. 
(k) It is the local ratio of RANKL to OPG that ultimately determines if osteoclast 
formation will occur by regulating the amount of available RANKL. 
(1) 	Therefore, RANKL'OPG ratio is an important determinant of bone mass and 
skeletal integrity [Boyce and Xing, 2007]. 
(m) 	RANKL induces osteoclastogenesis through the activation of NF-xB [Bharti et 
al., 2004]. 
7.6.4.3 Receptor Activator of Nuclear Factor K B (RANK) 
RANK (receptor activator of nuclear factor xB) is stimulated by RANKL. RANK is 
also called osteoclast differentiation factor receptor (ODFR), TNF receptor super 
family member II  (TNFRSFI IA) and TNF-related activation induced cytokine 
receptor (TRANCE-R) [Wada  et at, 2006]. 
Properties 
(a) 	RANK is also expressed on dendritic cells and facilitates immune signaling. 
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(b) RANKL then binds to its receptor RANK, present at the surface of osteociast 
precursors and mature osteoclasts, inducing osteoclast formation and 
activation Nakagawa er al., 1998; Khosla, 20011. 
(c) The interaction between RANK and RANKL plays a critical role in promoting 
osteoclast differentiation and activation leading to bone resorption. 
(d) The binding of RANKL to its receptor RANK leads to recruitment of the 
adaptor protein TNF receptor-associated factor 6 (TRAF6) to the cytoplasmic 
domain of RANK, thereby resulting in the activation of distinct signaling 
cascades mediated by MAPK, including JNK, p38 MAP kinase (p38), and 
cxtraccllular signal-regulated kinase (ERIC), leading NF-icB activation [Boyle 
et al., 2003]. 
(e) NE-KB increases c-Fos expression and c-Fos interacts with NFATcl to trigger 
the transcription of osteoclastogenic genes leading to the osteoclast 
differentiation [Jilka, 2003; Raisz, 2005; Boyce and Xing, 2007J. 
(f) JNKI- activated c-Jun signaling in cooperation with NEAT is a key to 
RANKL-regulated osteoclast differentiation [Ikeda et al., 2004]. 
(g) Stimulation of p38 results in the downstream activation of the 
microphthalmia/microphthalmia transcription factor (mi/Mitt). 
(h) This factor controls the expression of the genes encoding TRAP and CTSK, 
indicating the importance of p38 signaling cascades [Boyle et al., 2003). 
(i) RANKL-induced NFATc1 is a downstream event of NF-icB signal pathway 
[Moon et at, 2012). 
(j) RANKL/RANK signaling regulates osteoclast formation, activation and 
survival in normal bone modeling and remodeling and in a variety of 
pathologic conditions characterized by increased bone turnover. 
(k) RANKURANK signaling is also required [or lymph node formation and 
matmnary gland laetatlonal hyperplasia [Royce and Xing, 2007]. 
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(l) 	RANK has been shown to interact with I RAF6 [Junko eral., 2002; Darnay et 
al., 1998; Damay et al , 1999; Galibert et al., 1998; Kim et al., 1999], TRAFS 
[Damay et al., 1998; Damay et al., 1999; Galibert et at, 1998], TRAFI 
[Galibert et at, 1998: Kim et al., 1999], TRAP 2 [Darnay et al., 1998; Darnay 
et al., [999; Galibert el at, 1998; Kim et al., 1999] and TRAF3 [Galibert at 
al., 1998; Kim etal., 1999]. 
1.6.5 Regulation of Bone Turnover 
Bone turnover is characterized by the formation of new bone by osteoblasts and the 
resorption of old hone by osteoclasts. Local production of eicosanoids and ILs is 
thought to participate in the regulation of bone turnover, and excess or reduced 
production of these mediators may underlie the development of osteoporosis [Raisz, 
2005]. 
1.7 Diagnosis 
The diagnosis of osteoporosis can be made using conventional radiography and by 
measuring BMD [Guglielmi and Scalzo. 2010]. The diagnosis of osteoporosis also 
requires investigations into potentially modifiable underlying causes; this may be 
done with blood tests. 
1.7.1 Conventional Radiography 
Conventional radiography is useful for detecting complications of osteopenia, such as 
fractures; for differential diagnosis of osteopenia; or for follow-up examinations in 
specific clinical settings. such as soft tissue calcifications, secondary 
hyperparathyrrsidism, or ostcomalacia in renal osteodystrophy. Osteopenia is basically 
the reduced bone mass; it is also called as preosteoporosis. 
1. Z2 Dual-Energy X-ray Absapriometry (DEXA) 
DEXA is the most popular method of measuring BMD. DEXA is considered the gold 
standard for the diagnosis of osteoporosis. Osteoporosis is diagnosed when 
the BMD is less than or equal to 2.5 standard deviations below that of a young (30-
40-year-old, healthy adult women reference population [WHO, 2003]. This is 
translated as aT-score. But because bone density decreases with age. more people 
45 
Introduction 
become osteoporotic with increasing age [WHO, 2003]. WHO has established the 
following diagnostic guidelines [~VHO, 1994; WVHO, 2003]. 
Table 2: Relationship between T-Score Ranges and Disease State. 
Category T-Score Range % Young Women 
Normal T-Score-1.0 85% 
Osteopenia -2.5<T-Score<-1.0 14% 
Osteoporosis T-Score<-2.5 0.6% 
Severe Osteoporosis T-Score<-2.5 with fragility fracture 
1.8 Bone Turnover Markers (BT.'11s) 
Biochemical bone turnover markers (BTMs) can be divided into two groups: 
(a) Markers of bone formation 
(b) Markers of bone resorption. 
However, in disease states in which both processes are coupled and disclose similar 
increase, BTMs reflect the overall rate of bone turnover. In such cases, levels of the 
bone resorption markers are correlated positively with histomorphometric parameters 
of bone formation. BTMs cannot discriminate between bone turnover changes in the 
cortical and trabecular envelopes. The increase in the BTM levels is followed by an 
increase in BMD during puberty but by a decrease in BMD after menopause. 
Table 3: Biochemical Markers for Bone Remodeling 
Markers of bone formation 
Serum 
Osteocalcin (bone Gla protein) [ Li et al., 20111 
*Total and bone ALP [Li etal.. 2011 ] 
*N-terminal propeptide of type I collagen (P1 NP) 
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C-terminal propeptide of type I collagen (P1CP) 
1larkers of bone resorption 
Plasma/serum 
Tartrate-resistant acid phosphatase (TRACP) 
I 	Pyridinoline (PYD) and deoxypyridinoline (DPD) 
C-terminal cross-linking telopeptide of type I generated by rnetalloproteinases 
(CTX-MMP) 
*C-terminal cross-linking telopeptide of type I collagen (CTX-I) 
N-terminal cross-linking telopeptide of type I collagen (NTX-I) 
Urine 
Pyridinoline (PYD) and deoxypyridinoline (DPD) 
C-terminal cross-linking telopeptide of type I collagen (CTX-I) 
N-terminal cross-linking telopeptide of type I collagen (NTX-I) 
Calcium 
Hvdroxyproline 
Galactosyl-hydroxvlysine 
*ALP acts as a transmembrane receptor involved in osteoprogenitor-osteoblast 
adhesion, migration and differentiation [Hui et al., 1993; Li et al., 2011]. 
*PINP is marker of collagen metabolism before its integration to bone matrix and 
retlects a bone formation [Zivna et al., 2013]. 
*CTX-1 is released from C-terminal part of telopeptide of collagen I by proteolytic 
enzymes and its detection is a sensitive indicator of bone resorption [Hcrnnann etal.. 
2008: Zivna etal., 20131. 
1.9 Reactive O.rti'eir Species (ROS) 
ROS are chemically reactive molecules containing oxygen. Fxamples include oxygen 
ions and peroxides. ROS forni as a natural byproduct of the normal metabolism 
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of oxygen and have important roles in cell signaling and homeostasis [Devasagayam 
et al., 2004]. However, during times of environmental stress, ROS levels can increase 
dramatically [Devasagayam et at., 20041. This may result in significant damage to cell 
structures. Cumulatively, this is known as oxidative stress. ROS are also generated by 
exogenous sources such as ionizing radiation. 	 - 
0:0: :0:0: 
Oxygen Superoxide anion Peroxide 
02  .02 022 
H:O=O'H '0:H :O:H 
Hydrogen Peroxide Hydroxyl radical Hydroxyl ion 
H202 OH 0H 
Figure XVIII: Electron structures of common reactive oxygen species, Source: 
http://www.bintek.com/resou rees/articles/reactive-oxygen-spccies.html 
1.9.1 Oxidative Stress 
Oxidative stress is caused by an imbalance between the systemic manifestation 
of ROS and a biological system's ability to readily detoxify the reactive intermediates 
or to repair the resulting damage or antioxidant defense [Morgan et al., 2014]. 
Disturbances in the normal redox state of cells can cause toxic effects through the 
production of peroxides and free radicals that damage all components of the cell. 
including proteins, lipids, and deoxyribonucleic acid (DNA). Some ROS act as 
cellular messengers in redox signaling. Thus, oxidative stress can cause disruptions in 
normal mechanisms of cellular signaling_ Cellular protective mechanisms against 
oxidative stress include transcriptional control of cytoprotective enzymes by the 
transcription factor, nuclear factor E2-related factor 2 (_Nrt2) Kanzaki et al., 2014]. 
Recently. it has been reported that loss of ovarian function causes oxidative stress as 
well as bone loss. ROS induced by the failure of ovarian function are responsible for 
the bone loss by increasing the number of osteoclasts (OC). ROS enhanced OC 
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survival via Src homology 2 domain-containing phosphatase-I (SHP-1), c-Src, Akt, 
and ERK. Thus, the association and oxidation of c-Src and SHP-1 by ROS are key 
steps in enhancing OC survival, which are responsible for increased bone loss when 
ovarian function ceases [Ke et aL, 2014]. 
L 9.2 Oridarive Darnage 
In aerobic organisms the energy needed to fuel biological [Inactions is produced in 
the mitochondria via the electron transport chain (ETC). ROS with the potential to 
cause cellular damage are also produced in addition to energy. ROS can 
damage DNA, RNA and proteins, which, contributes to the physiology of ageing. 
Hydrogen peroxide (H:O,) is a major contributor to oxidative damage. It is converted 
from superoxide that leaks from the mitochondria. Catalase and superoxide 
dismutase ameliorate the damaging effects of H202 and superoxide, respectively, by 
converting these compounds into oxygen and water. This conversion is not 100% 
efficient, and residual peroxides persist in the cell. While ROS are produced as a 
product of normal cellular functioning, excessive amounts can cause deleterious 
effects [Patel et aL, 1999]. 
1.9.3 ROS Scavengers 
1.9.3.1 Enzymes 
Normally, cells defend themselves against ROS damage with enzymes such as 
(a) Alpha-I -Imicroglobulin 
(b) Superoxide dismutases (SOD) 
(c) Catalases 
(d) Lactoperoxidases 
(e) Glutathione peroxidases (GPx) 
(t) 	Pemxiredoxins 
(g) 	Thioredoxins 
1.9.3.2 Cellular Antioxidants 
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Some small molecular antioxidants also play important roles as cellular antioxidants 
such as 
(a)  Ascorbic acid (vitamin C) 
(b)  Tocopherol (vitamin F) 
(c)  Uric acid 
(d)  Glutathione 
1.9.3.3 Polyp/rend Antioxidants 
Polyphenol antioxidants assist in preventing ROS damage by scavenging free 
radicals. 
1.9.3.4 Plasma antioxidant 
The antioxidant ability of the extracellular space is less - e.g., the most important 
plasma antioxidant in humans is uric acid. 
1.9.4 Useful Effects of ROS 
Effects of ROS on cell metabolism are well documented in a variety of species. 
(a) 	Roles in apoptosis or programmed cell death 
(h) 	The induction of host defense genes [Rada and Leto, 2008; Conner et al., 
2002]. 
(c) Mobilization of ion transport systems 
(d) Control of cellular function such as platelets involved in wound repair 
and blood homeostasis release ROS to recruit additional platelets to sites 
of injury. 
(e) These also provide a link to the adaptive immune system via the recruitment 
of leukocytes. 
50 
Introduction 
1.9.5 Harmful Effects of ROS 
According to [Brooker. 2011 ]. the harmful effects of ROS on the cell are most often: 
(a) damage of DNA 
(b) oxidations of polyunsaturated fatty acids in lipids called lipid peroxidation 
(c) oxidations of amino acids in proteins 
(d) oxidatively inactivate specific enzymes by oxidation of co-factors 
1.9.6 Cellular localization of ROS production. 
KAOPH oxidase 
WS 
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Monownine oxidase 
Cytodtome P 450 
Respiratory chain 
Lomond 	Cydoorygemse 
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Lipoxygenase 
cy 
Figure XIX: Cellular localization of ROS production (Wauquier et al., 2009]. 
(a) ROS are produced in cells at various sites including the plasma membrane, 
mitochondria and cytoplasm. 
(b) The largest amounts of ROS are produced in mitochondria because of electron 
leaks in the respiratory chain. 
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(c) At the surface of the cell, NADPII oxidases transport electrons across the 
plasma membrane to generate superoxide (02.-). 
(d) Superoxide is unstable and so is rapidly converted to H202. 
(e) H20, can diffuse through the cell membrane [Wauquier ct at, 20091. 
1.9.6 Types of ROS 
1.9.6.1 Exogenous ROS 
Exogenous ROS can be produced from pollutants, tobacco, smoke, drugs, 
xenobiolics, or radiation. 
1.9.6.1.1 Radiolysis 
Ionizing radiation can generate damaging intermediates through the interaction with 
water, a process termed radiolysis. Since water comprises 55-6O% of the human body, 
the probability of radiolysis is quite high under the presence of ionizing radiation. 
1.9.6.1.1.1 Mechanism 
In the process, water loses an electron and become highly reactive. Then through a 
three-step chain reaction, water is sequentially converted to hydroxyl radical (OH), 
H202, superoxide radical (-O j and ultimately oxygen (O,). The hydroxyl radical is 
extremely reactive that immediately removes electrons from any molecule in its path, 
turning that molecule into a free radical and so propagating a chain reaction. But H,02 
is actually more damaging to DNA than hydroxyl radical since the lower reactivity of 
H202 provides enough time for the molecule to travel into the nucleus of the cell, 
subsequently wreaking havoc on macromolecules such as DNA. 
1.9.6.2 Endogenous ROS 
There are multiple sources of ROS in the cell including NADPH oxidase (NOX) 
[Block and Gorin, 20121, xanthine oxidase (XO), uncoupling of nitric oxide synthase 
(NOS), cytochrome P450, and mitochundrial ETC [Li et al., 2013.  1 ROS are produced 
intracellularly through multiple mechanisms and depending on the cell and tissue 
types. 
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1.9.6.2.1 Role of Mitochondria 
Mitochondria convert energy for the cell into a usable form, adenosine 
ttiphosphate(ATP) [Li et al., 2013]. The process, in which ATP is produced, is 
called oxidative phosphorylation which involves the transport of protons across the 
inner mitochondrial membrane by means of the ETC. In ETC, electrons are passed 
through a series of proteins via oxidation-reduction reactions, with each acceptor 
protein along the chain having a greater reduction potential than the previous. An 
oxygen molecule is the last destination for an electron along this chain. 
L 9.6.2.2 Superoxide radical Generation 
In normal conditions, the oxygen is reduced to produce water. In about 0.1-2/0 of 
electrons passing through the chain, oxygen is instead prematurely and incompletely 
reduced to give the superoxide radical (•O,-). [Li el al., 20131. Superoxide is not 
particularly reactive by itself, but can inactivate specific enzymes or initiate lipid 
peroxidation in its protonated form, hydroperoxyl HO,. The pKa of hydroperoxyl is 
4.8. Thus, at physiological pH, the majority will exist as superoxide. Mitochondtial 
ROS (rot ROS) directly stimulate the production of proinflamrnatory cytokines [West 
et al., 2O 1] and pathological conditions as diverse as malignancies, autoimmune 
diseases, and cardiovascular diseases all share common phenotype of increased 
mtROS production abov=e basal levels [Li et al., 2013]. Recently it has been reported 
that mitochondrial-derived reactive oxygen species (rot ROS) regulate the strength of 
postsynaptic GABAA receptors at inhibitory synapses of cerebellar stellate 
cells. GABA, i.e., y-aminobutyric acid is the chief inhibitory neurotransmitter in 
the mammalian central nervous system [Accardi et al., 2014] 
1.9.6.2.3 RO.S and .Apoptosis 
If too much damage is present in mitochondria, a cell undergoes apoptosis or 
programmed cell death. 
1.9.6.2.3.1 Mechanism 
(1) 	B-cell lymphoma 2 (Bcl-2) proteins are layered on the surface of the 
mitochondria, detect damage, and activate a class of proteins called bcl-2-
associated X pmteins (BAX). 
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(2) Bax punch holes in the mitochondrial membrane. causing cytochrome C to 
leak out. 
(3) This cytochrome C binds to Apaf-I, or apoptotic protease activating factor-I, 
which is free-floating in the cell's cytoplasm. 
(4) The Apaf-1 and cytochrome C bind together to form apoptosomes by using 
energy from the AI'Ps in the mitochondrion. 
(5) The apoptosomes bind to and activate caspasc-9, another free-floating protein. 
(6) The caspasc-9 then cleaves the proteins of the mitochondrial membrane, 
causing it to break down and start a chain reaction of protein denaturation and 
eventually phagocytosis of the cell. 
1.9.7 Antioxidant Enzymes 
There are three major types of primary intracellular antioxidant enzymes in 
mammalian cells: 
(a) Superoxide dismutase (SOD) 
(b) Catalase 
(c) Peroxidase, of which glutathione peroxidase (GPx) is the most prominent. 
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Figure XX: Antioxidant enzyme schematic I W eydert and Cullen, 2010]. 
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1.9.8 Superoxide Dis,n,,tase (SOD) 	 ti--- - _ 
Superoxide Dismutascs (SOD) are the enzymes that catalyze the 
dismutation of superoxide (- O;) into oxygen and H,O2 [Li et al., 2013]. They convert 
02 into H302 IWeydert and Cullen, 2010]. Thus, they are an 
important antioxidant defence in nearly all cells exposed to oxygen. 
1.9.7.1 Reaction Catalyzed 
The SOD-catalysed dismutation of superoxide may be written with the following half-
reactions: 
• M-SOD +Oi — D7"'-SOD + 02 
• M"+-SOD+O= +2H+ —Ml I +  -SOD +H202. 
Where M = Cu (n=1); Mn (n=2); Fe (n=2); Ni (n=2). 
In this reaction the oxidation state of the metal cation oscillates between n and n+l. 
1.9.7.2 SODs in Higher Plants 
SOD isozymes have been localized in different cell compartments. 
1,9, 7.2.1 Mn-SOD 
Mn-SOD is present in mitochondria and peroxisomes. 
1.9.7.2.2 Fe-SOD 
Fe-SOD has been found mainly in chloroplasts but has also been detected in 
peroxisomes. 
1.9.7.2.3 CuZn-SOD 
CuZn-SOD has been localized in cytosol, chloroplasts, peroxisomes, and apoplast 
[Corpas et al., 2001; Corpas et al., 2006]. 
1.9.7.3 SODS in Humans 
Three isoforms of SOD have been identified in humans, in all other mammals, and 
most chordates [Li er at, 2013]. 
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(a) SOD 1/copper-zinc SOD (CuZn-SOD), 
(b) SOD2/manganese SOD (kinSOD), and 
(c) Extracellular SOD3 (EC-SOD). 	 49  
Three forms of superoxide dismutase are present 
1.9.7.3.1 SODI 
SODI is widely distributed throughout the cell cytoplasm, nucleus, and 
intermembrane space of mitochondria [Okado-Matsumoto and Fridovich, 2001]. 
SODI is a dieter (consists of two units). SODI contains copper and zinc. 
The genes are located on chromosome 21 (21g22.1). 
13.7.3.2 .SOD2 
SOD2 is expressed only in the mitochondrial matrix [Okado-Matsumoto and 
Fridovich, 2001]. SOD2 is a ictramer (consists of four subunits). SOD2 
has manganese in its reactive centre. The genes are located on chromosome 6 
(6q25.3). The deficiency of SOD2 causes early neonatal death in gene knockout mice 
[Li et al., 1995] and endothelial dysfunction in carotid artery of proatherogenic 
apolipoprotein E (ApoE)-deficient mice [Madamanchi and Runge, 2007; Ohashi et 
a1, 2006]. 
1.9.7.3.3 SOD3 
SOD3 is found in the extracellular space [Li et al., 2013]. SOD3 is a dimer (consists 
of four subunits). SOD3 contains copper and zinc. The genes are located on 
chromosome 4 (4p! 5.3-p  15. I). 
1.9.8 Catalase 
The catalases (CAT) and peroxidases (GPx) convert H,O2 into water [Weydert and 
Cullen, 2010]. CAT is a heme-containing tetramer of four polypeptide chains that 
reduces H202 to water [Li et at, 2013]. Although catalasc is highly efficient at 
reducing H2O,, it may not play a central role in scavenging ROS in the mitochondria 
since it is localized mainly in peroxisonres except that rat heart mitochondria does 
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partially depend on catalase to scavenge ROS [Radi etal., 1991]. If HAO, removal is 
inhibited, then there is direct toxicity resulting from H'02-mediated damage [Weydert 
and Cullen, 2010]. If CAT is inhibited, cells also cannot remove H202 [Weydert and 
Cullen, 2010]. 
2 1120; 2 HO + Oi 
1.9.9 Glutathiote Peroxidase (GP.v) 
GPx is the general name of an enzyme family with peroxidasc activity whose main 
biological role is to protect the organism from oxidative damage. 
1.9.9.1 Biochemical Function 
GPx requires several secondary enzymes, including glutathione reductase (OR) and 
glucose-6-phosphate dehydrogenase (G-6-PD), and cofactors, including glutathione 
(GSH), NADPH and glucose 6-phosphate, to function at high efficiency [ Weydert and 
Cullen, 2010]. The biochemical function of GPx is to reduce lipid hydro peroxides to 
their corresponding alcohols and to reduce free H2O, to water. GPx catalyzes the 
reductive inactivation of Hz02 by transferring the energy of the reactive peroxides to a 
very small sulphur-containing protein called glutathione using reduced glutathione 
(GSH) as a cofactor [Li et at., 2013]. GSH is a tripeptide containing of three amino 
acid residues including glutamate, cysteine, and glycine. 
1.9.9.2 Reaction Catalyzed 
The main reaction that GPx catalyzes is 
2GSH + H202 —~ GS-SG + 2H2O 
During the process of reducing H2Oz, GSH is oxidized to oxidized glutathione 
(GSSG). Where, 
(a) 	GSII represents reduced monomeric glutathione 
(b) 	GS—SG represents glutathione disulfide. 
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1.9.9.2.1 Mechanism of Reaction  
(1) The mechanism involves oxidation of the selenol of a selenocysteine residue 
by H:Q. 
(2) This process gives the derivative with a selenenic acid (RSeOH) group. 
(3) The selenenic acid is then converted back to the selenol by a two step process 
that begins with reaction with GSH to form the GS-ScR and water. 
(4) A second GSH molecule reduces the GS-SeR intermediate back to the selenol, 
releasing GS-SG as the by-product. 
(5) 	A simplified representation is shown below [Bhabak and Mugesh, 2010]. 
• 	RSeH + 11202— RSeOH + H10 
• 	RSeOH + GSH —~ GS-SeR + HO 
• 	GS-SeR + GSH —, GS-SG + RSeH 
1.9.9.3 Glutathione Reductase (GR) 
OR then reduces the oxidized glutathione to complete the cycle: 
• GS—SG +NADPII+II+ —* 2 GSII+NADP+. 
Thus, GSSG is then recycled hack to GSH by the enzyme OR using NADPH as a 
substrate [Handy and Loscalzo, 2012]. Thus, the maintenance of GSH for optimal 
scavenging capacity is dependent on the bioavailability of NADPH stores [Li or ad., 
2013]. If GR is inhibited, cells cannot remove HzO2 through the glutathione 
peroxidase system and the levels of glutathione disulfide (GSSG) increase [Weydert 
and Cullen, 2010]. 
Note: If glutathione synthesis is inhibited, either by inhibiting glutathione synthetase 
(GS) or by y-glutamyl cysteinc synthetasc (y-GCS), glutathione will be depleted and 
GPx will not be able to remove H=O, [Weydert and Cullen, 2010]. If glucose uptake is 
inhibited creating a chemically induced state of glucose deprivation, hydroperoxide 
detoxification will also be inhibited [Weydert and Cullen, 2010]. 
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1.9.9.4 Selenium Reactive Centre 
The selenium contained in these enzymes acts as the reactive centre, carrying reactive 
electrons from the peroxide to the glutathione. As the integrity of the cellular and sub 
cellular membranes depend heavily on GPx, its antioxidative protective system itself 
depends heavily on the presence of selenium. 
1.9.9.5 Isoen:wne of Glutathion e Peroxidase 
Several isozymes are encoded by different genes, which vary in cellular location and 
substrate specificity. So far, eight different isoforms of GPx (GPxl-8) have been 
identified in humans. 
L9.9.5.1 Glutathione Peroxidase I (GP.XI) 
GPxl is the most abundant version, found in the cytoplasm of nearly all mammalian 
tissues, whose preferred substrate is H2O,. Mammalian OPxI has been shown to 
be selenium-containing enzyme. GPxI is a homotetrameric protein. 
1.9.9.5.2 Glutathione Peroxidase 2 (GPx2) 
GPx2 is an intestinal and extracellular enzyme. Mammalian GPx2 has been shown to 
be selenium-containing enzyme. GPx2 is a homotetrameric protein. 
1.9.9.5.3 Glutathione Peroxidase 3 (GPx3) 	 i' 
GPx3 is extracellular, especially abundant in plasma [Muller at at. 2007]. 
Mammalian GPx3 has been shown to be selenium-containing enzyme. GPx3 is a 
homotetrameric protein. 
1.9.9.5.4 Glutathione Peroxidase 4 (GPx4) 
GPx4 has a high preference for lipid hydro peroxides. It is expressed in nearly every 
mammalian cell, though at much lower levels. Mammalian GPx4 has been shown to 
be selenium-containing enzyme. GPx4 has a monomeric structure. 
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1. R 9.5.5 Glutatltione Peroxidase 6 (GP_v6) 
GPx6 is a selenoprotein in humans with cysteine-containing homologues in rodents. 
1.9.10 Peroxiredoxins 
Peroxiredoxins are a family of antioxidant enzymes that regulate cytokine-induced 
peroxide levels and mediate signal pathways [ghee et al., 2005]. Peroxiredoxins also 
degrade HO,, within the mitochondria, cytosol, and nucleus. There are six 
peroxiredoxins in this family. H2O2 has the highest affinity to peroxiredoxin 2 
(100%), then to GSH (<0.010/o), to Cdc25B (<0.0001%) and to protein tyrosine 
phosphatase 1 B (<0.000001 %), demonstrating the importance of peroxiredoxins 
[Winterbourn, 2008]. 
1.9. 11 Thioredoxins 
Thioredoxins are small proteins that play a variety of roles depending upon binding 
interactions and oxidoreductase activity. Mammalian thioredoxin-2 (Trx2) is a 
mitochondrial protein. Trx2 deficiency results in embryonic lethal at gestational day 
10.5 and embryos show massive apoptosis. The timing coincides with the maturation 
of mitochondrial function [Li et al., 20131. 
1.10 Tea (Camellia sinensis) 
Tea is the most consumed beverage worldwide next to water. Tea is a flavonoid-rich 
beverage and contributes substantially to the intake of dietary catechins. Tea also 
contains some flavonols, particularly quercetin and kaempferol [McKay and 
Blumberg, 2007]. 
1.10.1 Physiological Effects of the Tea Polyphenol 
Various physiological effects of the tea Polyphenol catechin for improving diseases 
such as cancer, arteriosclerosis, hyperlipemia, and osteoporosis have been reported 
[McKay and Blumberg, 2002; Crespy and Williamson. 2004; Kamon et al., 20101. 
Flavonoids are commonly defined as dietary antioxidants and catechins can quench 
reactive oxygen and nitrogen species [Higdon and Frei, 2003], their b:oactivity may 
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result as well from other mechanisms of action [Lotito and Frei, 2006], e.g., inhibition 
of inflammation [Wheeler c't al., 2001], regulation of nitric oxide [Vita, 2003], 
stimulation of specific signal transduction pathways. and modulation of other cellular 
processes such as apoptosis [Lambert and Yang, 2003]. EGCG has various 
physiological functions such as the protection of DNA damage/methylation, 
suppression of protease activity, induction of apoptosis, and regulation of cell cycle 
and arrest, in the cell [Khan et al., 2006; Chen et al., 2008]. EGCG acts on a specific 
signaling pathway through binding to the 67 kDa laminin receptor (67LR) [Tachibana 
et al., 2004]. Tea polyphenol is known to mitigate osteoporosis as one of its 
physiological roles [Hegarty et al., 2000]. 
1.10.2 The .Von Herbal Teas 
All non-herbal teas, including green, oolong, black, and white teas, are derived from 
the leaves of the tropical evergreen Camellia sinensis [McKay and Blumberg, 2007]. 
1.10.2.1 Green: Tea 
About 20% of the consumed tea is green tea, which is primarily consumed in China 
and Japan and contains mostly nonoxidized Polyphenols, more particularly catechins 
[Graham, 1992; Mukhtar and Ahmad, 2000]. Green tea extract contains 85% 
polyphenols by weight. Composition of polyphenols in green tea extract used is 
shown as % total polyphenols (Zhong et al., 2003) (Fig. XXI). After harvesting, the 
leaves of the bush are steamed and dried to produce green tea leaves. In green tea 
leaves, the following polyphenolic compounds are found: 
(a) (-)-epigallocatechin-3-gallate (EGCG): major component. 
(b) (-)-epicatechin (EC), 
(c) (-)-epigalIocatechin (EGC) and 
(d) (-)-epicatechin-3-galIate (ECG) 
Note: (b). (c) and (d) are present in green tea at lower levels [Graham, 1992; Mukhtar 
and Ahmad. 2000]. ECG has been reported to stimulate osteoblast differentiation 
through a transcriptional activation [Byun et al., 2014]. 
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Figure XXI: Molecular structures of C. sinenesis polyphenols (Zhong et at., 
2003). 
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Figure XXII: Structure of Epigallocatechin-3-gallate (EGCG), source 
http://en.wikipedia.org/w iki/File:Epigallocatechin_gallate_structure.svg 
1.10.2.1.1 Epigallocatechin gallate (EGCG) 
Epigallocatechin-3-gallate (EGCG) is the ester of epigallocatechin and gallic acid, 
and is a type of catechin. EGCG is the most abundant catechin in tea and is a 
potent antioxidant that may have therapeutic applications in the treatment of many 
disorders. EGCG accounts for more than 50% of the total of catechins [Nagai et al., 
2006]. EGCG, a green tea polyphenol has been reported to exert potent anti-oxidant 
and anti-inflammatory effects by inhibiting signaling and gene expression (Yang et 
al., 2014]. 
1.10.2.1.2 EGCG and Osteoporosis 
EGCG has the physiological role in the induction of osteoclast cell death [Nakagawa 
et al.. 2002: Yun cat al., 2007] and mineralization of osteoblasts [Takita et al., 2002; 
Vali et al., 2007]. EGCG is found to reduce the generation of TRAP positive 
multinucleated cells, hone resorption activity, and osteoclast-specific gene expression 
without affecting cell viability [Morinohu et al., 2008]. EGCG down-regulated 
expression of nuclear factor of activated T cells c 1 (NF-ATc 1), but not of NF-KB, c- 
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Fos, and c-Jun, suggesting that down regulation of NF-ATcl is one of the molecular 
bases of EGCG action [Morinobu et aL, 20081. EGCG is found to suppress osteoclast 
differentiation and ameliorated experimental arthritis in mice over the short term 
[Morinobu et al., 20081. The inhibitory effect of EGCG to ostcoclastogenesis has 
been reported to he associated with a down regulation of RANKL/RANK signal, and 
increased apoptosis of preosteoclasts [Zhao ci al., 2014]. Mali et at has reported 
EGCG at a low concentration can slightly enhance the osteogenic effect in vivo, 
whereas at a higher concentration it can prevent the osteogenic differentiation of 
human alveolar bone-derived cells (hABCs) both in vitro and in vivo [Mah et al, 
2014]. 
1.10.2.1.3 Effect of Higher Temperature 
In a high temperature environment, an epimerization change is more likely to occur. 
As exposure to boiling water for 30 straight minutes leads to only a 12.4% reduction 
in the total amount of EGCG, the amount lost in a brief exposure is insignificant. 
Even when special conditions were used to create temperatures well above that of 
boiling water, the amount lost increased only slightly [Wang et at., 2008]. Depending 
on brew time and temperature, a single cup of green tea may contain 100-200 mg 
EGCG. To control the dose of FGCG administered in experimental studies, green tea 
solids (GTS) or capsules of green tea extract standardized to EGCG content are often 
employed [McKay and Blumberg, 2007). 
1.10.1.2 Black Tea 
About 78% of the consumed tea is black tea, a popular drink in many Western 
countries, which contains mainly oxidized Polyphenol [Graham. 1992; Mukluar and 
Ahmad, 2000]. If the leaves are left to ferment, the leaves are used for black tea. 
During black tea production, the catechins are converted to theaflavins and 
thearubigins [Lorenz and Urban, 2009]. In black tea, the polymerized catechins, 
theaflavins (TF) and thearubigins are found predominately [MeKay and Blumberg, 
20071. 
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1.10.2.3 On/wig Tea 
The leaves used for oolong tea are only partially fermented [McKay and Blumberg, 
2007]. 
1.10.2.4 White Tea 
White tea is made from unopened buds that are fired or steamed belbre drying, and, 
like green tea leaves, are not subjected to fermentation [McKay and Blumberg, 2007]. 
1.10.3 Role of Fermentation 
The fermentation is done via the action of Polyphenol oxidase and pemxidase. The 
fermentation process forms catechin oligners and high molecular weight complexes 
of catechins with proteins, caffeine or other leaf ingredients. Post-harvest 
fermentation alters the relative catechin content of the leaves [McKay and Blumberg, 
2007]. 
1.10.4 Biosynthesis of Tea Flavonoids 
The key enzymes in the biosynthesis of tea flavonoids appear to be 
(a) 5-dehydroshikimatereductase 
(b) phenylalaninc ammonia lyase and 
(c) Those associated with the shikimate'arogenate pathway [Balentine et al., 
1998]. 
1.11 Resveratro( (3, 5, 4'-trihydroxy-trans-stilbene) 
Resveratrol (RES. 3, 5, 4'-trihydroxy-trans-stilbene) is a stilbenoid, a type of natural 
phenol, and a phytoalexin produced naturally by several plants including grapes 
[Zivna et al., 2013], mulberries, cranberries, and peanuts when under attack by 
pathogens such as bacteria or fungi [Melchior and Kindl, 1990; Rayalam el al., 2011; 
Li er al., 2011, Wang et at. 2013]. Its relatively supple molecular structure enables 
free radicals overproduced in disease conditions to be scavenged and the redox 
signaling pathways of the cells to be regulated I Kelkel el a1., 2010]. 
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Figure XXIII: Skeletal Formula of tans-resveratrol, source 
http://en.wikipedia.org/wiki/ File:Resveratrol.svg 
Properties 
Resveratrol is a powerful phytoestrogen [Zivna at al., 2013]. The molecule 
demonstrated wide variety of beneficial effects in cardiovascular diseases, cancers, 
diabetes, and neurodegenerative disorders [Yu et al., 2012]. Resveratrol is reported to 
display antitumor activities on a variety of human cancer cells [Boissy etal., 2005]. It 
is an orally active phytochemical that has many beneficial actions in a variety of 
animal disease models [Rayalam et at, 20111. Resveratrol was found to be one of the 
most active of Polyphenols that directly or indirectly stimulate Sir2 activity (Silent 
Information Regulator, sirtuin protein) in yeast [Howitz et al., 2003]. The increased 
NAT) concentrations stimulate the activity of Sir2. Sir2, the mammalian homologue of 
which is known as Sirtl, a NAD~ dependent protein dcacetylase, and has been 
demonstrated to mimic estrogen [He at al., 2010], was shown to modify several 
proteins that are involved in cellular processes affecting longevity [Rayalam et at., 
2011]. It was shown that adding additional copies of the gene coding for the 
production of Sir2 increased the Zile span of yeast and Caenorliubdius elegans 
[Kaeberlein et al., 1999; Tissenbaum and Guarente, 200l] 
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1.11.1 'The French Paradox' 
Frenchmen suffer a relatively low incidence of coronary heart disease, despite having 
a diet relatively rich in saturated tats. The Frenchman's high red wine consumption is 
a primary factor for the trend. One of the components of red wine potentially related 
to this effect is resveratrol [Rayalam ct al., 20111. 
1. 11.2 Resveratrol and osteoporosis 
Some natural flavonoids with potent antioxidant activity including scopoletin, 
resveratrol. and baicalein have found to exert antiosteoporotic activities through 
suppressing osteoclast formation and TRAP [Morgan et al., 2014]. The bone 
protective effects of resveratrol have been demonstrated in several osteoporosis 
models while the underlying mechanism is largely unclear [He et al., 2010]. 
Resveratrol may inhibit the differentiation and bone resorbing activity of osteoclasts 
and promote the formation of osteoblasts from mesenchy nal precursors in vitro 
[Kupisiewicz et al., 20111; Zivna et al., 2013]. Resveratrol is found to increase 
osteoclastic and decreased osteoblastic activities resulting in bone resorption and loss 
of bone mass [Shakibaei et al., 2011; Zivna et al., 2013]. It is known to increase DNA 
synthesis and ALP activity in osteoblasts and to prevent femoral bone loss in 
ovariectomized (OVX) rats [Li et al., 2011]. The incorporation of resveratrol is found 
to cause increased ALP activity of rat bone marrow stromal cells and enhanced 
mincralization of the cell-scaffold composites in vitro [Li et al., 2011]. Resveratrol is 
a naturally occurring phytoestrogen possesses bone-protective effects by antagonizing 
adipogenesis [Tseng et al.. 2011]. Resveratrol promotes osteogenesis of human 
mesenchymal stem cells (hMSCc) by up regulating RUNX2 gene expression via the 
SIRT I /FOXO3A axis as a novel mechanism [Tseng et al.. 20111. RES has protective 
effects on multiple events associated with osteoporosis. Treatment with RES delayed 
age-related bone loss in rats and mice [Pearson et al., 2008] and protected against 
hone loss induced by estrogen deficiency [Liu et al., 2005]. Chronic RES 
supplementation maintained the BMD and strength of the femur of rat hind limb 
unloading [Momken et al.. 201 1 ]. Prior treatment with RES preserved density and 
structure of rat long bones under tail-suspension [I labold et cil.. 201 1 ]. Resveratrol at 
non-toxic concentrations dose-dependently inhibited RANKL-induced osteoclast 
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differentiation and induced apoptosis of murine osteoclast progenitor RAW 264.7 
cells [He et al., 2010]. In cultures of human primary monocytes, resveratrol inhibits 
dose-dependently RANKL—induced formation of TRACP—positive multinucicated 
cells, TRACP activity in the medium, up regulation of CTSK gene expression, and 
bone resorption [Boissy et n!., 20053. Resveratrol promotes dose dependently the 
expression of osteoblast markers like OCN and OPN in human bone marrow 
mesenchymal stem cells (hMSC-TERT) and stimulates their response to 1.25(OH)2 
vitamin D3 [1,25(OH)2D3] [Boissy er aL, 20051. Resveratrol up-regulates dose-
dependently the expression of 1,25(01-1)21)3 nuclear receptor [6oissy or al., 20053. 
Rcsveratrol is found to suppress RANKL-induced ROS generation in a concentration 
dependent manner. The direct inhibitory effects of resveratrol on osteoclastogenesis 
induced by RANKL in several cell models [Lin el al., 2013], are mediated via 
inhibition of ROS generation [He et al., 2010.] Resveratrol at non-toxic 
concentrations dose-dependently is found to inhibit the formation of osteoclasts and 
the activation of TRAP [Lin et al., 2013]. Rcsveratrol might inhibit the differentiation 
of RAW264.7 cells into osteoclasts and decrease osteoclast activation possibly via 
suppressing monocytes to differentiate preosteoclasts [Lin etal., 2013]. 
1.12 Garlic 
Garlic (All/urn .sari rum I..) is one of the plants that were seriously investigated over 
several years and used for centuries to fight infectious diseases [Onyeagba etal., 
2004; Gebreyohannes and Gebreychannes, 2013]. Garlic is nicknamed as Russian 
penicillin for its widespread use as a topical and systemic antimicrobial agent; it is 
commonly used in many cultures as an excitement and reputation of healing power 
[Timbo etal., 2006]. 
1.12.1 Constituents of Garlic 
Garlic contains at least 33 sulfur compounds, several enzymes and the minerals 
germanium, calcium, copper, iron, potassium, magnesium, selenium and zinc; 
vitamins A, BI and C, fiber and water. It also contains 17 amino acids to be found in 
garlic: lysine, histidine, arginine, aspartic acid threonine, swine, glutamine, praline, 
glycine, alanine, cysteine, valine, methionine. isoleucine, leucine, tryptophan and 
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phenylalanine [Josling, 2005]. Whole garlic and aged garlic extract exhibit direct 
antioxidant effects and enhance the scrum levels of two antioxidant enzymes, catalase 
and GPx [Prasad et o!_, 1995] 
1.12.2 Allicin 
Allicin (diallyl thiosulfinate or diallyldisulfide) is one of the most biologically active 
compounds in garlic. Alliin (S-allylcysteine sulfoxide) is the most abundant sulfur 
compound in garlic. It is present at 10 and 30 mg/g in fresh and dry garlic, 
respectively [Lawson., 1998]. Allicin is garlic's defense mechanism against attacks by 
pests. Allicin is an organosulfur compound obtained from garlic, a species in the 
familyAlliaceae [Block, 1985]. Allicin is efficiently scavenged exogenously 
generated hydroxyl radicals in a dose dependent fashion, but their effectiveness was 
reduced about 10% by heating to 100 °C for 20 min [Gebreyohannes and 
Gebreyohannes, 2013]. 
1.12.2.1 Structure of A lficin 
Allicin features the thiosulfinate functional group, R-S-(0)-S-R. The compound is not 
present in garlic unless tissue damage occurs. Typical garlic food preparation such as 
chopping, mincing and crushing disturbs S-allyl cysteine sulfoxidc and exposed it to 
the allinase enzymes, then quickly converted it to diallyl thiosulfinate, which give off 
garlic's characteristic aroma. The allinase enzyme responsible for diallyl thiosulfanate 
conversion becomes inactivated below a pH of 3.5 or with heating [Block, 1985; 
Pedrazza-Chaverri et al., 20061. Allicin is chiral but occurs naturally only as 
a racemate [Block, 2010]. The racemic form can also be generated by oxidation 
of diallyl disulfide [Cretnit'n, 19961. 
(SCH2CH=C112)2 f RCO3H , CH2'CHCH2S(0)SCII2CH=CH; + RCO.H 
Alliinase is irreversibly deactivated below pH 3. Allicin is generally not produced in 
the body from the consumption of fresh or powdered garlic [Brodnitz et aL, 1971; Yu 
and Wu, t989]. Allicin can he unstable, breaking down within 16 hat 23 °C [Hahn, 
19961. 
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Figure 	XXIV: 	Skeletal 	Formula 	of 	(R)-allicin, 	Source: 
http://en.wikipedia.org/wiki/ File:R-allicin-2D-skeIetaI.png 
1.13 Turmeric 
Turmeric is the popular South Asian dietary spice, which is a member of the ginger 
family (Zingiberaceae). 
1.13.1 Curcurninoids 
Turmeric has three curcuminoids: 
(a) Curcumin 
(b) Desmethoxycurcumin 
(c) bis-desmethoxycurcumin 
The curcuminoids are natural phenols that are responsible for the yellow color of 
turmeric. 
1.13.2 Curcumin 
Curcumin [1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-hepadiene-3,5-dion or 
difemloylmethane] is a hydrophobic polyphenolic compound or pigment derived from 
turmeric [Kolev et at, 2005]. Curcumin is known to be powerful antioxidant [Moon 
et aL, 20121. The antioxidant activity of curcurnin arises from scavenging of several 
biologically free radicals that are produced during physiological processes and 
possesses several pharmacological effects including anti-inflammatory, antioxidant, 
antiproliferative, and antiangiogenic activities [Aggarwal et at, 2003]. Curcutnin is 
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the principal curcuminoid of Turmeric. Curcumin can exist in several 
tautomeric forms, including a 1.3-diketo form and two equivalent enol forms. The 
main drawback associated with the therapeutic potential of curcumin is its poor 
aqueous solubility and stability, which leads to poor bioavailability [Aggarwal et al., 
2003]. The cool fort is more energetically stable in the solid phase and in solution 
[Kelev et al., 2005]. 
CH3 	0 OH 	CH, 
Figure XXV (a): Structure of Curcumin ([no! Form), source 
http://en.wikipedia.org/ rvikiiFile:Curcumin.svg 
Ho 	 .~ OH 
Q L> 0 
CHs 	C 0 	Chi 
Figure XXV (h): Structure of Curcumin (Keto Form), source 
bttp:/Jen.Nvikipedia.org/ wiki/File:CurcuminKeto.svg 
Li 3.3 Curcumin and Osteoporosis 
Curcumin is a potent inhibitor of the transcriptional factors activator protein-I and 
NE-KB [Ozaki et at, 2000]. Curcumin is found to be a potent stimulator of apoptosis 
process in rabbit osteoclasts, as evidenced by morphological changes in nuclei and 
DNA fragmentation as criteria of apoptosis, in a dose-and treatment tine-dependent 
manner [Ozaki et al., 2000]. Curcumin is found to have the ability to suppress 
RANKI. signaling and osteoclastogenesis in RAW 264.7 cells, a murine monocytic 
cell line [Bharti eta?., 2004]. Curcumin is found to inhibit the pathway leading from 
activation of IKBa kinase and IcBa phosphorylation to IKBa degradation [Bharti et 
al., 2004]. RANKL is found to induce osteoclastogenesis in these monocytic cells, 
and curcumin is found to inhibit both RANKL- and TNF-induced osteoclastogenesis 
and pit formation [Bharti et at, 2004]. Curcumin suppressed osteoclastogenesis 
maximally when added together with RANKL and minimally when it was added 2 
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days after RANKL [Rharti et al.. 20047. Curcumin is found to markedly inhibit the 
formation of TRAP-positive multinucleated cells in both bone marrow-derived 
monocytes (BMMs) and RAW 264.7 cells [Moon et at, 2012]. Curcumin is found to 
scavenge intracellular ROS generation within osteoclast precursors during RANKL-
stimulated osteoclastogenesis [Moon et al., 2012]. Curcumin is also found to 
significantly suppress the gene expression of NFATcl, TRAP, and osteoclast-
associated immunoglobulin-like receptor (OSCAR), which are genetic markers of 
osteoclast differentiation in a dose-dependent manner [Moon et al., 2012]. Curcumin 
is found to display the highest inhibitory effect on osteoclast differentiation when 
concentrations were held constant [Moon ci al., 2012]. Curcumin together with 
CoQl0 and selenite, is found to act as inhibitor of RANKL-induced NFATcI through 
suppression of ROS generation, suggesting the potential usefulness for the treatment 
of bone disease associated with excessive hone resorption [Moon et al.. 2012]. Most 
recently, curcumin has been reported to inhibit prostate cancer bone metastasis by up-
regulating bone morphogenic protein-7 (BMP-7) in v iro [Dorai et aL, 2014]. 
Therefore, in view of the above, there is an immediate need to develop new 
cost-effective therapeutic strategies against osteoporosis which will help in improved 
survival as well as in combating the increase in the age-specific fracture rates. Thus, 
in the present study, resveratrol. cureumin as well as allicin from garlic were 
employed as valuable natural antioxidants / natural tools in order to investigate the 
above, which in turn. may prove beneficial in the management of osteoporosis. 
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MATERIALS AND METHODS 
2.1 Materials 
Anti-human IgG alkaline phosphate conjugate, bovine serum albumin (BSA), 
calcitonin (CT), chloroform (CHCh), Coomassie Brilliant Blue G-250 and R-250, 
dithiothreiotol (DTI'), epigallocatechin-3-gallate (EGCG), ethidium bromide (EtBr), 
isoamyl alcohol. monoclonal anti-TNF-u antibody., phenylmethylsulphonyl fluoride 
(PMSF), p-nitrophcnyl phosphate (pNPP), recombinant human (rh) TNF-n, reduced 
glutathione (GSH) and glutathione reductase (GR) and SN50 (an inhibitor of NF-KB) 
and its analogue SN50/M, sodium azide (NaN3), soluble N-acetyl-cysteine, Hydrogen 
peroxide (H2O,), standard protein markers and tween-20 were from Sigma Chemical 
Company, U.S.A. SN50 is a hybrid peptide containing nuclear localization sequence 
of p50 subunit of NF-KB heterodimer and has been shown to completely inhibit the 
translocation of NF-icB in human cell lines at 100 pg/ml [Lin et al., 1995]. 
Resveratrol and Curcumin were also of Sigma Chemical Company. U.S.A., whereas 
Allicin was obtained from LKT Laboratories, Inc. U.S.A. Fieoll-Payue was from 
Pharmacia, Piscataway. NJ, U.S.A. RPMI-1640 and a-MEM medium were from 
HiMedia, India. MTT cell viability assay kit and immunoassay kits for Osteopontin 
and TNF-a were from R & D Systems, U.S.A., and that for soluble RANKL was of 
Enzo life Sciences, U.S.A. Furthermore, I2-wells tissue culture plates were obtained 
from Techno Plastic Products (TPP), Switzerland. Polystyrene microtitre flat bottom 
ELISA plates having 96 wells (7 mm diameter) were from NUNC, Denmark. All 
other chemicals were of the highest analytical grade available. 
2.1.1 Study subjects: 
Venous blood was obtained from healthy volunteers of both sexes (n=30) with no 
history of osteoporosis. Also, blood from patients with osteoporosis (n=50) was 
obtained From the patients attending I.N. Medical College Hospital of A.M.U. Serum 
was separated and stored at --20 °C until required. The study had clearance from the 
Institutional Ethical Committee. 
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2.2 Methodology  
2.2.1 Determination ofprotein concentration: 
Protein was estimated by the methods of Lowry and Bradford ILowry et al., 1951; 
Bradford, 19761. 
2.2.1.1 Protein estimation by the Lowy (Folio-Cioeaireat) utethod: 
Protein estimation by this method involves complexing of the protein's peptide bonds 
with Cu'- under alkaline conditions (Lowry et al, 1951]. The resultant Cu appears 
to catalyze the oxidation of tyrosine and tryptophan residues by reducing 
phosphomolybdotungstate anions in the Polin reagent (a mixture of sodium tungstate, 
molybdate and phosphate), added subsequently. This reaction develops a blue color 
due to the formation of heteropolymolybdenum blue, which can be quantified by its 
absorbance at 660 urn. 
2.2.1.1.1 Reagents: 
1.2.1.1.1.1 Folio-Ciocalteau Reagent 
The reagent was diluted 1:4 with distilled water before use. 
2.2.11 L2 Alkaline Copper Reagent 
The components of alkaline copper reagent were prepared as follow,: 
(a) 2% sodium carbonate in 100 mM NaOH 
(b) 0.5% copper sulphate in 1% sodium potassium tartrate 
The working reagent was prepared fresh before use by mixing the two components in 
the ratio 50:1, respectively. 
2.2.1.1.2 Procedure: 
To 1.0 nil of protein sample was added 5.0 ml of freshly prepared alkaline copper 
reagent. After thorough mixing, the reaction mixture was allowed to stand at room 
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temperature for 10 minutes, followed by the addition of 1.0 ml of 1:4 times diluted 
Folin-Ciocatteau reagent. The contents were mixed immediately. The reaction was 
allowed to proceed for 30 minutes at room temperature and each tube was 
subsequently monitored at 660 nm. The protein content of the unknown sample was 
determined by using bovine serum albumin to construct a standard calibration curve. 
2.2.1.2 Protein estimation by the Bradford method: 
This method is based on strong binding of the dye Coomassie Brilliant Blue G-250, 
in acidic medium, to protein hydrophobically and at positively charged groups 
(Bradford, 19761. In the environment of these positively charged groups, 
protonation is suppressed and a blue color develops (X-595 not). 
2.2.1.2.1 Preparation of dye: 
100 mg of Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% ethanol 
and 100 ml of 85% (v. v) orthophosphoric acid was added. The resulting solution was 
diluted to a final volume of 1.0 liter and filtered through Whatman No. I filter paper 
to remove undissolved particles. 
2.1.1.2.2 Procedure: 
To 1.0 ml of solution containing 10-100 µg protein was added 5.0 ml of dye solution. 
The contents were mixed thoroughly by vortexing. The absorbance was read at 595 
nm after 5 minutes against a reagent blank. 
2.2.2 Polyacrylanride gel electrophoresis of proteins: 
Polyacrylamide gel electrophoresis was performed under denaturing conditions as 
described by Laemnili [Laemmli, 1970]. 
2.2.2.! Reagents: 
2.2.2.1.1 Acrylnmide-Bisacrylamide (30:0.8) 
A stock solution of 30% acrylamide containing 0.8"% bisacrylamide was prepared by 
dissolving 30 gin of acrylamide and 0.8 girt of bisacrylarnide in a total volume of 100 
ml. The solution was stored at 4°C in an amber colored bottle. 
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2.2.21.2 Resolving Gel Buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48 ml of I N HCl. 
The contents were mixed, pH adjusted to 8.8 and the final volume brought to 100 ml 
with distilled water. 
2.2.2.1.3 Stacking Ge! Buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH adjusted to 6.8 with I N 
HCI and the final volume adjusted to 100 ml with distilled water. 
1.1.2.1.4 Electrode Buffer 
3.03 gin Tris, 14.4 gm glycinc and 1.0 gm SDS were dissolved in distilled water, pH 
adjusted to 8.3 and the final volume made up to 1.0 liter with distilled water. 
2.1.1.1.5 .Sample Buffer 
(a) 6.0 gm of Tris was dissolved in 80 ml distilled water and p11 adjusted to 6.8 
with phosphoric acid. The final volume was brought to 100 nil with distilled 
water. 
(b) 1.0 mg of bromophenol blue and 12.5 ml of glycerol were added to 12.5 ml of 
the above solution. p-mercaptocthanol was added just before use. 
2.2.2.2 Recipe for 10-20% Gradient Gel 
Table 4: Resolving Gel (total volume: 30 ml). 
Reagents J 20% 
Acrylanride-bisacrylamide (30:0.8) 5.0 ml 10 ml 
Resolving gel buffer 3.8 ml 3.8 ml 
10% SDS I50 µI 150 µl 
10% Ammonium persulphate 50 µl 50 µl 
TEMED 10 NI 10 pl 
the final volume was raised to 15 ml each with distilled water. 
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Table 5: 2.5 % Stacking Gel (total volume: 10 ml). 
Acrylamide-bisacrylamide (30:0.8) 0.8 ml 
Stacking gel buffer 25 ml 
10% SDS 100 µl 
10% Ammonium persulphate 75 pl 
TEMED 25 Ill 
The final volume was raised to I Urn! with distilled water. 
Table 6: Recipe for 7.5% SDS-PAGE (total volume: 10 ml). 
Acrylamide-bisacrylamide (30:0.8) 2.5 not 
Resolving gel buffer 2.5 ml 
10% SDS 100 pl 
10% Ammonium persulphate 50 µl 
TEMED l0 µl 
The final volume was raised to 10 ml with distilled water. 
2.2.2.2 Procedure: 
The glass plates (I8 cm * 16 cm) were soaked in chromic acid and thoroughly washed 
with tap water followed by a final rinse with distilled water and ethanol. The plates 
were dried and sealed with I% agarose and 1.5 mm thick spacers. The reagents were 
mixed and poured between the glass plates. The resolving gel was allowed to 
polymerize at room temperature, following which, the stacking gel was layered on 
top. A well-fbnning comb was inserted immediately and the gel was left to 
polymerize at room temperature. in case of gradient gels, a gradient of resolving gel 
was formed with the help of a gradient former (Bio-Rad, model 385). After ensuring 
complete polymerization, the protein samples (25-100 µg) in one-fourth volume of 
sample buffer were electrophoresed at 80 volts at room temperature. The gels were 
stained using 0.25% Coomassie Brilliant Blue R-250 or with silver stain reagent. 
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1.2.2.4 Silver staining: 
Silver staining was done by the method of Merril [Merril et al., 1983]. Briefly, the get 
was incubated in 40% methanol and 12% acetic acid for 45 minutes followed by 
incubation in 50% ethanol for 30 minutes. Next the gel was treated with 0.02% hypo 
(sodium thiosulpliatc) for l minute. After washing with distilled water, the gel was 
placed in 0.2% silver nitrate (with 0.05% v/v formaldehyde). washed again with 
distilled water, and transferred to a 6%i6 solution of sodium carbonate (with 0.05% vv 
formaldehyde). After color development, the gel was washed with distilled water and 
the reaction was arrested by treating the gel with 3% v/v acetic acid and 5% v/v 
methanol. Al! the reagents used in this procedure were freshly prepared. 
2.2.3 Preparation of RPMF-1640 medium: 
Dehydrated RPMI-1640 medium of one unit vial (16.3 gm) was suspended in 950 ml 
of tissue culture-grade water at room temperature with constant, gentle stirring until 
the medium was completely dissolved. The container was rinsed with tissue culture 
grade water to remove all traces of powder and added to the above solution. 3.7 gm 
sodium bicarbonate was added to the medium and stirred until dissolved. The final 
volume was brought to 1000 ml with tissue culture grade water. The medium was 
sterilized immediately by filtering through a sterile membrane filter with a porosity of 
0.22 micron using positive pressure rather than vacuum to minimize the toss of carbon 
dioxide, and stored at 4 °C till use. 
2.2.4 Preparation of PBMNC: 
Step 1: In order to isolate peripheral blood mononuclear cells (PHMCs). 30 ml of 
blood was drawn from a healthy volunteer and patients into 60 cm3 syringes 
containing 3.8 units heparin/ml. Prior consent was taken from such donors. 
The heparinized blood, in 15 ml aliquots, was transferred to sterile 50 ml 
polypropylene centrifuge tubes and diluted 1:1 with sterile 10 mM, PBS, pH 
7.4 at room temperature, followed by gentle mixing by inverting the tube a 
few times. 
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Step 2: Diluted blood was under layered with 15 ml of Ficoll-Paque at room 
temperature using an I S gauge spinal needle. Care was taken to prevent mixing 
of the layers. The gradient was centrifuged at 1800 rpm for 30 minutes at room 
temperature with the centrifuge brake turned off. 
Step 3: Using a sterile pipette, the upper clear layer containing plasma was removed. 
The PBMCs appeared as a dense white band (buffy layer) above the red blood 
cells and granulocytes layer. This was removed with another sterile pipette. 
The banded cells were combined in 10 ml aliquots. 
Step 4: Ten milliliters of banded PBMCs were diluted with 25 ml of PBS in sterile 50 
ml polypropylene centrifuge tubes and centrifuged at 1100 rpm for 12 minutes 
at room temperature to remove platelets, which remain in the supernatant. The 
PBMC pellets were combined to four tubes, diluted in 30 ml PBS and 
centrifuged at 1100 rpm for 10 minutes at room temperature. This wash was 
repeated. 
Step 5: The pellets were then combined and resuspended in 30 ml complete medium 
(CM) (RPMI-1640 medium containing 2 M L-glutamine, 25 mM HEPES, and 
no antibiotics). An aliquot was diluted 20-fold and counted using a 
hemocytometer under a light microscope using 10 x ocular and 40 x 
objectives. 
2.2.5 Preparation of autologous serum for monncyte culture: 
From the same donor, 30 ml of blood was drawn without anticoagulant and 
transferred to serum separator tubes. The blood was allowed to clot for at least 30 
minutes, then centrifuged at 3000 rpm for 15 minutes at room temperature and the 
serum filtered through a sterile 0.22 µm filter unit, Autologuus serum can be stored 
for a year or longer at —20°C. 
2.2.6 Assay for Cellular Glutathione (GSH) Content 
Glutathione was measured according to the method described by Anderson 
[Anderson, 19853. Adherent monocytes obtained from PBMCs of healthy and 
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osteoporosis patients, treated with Allicnt/ Resveratrol /Curcumin, were collected 
(600 g, 7 min, 4°C) and washed with PBS. After protein precipitation with 5% 
metaphosphoric acid (0.2-0.3 ml/5x106  cells) by centrifugation (10,000g, for 30 min), 
the supernatant was used for GSH quantization, and the pellet, dissolved in 0.2- 0.3 nil 
of 0.5 M NaOH, was used for protein determination. Samples (40 till were neutralized 
with 2 M tricthanolamine (10 µl) in a U6-well plate. The reaction was started by 
adding 200 at per well of 0.4 U!ml Glutathione reductase enzyme in 143 mM 
phosphate buffer pH 7.5 containing 0.3 rnM reduced nicotinamide adenine 
dinucleofide phosphate, 0.6 mM DTNB and 6.25 mM EDTA. The initial rate of 5-
thio-2-nitrobenzoic acid fomtation was monitored. Similarly, effect of pretreatment of 
BSO (100 tM, 24 h) on the GSH content of monocytes from PBMCs, treated with or 
without Allicin/Resveratrol/Curcumin, was also determined. 
2.2.6.1 Assay for Ghrtathione Peroxidase (GP.vi activity: 
The activity of GPx was measured as described elsewhere [Mohandas et at, 1984; 
Mates etal., 1999]. The oxidized glulathione (GSSG) produced during GPx reaction 
was immediately reduced by NADPH and glutathione reductasc. Therefore, the rate 
of NADPH consumption was regarded as the rate of GSSG formation during the GPx 
reaction. Monocytes from healthy donors and patients with osteoporosis were co-
cultured for 24 hours with or without 10 mM NAC, 100 .tg(ml SN50, 100 gglml 
SNSO/M and 0-500 ng/ml allicin. Thereafter, cells were gently scraped with lysis 
buffer containing protease inhibitors (50 mM Trig/HO, pH 7.4; 1 mM EDTA; 500 
mM PMSF). Protein concentrations of supernatants were determined by the method of 
Bradford with BSA as the standard, and were subjected to GPx activity determination. 
The reaction mixture (1.0 ml) containing 50 mM potassium phosphate (pH 7.0), 1 
mM sodium azide, 2 mM GSH, 0.2 mM NADPH, I unit/ml glutathione reductase, 1.5 
mM cumene hydroperoxide, and 2100 µl of samples were incubated at 25 °C for 5 
minutes. The reaction was initiated by the addition of cumene hydroperoxide. The 
kinetic change was spectrophotometrically recorded at 3 40 urn (37 °C) for 3 minutes. 
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GPx activity was calculated after subtraction of the blank value, as umol of NADPH 
oxidized•minute/mg protein (U/mg protein). 
2.2.7 Determination of ltalondialdelzyde (1'IDd) Levels: 
Determination of MDA levels were carried out as described by Kaur et at [Kaur et 
al., 2012]. The lipid peroxide levels in treated/untreated monocyte cultures in healthy 
subjects as well as patients were measured by precipitating the lipoproteins with 
trichloroacetic acid and boiling them with thiobarbitwic acid, which reacted with 
malondialdehyde to form a pink color, as per the 'Kei Satoh' method [Satoh, 1978]. 
The resulting chronrogen was extracted with n-butyl alcohol and the absorbance of the 
organic phase was determined at the wavelength of 530tun. The determined values 
were expressed in terms of malondialdehyde in nmol%ml. 
2.2.8 Cell culture: 
PBMCs (5x106 cells/well) were added in 12-wells tissue culture plates in complete 
RPMI-1640 medium, and were subsequently incubated at 37°C, 5% CO, for 1-2 
hours for adherence. Thereafter, non-adherent cells were removed by washing the 
plates extensively 4 dines with RPMI-1640 medium. The adherent monocytes were 
cultured in RPMI-1640 supplemented with 2% autologous serum, followed by 
overnight testing at 37°C, 5% CO,. This population of adherent cells is up to 95% 
monocytes. as observed by cytostaining and is 99% viable [Toossi et al., 1996]. Prior 
to treatment with supplements./compounds, the plates were washed twice with RPMI-
1640 medium. 
2.2.9 Treatment with Allicitr / Resveratrol / Curcumin and monocytes viability 
assay: 
The effect of allicin (0--500 ng/ml), Resveratrol (0-20 µg/ml) and Curcumin (0-20 
µg ml) on the viability of monocytes as assessed by using MTT Cell Viability Assay 
Kit (R & D Systems) according to the manufacturer's instructions provided. 
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Table 7: Reagents supplied in the 11TT cell viability assay kit. 	 ._ 
Component 	 Quantity 	 Storage conditions 
MTT reagent  	25 ml 	 2 - 8°C— 
Detergent reagent 	X250 ml 	 18 — 24`C 
2.2.9.1 Assay Procedure: 
Adherent monocytes from healthy donors and patients with osteoporosis were gently 
scraped with RPMI-1640 medium. After this, monocytes (3 * 10{ cells well in 100 
41) were added in 96-well tissue culture plates. Cells were incubated in RPMI-1640 
with 2% autologous serum containing allicin (0-1000 ng/ml) resveratrol and curcumin 
(0-50 pg/ml) respectively for 24 hours at 37°C, 5% CO,. After 24 hours, 10 MI of M7T 
reagent (3-[4, 5-dimethylthiazol-2-ylJ-2, 5-diphenylretrazolimn bromide) was added to 
each well and incubation was continued for an additional two hours. When a purple 
precipitate was clearly visible under the microscope, 100 pI of detergent reagent was 
added to all wells, including control wells and incubated for two hours in the dark at 
20°C. After incubation, the precipitate was solubilized and the absorbance of the 
resulting solution was measured at 570 nm using a micro plate reader. Control cells 
were treated exactly the same except that no allichtresveratrol/cureumin was added to 
the wells. The percentage of viable cells was calculated by the formula as described by 
[Islam etal., 20001 and the results are expressed as "Viable cells (% of control cells)". 
Absorbance of control cells Viable nionocytes (% of control cells) = 	- 	x100 
Absorbanceof treated cells 
2.2.10 Trypan Blue Exclusion Assay for Alonoeytes Viability: 
Adherent monocytes were gently scraped with RPMI-1640 medium. Trypan blue 
suspension (1.6 mg/nil in saline solution) was added to the monocytes at a final 
concentration of 0.8 mg/ml. The cells were kept at 37°C for 7 minutes in a CO, 
chamber (5%), mounted on a hemocytometer and then observed under light 
microscjpe. The cells taking up Trypan blue (dead cells), and cells excluding the dye 
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(viable cells) were counted. Percentage of viable cells was calculated by the following 
formula: 
~, 	 Total viable cells (unstained) 
o cell viabilty= 	 x 100 
Total cells (stained + unstained) 
2.2.11 Culture Conditions For Human Osteoclastogeinesis Assays: 
Whole population of freshly isolated PBMNC was plated in 96-well plates at 6 { l05 
cells per well in 0.2 ml of medium (u-MEM. Gibco, pH 7.4, containing 101,-0 FCS 
from Amimed, batch -S03485). Medium was also supplemented with the following 
cytokines, growth factors and hormones: 25 ng ml human M-CSF (R&D Systems, 
Abingdon, UK), 50 ngml human RANKL (Insight Biotechnology, Wembley, UK), 5 
ng'ml human TGF-R1 (R&D Systems, Abingdon, UK), and I .tM dexamethasone 
(Sigma. Buchs, Switzerland). The cells were re-fed twice weekly by demi-depletion 
(half of the medium withdrawn and replaced with the fresh medium). The culture 
duration was 17 days for TRAP staining. 
2.2.12 Effect of .Natural antioxidants like Allicin from Garlic, Resveratrol, 
Curcruuiir and Epigallocatechin gal/ate (EGCG) on the generation of Osteoclasts 
from PB.1IC.s: 
To investigate the effect of natural antioxidants on osteoclast generation from 
PBMCs, varying doses of Allicin (0-500 ng/mI), Resveratrol (0-25 p.g/ml), Curcumin 
(0-25 g'ml) and EGCG from green tea (0-20 pg/ml) were added to the PBMC 
cultures seeded at a cell density of 2x105 cells.'cm2 in a 96-well plate in a 
osteoclastogenic medium as described above and incubated for 24 h (1 day), 72 h (3 
day) and 120 h (5 days) at 37°C in a humidified atmosphere of 5% CO2. Thereafter, 
the cells were analysed with TRAP staining. 
2.2.13 TRAP staining: quantification of'TRAP-positive titultinucleated cell. 
TRAP staining of adherent cultures was done with a kit from Sigma (Buchs, 
Switzerland) exactly according to manufacturer's instruction. The stained cells 
developed red color of different intensity. The numbers of TRAP-positive 
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multinucleated cells were determined using the 1 x 1-mm grid placed in the ocular of 
the microscope. For TRAP assay, Zeiss Axiovert 100 microscope (Zeiss, Oberkochen, 
Germany) was used. The number of TRAP-positive multinucleated cells (>2 nuclei 
per cell) was measured at predetermined sites of the area of I * I nim. Five sites were 
measured in a well of a 96-well plate, and a mean value was calculated. Four wells 
were measured in total per one condition and these results were expressed as mean f 
SEM. 
1.2.14 Determination of soluble R11NKL in fonocyte Culture Supentatauts: 
The concentration of sRANKL in various 3 days monocyte culture supernatants of 
osteoporosis patients was determined by use of a commercial ELISA Kit (Enzo Life 
Sciences). The reagents used were those supplied in the kit. 
2.2.14.) Reagents: 
1. Prior to use, allow all reagents and samples to come to room temperature and mix 
well 
2. One holder with precoated strips 12 x 8 wells 
3. Wash buffer concentrate 
4. SOL: OPG-Solution, ready-to-use 5.5 ml 
5. STD: Standard, concentrate 
6. CTRL:Control, ready-to-use 
7. AB: Detection antibody, biotinylated 
8. CONJ:Conjugate, streptavidia peroxidase-laheled 
9. SUB: TMB substrate (Tetramethylbenzidinc), ready-to-usc 
10. STOP: ELISA stop solution, ready-to-use 
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2.2.1.1.2.4ssat procedure: 
1. Prior to use, allow all reagents and samples to come to room temperature and 
mix well. 
2. Mark the positions of STD 'SAMPLE/CTRL (StandardstSample Control) in 
duplicate on a protocol sheet. 
3. Take microtitre strips out of the kit. Store unused strips covered at 2-8° C. 
Strips are stable until the expiry date stated on the label 
4. Wash 5 times by dispensing 250 p1 of diluted WASHBUF (Wash butler) into 
each well. After the final washing step remove residual buffer by tapping the 
plate on absorbent paper. 
5. Add 50 p1 of STD/SAMPLE,'CTRL (Standard'Sample"Control) in duplicate 
into respective well. Use the wash buffer as STD 0 pgiml. 
6. Add 50 pl SOI. (OPG-solution) into each well. 
7. Cover the plate tightly and incubate for I6 - 24 hours at 2 - 8 °C 
3. Discard the contents of each well. Wash 5 times by dispensing 250 µI of 
diluted WASHBUF (Wash buffer) into each well. After the final washing step 
remove residual butler by tapping the plate on absorbent paper. 
9. Add 100 pl detection antibody into each well. 
10. Cover the plate tightly and incubate for 2 hours at room temperature 
11. Discard the contents of each well. Wash 5 times by dispensing 250 µl of 
diluted WASIIBUF (Wash buffer) into each well. After the final washing step 
remove residual bufkcr by tapping the plate on absorbent paper 
12. Add 100 pl CON! (conjugate) into each well 
13. Cover the plate tightly and incubate for I hour at 2 - 8 °C 
14. Discard the contents of each well. Wash 5 times by dispensing 250 p1 of 
diluted \VASHBUF (Wash buffer) into each well. After the final washing step 
remove residual butler by tapping the plate on absorbent paper 
15. Add 100 pl of SUB (substrate) into each well 
16. Incubate for 20-30 minutes at room temperature (I 8-26°C) in the dark 
17. Add 50 pI of STOP (stop solution) into each well, mix thoroughly 
18. Determine absorption immediately with an ELI SA reader at 450 nm against 
621) nm (or 690 nm) as a reference. If no reference wavelength is available, 
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read only at 450 nrn. If the extinction of the highest standard exceeds the range 
of the photometer, absorption must be measured immrdiatcly at 4(I5 rim 
against 670 rim as a reference "I he sensitivity is 1.56 pg/ml. 
2.2.15 Deterprumtion of0weoponmho (ORV) in :Vonocl ,re Culture Superna/ants: 
The concentration of Osteepontin in various 3 days monocvte culture supernatants of 
osteoporosis patients was determined by use of a commercial ELISA Kit (R & D 
Systems). 
2.2.15.1 Reagents supplied in the kit: 
Assay Diluent R1)1-6: I n[/vial or  buffered protein base with preservatives. May 
contain a precipitate. Mix well before and during use. 
Calibrator Diluent RI)5-24: 21 m[Jvia of a buffered protein base with 
preservatives. 
Color Reagent A: 121nUvial ofstabilized hydrogen peroxide. 
Culor Reagent B: 12 rnL/xia] of stabilized chromogcn (lcuamethylueazidise). 
OPN Conjugate: 21 mLivial of a polyclonal antibody against OPN cumupatsd to 
purse adisl peroxidase with preservatives. 
OPN Micro plate: 96 well polystyrene micrnplate (12 strips of 8 wells) coaled with 
a mouse monoclonal antibody against OPN. 
OPN Standard: 200 ng'viul of recombinant human OPN _rn a buffered protein base 
with preservatives; lyophilized. 
Plate Sealers: Adhesive skips. 
Stop Solution: 6 mL/viat oft N sulfuric acid 
Wash Buffer Concentrate: 21 mUvial of z25-fold concentrated solution ofbuffered 
surfactant with preservatives, 
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2.2.15.2 Reagent Preparation: 
Bring all reagents to room temperature before use. 
Wash Buffer - If crystals have formed in the concentrate, warm to room temperature 
and mix gently until the crystals have completely dissolved. Dilute 20 mL of Wash 
Buffer Concentrate into deionized or distilled water to prepare 500 mL of Wash 
Buffer. 
Substrate Solution - Color Reagents A and B should be mixed together in equal 
volumes within 15 minutes of use, Protect from light. 200 pL of the resultant mixture 
is required per well. 
OPN Standard - Reconstitute the OPN Standard with 1.0 mL of deionized or 
distilled water. This reconstitution produces a stock solution of 200 ng/mL. Mix the 
standard to ensure complete reconstitution and allow the standard to sit for a 
minimum of 15 minutes with gentle agitation prior to making dilutions. Pipette 540 
µL of Calibrator Diluent RD5-24 into the 20 ng/mL tube. Pipette 300 µL of Calibrator 
Diluent RD5-24 into the remaining tubes. Use the stock solution to produce a dilution 
series. Mix each tube thoroughly before the next transfer. The 20 ng/mL standard 
serves as the high standard. Calibrator Diluent RD5-24 serves as the zero standard (0 
ng/mL). 
Sensitivity: The minimum detectable dose of OPN ranged from 0.006-0.024 ng/mL. 
The mean minimum detectable dose was 0.011 ng1mL. 
2.2.15.3 Assay Procedure: 
Bring all reagents and samples to room temperature before use. It is recommended 
that all standards, samples. and controls be assayed in duplicate. 
I. Prepare all reagents, working standards, and samples as directed in the previous 
sections. 
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2. Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing the desiccant pack, and reseal. 
3. Add 100 pL of Assay Diluent RDI-6 to each well. Assay Diluent RDI-6 may 
contain a precipitate. Mix well before and during use. 
4. Add 50 pL of Standard, control, or sample per well. Cover with the adhesive strip 
provided. Incubate for 2 Lours at room temperature. A plate layout is provided to 
record standards and samples assayed. 
5. Aspirate each well and wash, repeating the process three times for a total of four 
washes. Wash by filling each well with Wash Buffer (400 ltL) using a squirt bottle, 
manifold dispenser, or autowashcr. Complete removal of liquid at each step is 
essential to good peifonnance. After the last wash, remove any remaining Wash 
Buffer by aspirating or decanting. Invert the plate and blot it against clean paper 
towels. 
6. Add 200 µL of OPN Conjugate to each well. Cover with a new adhesive strip. 
Incubate for 2 hours at room temperature. 
7. Repeat the aspiration/wash as in step 5. 
8. Add 200 µL of Substrate Solution to each well. Incubate for 30 minutes at room 
temperature. Protect from light. 
9. Add 50 pL of Stop Solution to each well. The color in the wells should change 
from blue to yellow. If the color in the wells is green or the color change does not 
appear uniform, gently tap the plate to ensure thorough mixing. 
10. Determine the optical density of each well within 30 minutes, using a microplate 
reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. 
If wavelength correction is not available, subtract readings at 540 nm or 570 nm from 
the readings at 450 nm. This subtraction will correct for optical imperiections in the 
plate. Readings made directly at 450 nm without correction may he higher and less 
accurate. 
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2.2.16 Eaiyxte lurked mtHaurosorbeirt assay (ELJSz): 
Antibodies were detected and quantified by ELISA using polystyrene flat bottom 
microtiter plates as solid phase [Alam and Ali, 1992; Islam and Ali, 1998]. the 
method described by [Islam and Ali, 1998; Arif et al, 19941 was followed for the 
assay. 
2.2.16.1 	Buffers and Reagents: 
(a) Bicarbonate buffer: 15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 
9.6 
(b) Substrate buffer (for anti-human IgG alkaline phosphate conjugate): 15 mM 
sodium carbonate, 35 mM sodium bicarbonate and 2 mM MgCl,, pH 9.6. 
(c) Substrate: 0.5 mg/ml ofp-nitrophenyl phosphate (p-NP?). 
(d) Tris buffered saline (TBS): 10 M Tris, 150 mM NaCI, pH 7.4 
(e) Tris buffered saline twecn-20 (TBS-T)'. 20 M Tris, 144 mM NaCI, 2.68 mM 
KCI and 1.0 mI.litre Tween-20, ph 17.4 
2.2.16.2 Direct binding ELISA: 
Polystyrene micro titer plates were incubated with 100 µ1 of protein antigen (30 µgml 
in carhonate/bicarbonate buffer, pH 9.6) for two hours at room temperature followed 
by overnight incubation at 4 °C. The plates were washed thrice with TBS-T and 
unoccupied sites blocked by I50 pl of BSA (1.5% in TBS, pH 7.4) for 4-6 hours at 
room temperature. Serially diluted sera in TBS were added to antigen-coated as well 
as control (antigen uncoated) wells. The antigen-antibody interaction was allowed to 
proceed for two hours at room temperature followed by overnight incubation at 4 °C' 
and subsequently the plates were washed four times with TBS-T in order to remove 
the unbound antibodies. Bound antibodies were assayed by means of appropriate anti-
immunoglobulin alkaline phosphatawe conjugate using p-nnrophcuyl phosphate as 
substrate. The reaction was stopped with 3.0 N NaOH and the absorbance of each 
well was monitored at 405 non on an ELISA micruplate reader. Each sample was 
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coated in duplicate and the results were expressed as a mean of A„n, - 	For 
nucleic acid antigen, the plates were coated with 100 µl of calf thymus DNA at a 
concentration of 2.5 tglml in TBS, pH 7.4 and incubated for two hours at room 
temperature followed by overnight incubation at 4 °C. The rest of the steps were same 
as described above. 
2.2.16.3 Inhibition ELISA: 
The antigen binding specificity of antibody was determined by inhibition experiments 
(Hasan e( at, 19911_ Varying concentration of inhibitors (0-20 pe,Jml) were mixed 
with a constant amount of antiserum or lgG. The mixture was incubated for two hours 
at 37 °C followed by overnight incubation at 4 °C. The resulting immune complex 
was employed in the immunoassay instead of serum. The rest of the steps were as in 
direct binding ELISA. The results were expressed as percent inhibition. 
A. 
°i° inhibition =I-- Inhibited  x100 
A uninhibtcd 
2.2.17 TNF-a fin tnu noassay: 
The concentration of TNF-a in various culture supernatants as well as in serum of 
osteoporosis patients was detennined by use of a commercial ELISA Kit (R & D 
Systems). This assay employed the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody specific for TNF-a was available pre-coaled onto a 
micro plate. Standards and samples were pipetted into the wells and any soluble TNF-
a present was bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for TNF- a was added to 
the wells. Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution was added to the wells and color developed in proportion to the 
amount of TNF-a bound in the initial step. The color development was stopped and 
the intensity of the color was measured. 
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2.2.17.1 Reagents supplied in the kit: 
(a) 	Assay diluent RD I F - 6 ml of a buffered protein base with preservatives. It 
contained a precipitate and was mixed well before and during use. 
(h) 	Calibrator diluent RD6-35 -21 ml of animal serum with preservatives. 
(c) Colour reagent A - 12.5 ml of stabilized hydrogen peroxide. 
(d) Colour reagent B - 12.5 ml of stabilized chromogen (tetramethylbenzidine). 
(e) Plate covers - 4 adhesive strips. 
(f) Stop solution - 6 ml of2 N sulphuric acid (H2SO4). 
(g) TYF-a conjugate - 21 ml of polyclonal antibody against TNF-u conjugated to 
horseradish peroxidase, with preservatives. 
(h) TNF-a microplate - 96 well polystyrene microplate (12 strips of 3 wells) 
coated with a mouse monoclonal antibody against TNF-a. 
(i) TNF-a standard - 10 ng of recombinant human TNF-a in a buffered protein 
base with preservatives, lyophilized. 
0) 	Wash buffer concentrate - 21 ml of a 25-fold concentrated solution of 
buffered surfactant with preservatives. 
2.2.17.2 Working reagents: 
(a) Diluted calibrator diluent RD6-35 - 20 ml of calibrator diluent RD6-35 was 
mixed with 80 ml of deionized or distilled water to yield 100 ml of diluted 
calibrator diluent RD6-35. 
(b) Substrate solution - Colour reagents A and B were mixed together in equal 
volumes within 15 minutes of use to form substrate solution. It was protected 
from light. 
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(c) TNF-a standard - TNF-u standard was reconstituted with 1.0 all of distilled 
water. This reconstitution produced a stock solution of 10,000 pg/ml. The 
standard was allowed to sit for a minimum of 15 minutes with gentle agitation 
prior to making dilutions. 
(d) Nash buffer - 20 ml of wash buffer concentrate was diluted into deionized or 
distilled water to prepare 500 nil of wash buffer. 
2.2.17. 3 Assay Procedure: 
50 pl of assay diluent RD IF was added to each well of 96 well polystyrene microplate 
coated with a mouse monoclonal antibody against TNF-u. Thereafter, 200 µl of 
standards, samples, or control per well was added, covered with the adhesive strip 
provided and incubated for 2 hours at room temperature. The plate was washed four 
times by filling each well with wash buffer using a squirt bottle. After washing, 200 
pl of TNF-a conjugate was added to each well, covered with a new adhesive strip and 
incubated for I hour for cell culture supernatants and 2 hours for serum samples at 
room temperature. After four washings with wash buffer, 200 pl of substrate solution 
was added to each well and incubated for 20 minutes at room temperature in the dark, 
a blue colour appeared. Thereafter, 50 µl of stop solution was added to each well to 
stop the reaction. Then the absorhance of each well was determined within 30 
minutes, using a microplate reader set at 450 nn'. The cut off or lower limit of 
sensitivity was 4.4 pg/ml. 
2.2.18 Interleukin-1(1 (IL-I/)) Inununoassays 
The concentration of IL-1(i in monocytic culture supemates were detemtined by 
Quantikine Human IL-hi Immunoassay Kits (R&D Systems, Inc., Minneapolis, MN, 
USA) according to manufacturer's instruction. This assay employs the quantitative 
sandwich enzyme immunoassay technique. A monoclonal antibody specific for IL- I (i 
has been pre-coated onto a microplate. Standards and culture supemates are pipetted 
into the wells and any IL-l(i present is bound by the immobilized antibody. After 
washing away any unbound substances, an enzyme-linked polyclonal antibody 
specific for IL-1(3 is added to the wells. Following a wash to remove any unbound 
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antibody-enzyme reagent, a substrate solution is added to the wells and color develops 
in proportion to the amount of IL-I (3 bound in the initial step. The color development 
is stopped and the intensity of the color is measured. 
2.2.19 RNA extraction: 
After lysis of monocytes in 0.5 ml TRIZOL reagent, 200 pl of chloroform was added 
to each sample, followed by vortexing for 2 minutes, and centrifugation at 3000 rpm 
for 5 minutes. Samples were then transferred to fresh eppendorf tubes and centrifuged 
at 14,000 rpm for 15 minutes at 4 °C. The aqueous layer was harvested and 
transferred to a fresh tube. The aqueous layer obtained was mixed with 500 µI of 
chloroform-isoamyl alcohol (24:1) and vortexed. RNA was precipitated using 50 µl of 
I M sodium acetate, and 475 µl of isopropanol at —20 °C for 3 hours in the presence 
of glycogen. This was followed by centrifugation at 14,000 rpm and the pellet 
obtained was washed two times with 75% ethanol, and resuspended in S7 it DEPC-
water. DNAase I digestion (10 pl of IOX DNAse I buffer in 0.5 M Tris pH 7.5, 0.1 
M MgCl,, I mM DT-1; and 50 pg/ml BSA, 2.0 Id RNAase inhibitor; IOU RNAase 
free DNAase 1) was employed to remove DNA. The reaction was stopped by the 
addition of 700 pl of 0.5 M NIi4OAc and the RNA was re-extracted using 500 pl of 
acid phenol-chloroform (1:1). the aqueous layer was harvested, extracted again with 
chloroform-isoamyl alcohol and precipitated. 
2.2.10 Reverse transcriptace polymerase chain reaction (RT-PCR): 
The DNAase-treated RNA was subjected to reverse transcription using oligo (dT) 
primers with Superscript 11 reverse transcriptase (Invitrogen, Life Technologies, 
USA) according to the manufacturer's instructions. RNA (2 µg) was transcribed into 
cDNA in a 20 Id reaction volume containing 50 mM Tris-HC1, pH 8.3, 75 mM KCI, 3 
mM MgCl,, 10 mM DTT, 0.5 mM of each deoxynucleotide triphosphate, 25 pgiml 
oligo(dT)i2-Is primers and 10 U'Id of Superscript 11 reverse transcriptase, at 42 °C for 
50 minutes. The reaction was then stopped by heating at 70 °C for 15 minutes 
followed by rapid chilling on ice- 
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2.2.21 Polymerase Chain Reaction (PCR): 
The primers used in the PCR are listed below. cDNA for (f-actin was amplified with 
various primer sets supplied by (Stratagene, La ,Jolla, CA. USA). For PCR, 2 tI of 
each eDNA sample was used as template in the PCR amplification. The reactions 
were carried out in a 50 pl reaction volwne containing 20 mM Tris-HCI, pH 8.4, 50 
mM KCI. 1.5 mM MgCb, 0.2 mM of each of the four dNTPs, 2U of Tag DNA 
polytnerase (Invitrogen) and 0.2 tM of each forward and reverse primers. After initial 
denaturation for 2 minutes at 95 °C, 35 cycles at 95 °C for l5 seconds, 60 °C for 45 
seconds were performed, followed by 72 °C for 1 minute. The reaction products were 
visualized by electrophoresis in 2% agarose after staining with 0.5 µg/ml EtBr. 
2.2.21.1 Human primer sequences for osteoclast markers. 
18S rRNA: 
Forward: 5'-ACGGGG AATCAGGGTTCGA-3', 
Reverse: 5'-CTCGAAAGAGTCCTGTATT-3' 
TNF-a 
TNF-a primer RT: GGTTTCTACAACA 
TNF-a primer R: GTTCGAGAAGATGATCTGACTGCC 
TNF-a primer F: AGGCGGTGCTTGTTCCTCA 
OPG 
OFG primer R: 5'-GGGGACCACAATGAACAAGTTG-3', 
OPG primer F: 5'-AGCTTGCACCACTCCAAATCC-3', 
2.2.22 Quantitative real-time RT-PCR: 
Real-time quantitative reverse transcriptase PCR (RT-PCR) provides a sensitive, 
reproducible, and accurate method for determining mRNA levels in tissues or cells. 
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The method is based on the detection of a fluorescent signal produced and monitored 
during the amplification process, without the need for post-PCR processing IHeid et 
at., 1996]. Two important findings led to the discovery of real-lime PCR. First, the 
Taq polymerase has a 5 3' exonuclease activity [Holland et al., 1991], apart from its 
polymerase activity. Second. dual-labelled fluorogenic uligonucleotide probes have 
been created which emit a fluorescent signal only upon cleavage, based on the 
principle of fluorescence resonance energy transfer [Cardullo et al., 1988]. In the 
TagMan assay (Applied Biosystems, Foster City, CA, GSA), these two principles are 
combined. In this system a probe, the so-called TaqMan probe, is designed to anneal 
to the target sequence between the classical forward and reverse primers. The probe is 
dually labeled, with a reporter fluorochrome (e.g., 5-carbofluorescein, or FAM) at one 
end and a quencher dye (e.g., N,N,N',N'-tetramethyl-6-carboritodamine, or TAMRA) 
at the other end. In the intact probe, the fluorescence emission of the reporter dye will 
be absorbed by the quencher dye. The probe will be degraded during the 
extension phase by the 5' 3' exonuclease activity of the Taq polymerase, separating 
the reporter and quencher. thus resulting in an increase in reporter fluorescence 
emission. The amount of fluorescence released is directly proportional to the amount 
of product generated in each PCR cycle and thus can he applied as a quantitative 
measure of PCR product formation. 
2.2.22.1 Procedure: 
Internal fluorescent hybridization probes were used in ABI Prism 7700 Detection 
System (ABI'PerkinElmer (PE) Biosystems, Foster City. CA, USA), which allows the 
sensitive and specific quantification of individual host [Hartel et al., 1999], by 
quantitative real-time RT-PCR. TagManTM PCR primers and probes as well as target-
specific RT primer for each assay were designed as described elsewhere [Islam et al., 
2004]. The primer and probe sequences used have been previously reported [Islam et 
a1., 2004]. All probes were dually labeled with FAM at the 5' end and TAMRA at the 
3' end. The proximity of the dye (FAM) and the quencher tetramethylrhodomine 
(TAMRA) on the intact probe prevents detection of any fluorescence. However. 
degradation of the probe during the course of PCR allows the release and detection of 
FAM [Holland et al., 1991]. The PCRs for all amplifications were similar: 5 al of 
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each cDNA, 20 µl of Tagman Universal PCR Master Mix (PE Biosystems), which 
contains optimal amounts of AmpliTaq Gold DNA polymerase (which protects 
against amplicon carryover) and of dNTPs, and optimal amounts of probe and primers 
calibrated to allow measurement of the targets. First, cDNA was synthesized in the 
presence of 0.5 µl of murine leukemia virus enzyme (Invitrogen, USA)/reaction and 
10 tM each RT primer, dNTPs, and other substrate. Conditions for PCR were similar 
for all products (I cycle of 2 minutes at 50 °C and I cycle of 10 minutes at 95 °C and 
then 40 cycles of 15 seconds at 95 °C and I minute at 60 °C). The cycle threshold for 
each sample was compared with the cycle threshold values of known amounts of a 
standard DNA constructed for each target and amplified simultaneously. To assure 
lack of DNA contamination in the RNA samples, in some experiments, a duplicate 
tube of sample with no RT enzyme was included as control. DNA contamination 
remained negligible. In each sample, host ISS ribosomal RNA was used as the internal 
control. Expression of TNF-a mRNA was corrected to internal control (host I SS rRNA) 
in the same sample and was expressed as copies of TNF-n in 101° copies of R18 
(equivalent to I x 10' monocytes). 
2.2.23 Statistical analysis: Results were analyzed by paired t-test. P<0.05 was 
considered statistically significant. 
2.2.24 Research Support: Part of this work was financially supported by Indian 
Council for Medical Research (ICMR). vide project file no.59:14/2008/BMS/TRM 
and Aligarh Muslim University (A.M.C). Aligarh, India. 	 t 
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Chapter —3 
RESULTS 
RESULTS 
the present study involves data on three aspects, which are depicted below: 
(A) Oxidative Stress Study in Serum and Monocyte Cultures 
(B) Immunological study by ELISA 
(C) A bone markers and osteoclast study by TRAP, ELISA and Quantitative , Real 
time RT-PCR 
In the present study, allicin- a natural antioxidant from garlic, curcumin and 
resveratrol were employed as natural antioxidants in order to investigate their 
regulatory effects on various parameters as discussed in the results depicted below. 
Also, a few experiments were carried out by employing EGCG- a green tea 
polyphenol (GTP) in the present study. 
Prior to any study, since most of the experiments involved in the present study 
involve PBMC/ monocyte cultures receiving various natural antioxidants like allicin, 
resveratrol and curcumin, thus an attempt was first made to see any adverse effect, if 
any, of these compounds. Therefore, MTT cell viability assay and assessment of 
human housekeeping gene R-18 by 'real time' RT-PCR was carried out. Assessment 
of human housekeeping gene R-18 has been reported in the study elsewhere under 
bone marker study by 'real time RT-PCR. Also, as evident from Table 8, allicin did 
not show any adverse effect till 500 ng/ml, while resveratrol and curcumin did not 
show any adverse effect till 25 pg/ml. Hence, the above said cuts off doses were 
selected in the present study. 
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Table 8: Dose response effect of Allicin, Resveratrol and Curcumin on the 
Viability of Monocytes from Osteoporosis patients 
Allicin, 
ng/ml 
Viable 
Cells (% 
of 
Control) 
Resveratrol, 
µg/ml 
Viable 
Cells (% 
of 
Control) 
Curcumin, 
pg/ml 
Viable Cells 
(% of 
Control) 
0 99 0 98 0 96 
50 97 2 99 2 97 
100 98 5 97 5 98 
250 99 10 98 10 95 
500 98 15 97 15 98 
750 71 20 98 20 99 
1000 68 25 98 25 97 
30 65 30 69 
40 60 40 65 
50 58 50 60 
*(n=10. p<0.001) 
Section (AI: A Study Related to Oxidative Stress in Serum and Monocyte 
Cultures: 
1. Glutathione peroxidase (GPx) activity in serum of osteoporosis patients. 
I ligh oxidative stress is well known to be associated with osteoporosis. Therefore, the 
antioxidant state of osteoporosis patients was assessed by determining the GPx 
activity in their sera. Upon comparison to healthy subjects, the GPx activity in serum 
of patients with osteoporosis was appreciably reduced by around 55.84% as evident 
from the results where GPx activity in sera of osteoporosis patients (n=30) and 
healthy controls (n-30) was recorded as 35.34 t1/ mg protein and 80.02 U/ mg protein 
respectively (Fig. 1). All values represent mean ± SE; p < 0.001. 
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2. GGrtafhione peroxiJase (GPx) activity in culture supernatants of mohlOrples. 
Human monocytes having the ability to adhere onto culture plates were obtained from 
PBMCs of healthy controls as well as patients with osteoporosis. In turn, they were 
cultured for 24 hours as described in methods, and finally, the supernatants were 
analyzed for GPx activity. Results show that the patient's samples exhibited an 
appreciably suppressed GPx activity (19.15 U/ mg protein) when compared to 
samples of healthy subjects (62.08 U/ mg protein) (Fig. 2) Thus, from the said data, it 
seems that antioxidant defense system is altered by around 69.15% in patients with 
osteoporosis. All values are mean ± SE; p <: 0.001. 
3. Determination of intrammaveyte glutathione (GSH) levels 
An attempt was made to evaluate the intramonoeyte glutathione (GSH, a major thiol 
antioxidant) levels in 24 hours monocyte cultures of osteoporosis patients (n=20) as 
well as in healthy individuals (n=20). As is evident in Fig. 3, the intramonocytc GSH 
levels were significantly down-regulated suppressed in samples of osteoporosis 
patients (129.02 pg/ml) in comparison to healthy controls (231.25 pg/ml). The percent 
decrease was computed to be -- 44%. The data indicates that antioxidant defense gets 
suppresscdireduced in osteoporosis patients in comparison to non-osteoporosis 
healthy subjects. All values are mean t SE; p < 0.001. 
4. Dose response effect of Curcurain and Recveratrol on GPx activity in cultured 
monocytes from healthy controls and osteoporosis patients 
Due to the established beneficial role of curcumin and resveratrol as a natural 
antioxidant in a wide spectrum of pathological conditions, thus an attempt was made 
to study their comparative effects on antioxidant state in supernatants of 24 hours 
cultured monocytes from patients with osteoporosis (n=20) and healthy individuals 
(n=20) which served as controls. 
Healthy monocytes serving as controls were therefore separately co-cultured for 24 
hours with varying concentrations of curcumin and resveratrol (0, 2, 5, 10, 15. 20 and 
25 µg/ml) respectively. Cultures were harvested and supernatants obtained were 
subjected to GPx activity determination. Insignificant variation in the activity; 73.37, 
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75.33, 70.83, 77.38, 73.27. 70.99 and 72.12 U/mg protein was recorded for healthy 
individuals at above mentioned curcumin concentrations respectively (Fig. 4). 
Similarly, no change was also observed when resveratrol was co-cultured with healthy 
munocytes. In this case, the GPx activity was recorded as 70.12, 73.98, 76.32, 74.54, 
78.12, 70.37 and 74.12 U rng proteins with 0, 2, 5, 10, 15, 20 and 25 pg/ml 
respectively (Fig. 4). 
On the contrary. in case of osteoporosis patients (Fig. 5). the GPx activity was found 
to increase in a dose-dependent manner from 33.09 U/mg protein, through 37.12, 
45.18, 56.08. 63.76, 65.12 and 68.87 U/mg protein at 0, 2, 5, 10, 20 and 25 µg/ml 
curcumin respectively. The above results clearly prove curcumin to be also an 
effective natural antioxidant capable of elevating the depressed antioxidant state in 
case of osteoporosis. All values are mean ± SE, p < 0.001 and n=8 in each study 
group. 
Similarly, resveratrol which is known to be a natural antioxidant as well as an 
iminuno-regulator, showed a high magnitude effect on GPx activity in monocyte 
culture supernatants of osteoporosis patients. 
Monocytes were co-cultured for 24 hours with varying doses of resveratrol (0, 2, 5, 
10, 15, 20 and 25 rig/nil). Supernatants when subjected to GPx activity showed 
progressive up-regulation in a dose-dependent manner from 32.88 U:mg protein 
through 42.16, 49.67, 6056, 67.54, 68.32 and 69.33 U/ mg protein (Fig. 6). 
Therefore, resveratrol. together with curcumin proved to be effective herbal 
antioxidant in osteoporosis. All values arc mean f SE; p < 0.001. 
Effect of varying doses ofAllicin on intranionocyle levels ofglatathione (GSH). 
Next, an attempt was also made to probe for any regulatory effect of varying doses of 
allicin (0, 50, 100, 250, and 500 ng,'ml) on intramonocyte GSiI levels in 24 hours 
monocyte cultures (n=20 each for healthy and osteoporosis patients). Substantially 
low level (117.66 pg/ml) of intramonocyte GSH was recorded at 0 ngtml allicin 
compared to healthy individuals monocyte cultures (310.35 pgiml). An apprcciablc 
and dose-dependent up-regulation of intramonocyte GSH levels through 156.76, 
201.32, 283.43, 288.11 pg!ml was recorded for osteoporosis patients at 0, 50, 100, 
100 
250. and 500 ng. ml allicin (Fig. 7). IC;,) was computed out to be — 100 Itg.-"ml. On the 
contrary, insignificant variation was obser - -d in case of healthy subjects; 310.05, 
305.11. 310?3. 300.54 and 312.32 pg ml (Fig. 7). Thus, allicin from garlic raised the 
depressed thiol antioxidant state in osteoporosis study subjects to an appreciable 
extent. All values are mean = SE, p < 0.001. 
Dose response effect of Resveratrol and Ciurcrunin on intramonocyte glutathione 
(GSII) levels 
Also, effect of varying concentrations of resveratrol and curcumin (0, 2, 5, 10, 15, 20 
and 25 pg ml) on intramonocyte GSH levels in 24 hours monocyte cultures was 
investigated (n=20 each for healthy and osteoporosis patients). Interestingly, 
significantly reduced levels of intramonocyte GSH were recorded at 0 ng'm1 
resveratrol (123.65 pg/ml) in case of osteoporosis patients when compared to healthy 
subjects (310.11 pg/ml). which thereafter, increased dose-dependently through 
162.43, 174.09, 266.45. 270.12, 283.65 and 288.12 pg/ml at 2, 5, 10, 15, 20 and 25 
pg'ml resveratrol respectively (Fig. 8). 
Similarly, curcumin exhibited a dose-dependent amelioration in intramonocyte GSH 
levels which was of the order of 116.32, 133.21, 161.68, 212.22, 263.12, 278.19 and 
286.33 pg-ml at 0, 2. 5, 10, 15, 20 and 25 p.g/ml respectively (Fig. 8). Insignificant 
variations were observed in case of healthy subjects at above mentioned doses of 
resveratrol and curcumin (Fig. 9). Thus, both, resveratrol and curcumin can be 
effectively used to improve the degenerating antioxidant state in the pathogenesis of 
osteoporosis. All values are mean ± SE, p < 0.001. 
5. .tibdalarion of in train onocyte glutathione (GSH) levels 
It is well known that intracellular signaling via NFKB is known to be ROS sensitive, 
and that because of high oxidative stress in osteoporosis. monocytes from the study 
groups (n=20 each for healthy and osteoporosis patients) were co-cultured for 24 
hours with 10 mM NAC or 100 µg'mI SN50 or 100 pg-ml SN50 M1 or 500 ng ml 
allicin or 25 pg/ml resveratrol or 25 pg ml curcumin for comparative modulation of 
intramonocN1e GSH levels. Control cultures (-) did not receive any treatment and 
revealed intramonocyte GSII levels of 321.50 as well as 134.61 pg/ml for 
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osteoporosis and healthy individuals respectively (Figs. 10 and 11 respectively). As 
evident from the results, at 24 hours, NAC, a known antioxidant, as well as SNSO, an 
inhibitor of NFKB activation, both up-regulated the intramonocyte GSH levels in 
cultures of osteoporosis patients (233.67 and 258.37 pg'mi respectively). However, 
SN50/M, an inactive analogue of SN50, at same concentration failed to cause any 
modulation in osteoporosis patients (137.02 pg/ml). Next, allicin from garlic as well 
as resveratrol and curcumin, which are well established natural antioxidants, were 
chosen for this modulation study. Interestingly, all the three natural antioxidants, 
namely allicin, resveratrol and curcumin appreciably up-regulated the intramonocyte 
GSH levels in osteoporosis patients (283.33, 278.11 and 259.12 pg/ml respectively). 
When compared, they were much more potently than either NAC or SN50. 
Insignificant variation was recorded in case of healthy individuals with any of the 
modulating agent used here (Fig. 11). These results indicate that the down-regulated 
intramonocyte GSH levels in osteoporosis patients is NFKB mediated and that all the 
three natural antioxidants, namely allicin, resveratrol and curcumin proved as 
potential natural and safer antioxidants in osteoporosis. All values are mean f SE, p < 
0.001. 
6. Levels of malondialdehyde (,,VDA) in serum of osteoporosis patients. 
Next, due to the results showing impaired antioxidant systems in osteoporosis patients 
as revealed by decreased GPx activity and reduced GSH levels as mentioned above, 
the levels of a by-product of lipid peroxidation i.e., malondialdehyde (1v1DA) was 
measured in the present study, in the sera of osteoporosis patients (n=20), in order to 
detect further signs of increased oxidative stress. In comparison to healthy group (8.01 
ng/ml), the serum MDA values were found to be almost three times higher in 
osteoporosis patients (25.11 ng/ml) as depicted in Fig. 12. All values are mean and p 
< 0.001 in each case. 
7. Estimation of MDA levels in culture supernatants of nnonocytes. 
Thereafter, adherent monocytes from f'BMCs were cultured for 24 hours and 
supernatants analysed for MDA levels. In osteoporosis patients (n=20), MDA levels 
stood to a near 3.5 times (26.84 ng/ml) the level found in healthy group (n=20) (7.68 
ng/ml) as depicted in Fig. 13. Data represent mean SE, p < 0.001 in each case. Hence. 
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osteoporotic patients are indeed exposed to high oxidative stress as indicated by high 
levels of MDA. 
8. Effect of varying Amts of Allicin on AIDA levels in .supernatants of cultured 
monocytes. 
In order to find out if allicin from garlic could prove beneficial in 
combating/neutralizing the augmented oxidative stress which is so common in 
osteoporosis, monocytes obtained from the study groups were co-cultured for 24 
hours with varying doses of allicin (0-500 ng/ml) and supernatants were subjected to 
evaluation for MDA levels. The MDA levels, ranging only from 115 ng/ml to 5.77 
ng/ml in the supernatants of monocyte cultures of healthy subjects, remained more or 
less unaltered at all the concentrations of allicin used (data not shown). While in case 
of osteoporosis patients, the MDA levels showed a dose-dependent decrease from 
24.24 ngiml when monocytcs were cultured alone through 17.23, 15.65, 10.23 to as 
low as 8.56 ng/ml when treated with 50, 100, 250, and 500 ng/ml allicin respectively 
(Fig. 14). Thus, at doses of 250 and 500 nghnl allicin, MDA levels in osteoporosis 
patients were comparable to those found in healthy subjects thereby successfully 
upholding the potential antioxidant property of allicin in combating high oxidative 
stress in osteoporosis. All values are mean SE, n— 20 in each study group and p < 
0.001 in each case. 
9. Dose response effect of Resveratrol and Curcumin on MDA levels in mmnoevte 
culture supernatants 
Next, monocytes were similarly treated for 24 hours with varying doses of resveratrol 
and curcumin (0-25 ag!ml) in order to explore if any positive impact resveratrol and 
curcumin would show in the pathogenesis of bone loss due to osteoporosis. Therefore, 
the supernatants of the said cultures when analyzed for MDA levels, which showed a 
progressive down-regulation in osteoporosis patients (n=20) from 25.32 ng/ml when 
monocytes were cultured alone and then through 22.67, 17.21, 12.33, 10.28, 6.12 to as 
only as 6.01 ng/ml when treated with 2, 5, 10, 15, 20 and 25 pgiml of resveratrol 
respectively as depicted in Fig. 15. No significant variation was observed at any of the 
above mentioned resveratrol doses in case of healthy group with MDA levels of 8.19, 
8.01.9.67, S.23, 7.93, 8.05 and 7.S7 ng/ml respectively (Fig. 16). All values are mean 
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SE of n=20 in each study group and p < 0.001 in each case. Therefore, the said data 
further substantiated that resveratrol was an efficient antioxidant in osteoporosis. 
Similarly, varying doses of curcumin (0-25 pglml) also exhibited an appreciable 
down-regulation in MDA levels in 24 hours culture supernatant of osteoporosis 
patients (Fig. 17). However, the effect was a bit lower when compared with that of 
resveratrol. No effect was observed in healthy controls (Fig. 18). 
(B]: Immunological Study by ELISA: 
1. Estimation of IL-I(t feve& in .sera and supernatants of atouocyte cultures of 
healthy individuals and osteoporosis patients by ELISA. 
Since, it is an established fact that the high levels of pro-inflammatory cytokine IL-I p 
are found in osteoporosis patients, thus, an attempt was made to probe the levels of 
IL-1(i in sera as well as monocyte culture supernatants of osteoporosis patients and 
consequently, the results were compared with those obtained from healthy subjects. 
ELISA results depicted in Fig. 19 show high basal levels of lL-1(3 in sera as well as 
monocyte culture supernatants of osteoporosis patients (172.26 pg/ml and 132.12 
pg/ml respectively) compared to IL-]O secretion in healthy sera and monocyte 
cultures (25.13 pglml and 8.15 pgiml respectively). All values are mean I SE; p < 
0.001 and n=8 in each study group. 
2. Effect of varying doses of Allicin on expression of IL-1/1 in inonocyte culture 
supernatants. 
Monocytes from osteoporosis patients were co-cultured for 24 hours with varying 
concentrations of allicin (0, 50, I00, 250 and 500 ng/rrsl). Cultures were harvested and 
supernatants obtained were subjected to ELISA for comparative evaluation of IL-1(3 
secretion. As is evident from Fig. 20, the secretion of IL-l[i was found to decrease 
dose-dependently in osteoporosis patients from 151.34 pg/ml through 140.11, 40.42, 
28.81 and 24.29 pg'ml at 0, 50, 100, 250 and 500 ng/ml allicin respectively. IC50  was 
computed out to be in between 50-100ng/mi. In case of healthy subjects, low IL-I(3 
secretion remained inure or less unaffected, which were to the order of 4.51 pg/ml, 
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4.38, 5.03. 4.06 and 5.25 pgiml respectively at the above varying doses of allicin (Fig. 
21). All values are mean f SE, p <0.001 and n=8 in each of the study groups. 
3. Dose-response effect of Resverutrol and furrunrin an the expression of IL-Ia in 
atonocyte culture supernatants 
Next, monocytes of study groups were similarly treated with varying concentrations 
of resveratrol (0, 2. 5. 10, 15, 20 and 25 pg'ml). A similar response was observed with 
resveratrol as was observed above with allicin, In case of osteoporosis patients, IL-I 13 
secretion dose-dependently decreased from 162.34 pg%ml through 140.36, 78.59, 
40.26, 27.21 and 21.09 pg/ml (Fig. 22). IC o was computed out to be — 8 pg/ml. In 
healthy individuals, 3.89, 4.35, 3.96, 4.91, 4.88 and 5.02 pglml IL-1(3 secretion levels 
were recorded at the respective varying doses of resveratrol (Fig. 23). All data 
represent mean f SE; p < 0,001 and n=8 in each study groups. 
Similarly, curcumin showed a dose-dependent down-regulation in IL-I(3 levels from 
165.09, 143.22, 89.32, 55.23, 35.19 and 29.12 po/ml with 0, 2, 5, 10, 15, 20 and 25 
pgiml of curcumin respectively (Fig. 24). IC sa  was computed out to be --9  tgml. On 
the contrary, no effect of curcumin was observed on IL-1(f in healthy control and 
monocyte culture supernatants (Fig. 25). 
[CJ Osteoclast and bone marker study by TRAP, ELISA and Quantitative 'real-
time' RT-PCR. 
1. Determination of Human sRAAKL levels in culture supernatants of lieu/thy 
controls and osteoporosis patients 
An attempt was made to probe the levels sRANKL in culture supernatants of healthy 
controls (n=8) and osteoporosis patients (n=8) by ELISA. In comparison to healthy 
controls (p < 0.01), patient's cultures (5 days) exhibited around 9-Ibld augmented 
levels of sRANKL (pg/ml; p < 0.001) (Fig. 26). 
2. Dose response effect of Allicia on sRANKL levels in culture supernatants of 
healthy controls and osteoporosis patients 
105 
Adherent monocytes were co-cultured with varying concentrations of allicin from 
garlic (0, 50, 100, 250 and 500 ng'ml). In case of osteoporosis patients. sRANKL 
secretion dose-dependently decreased from 33.16 pg/ml at through 27.54, 20.33, 
1298 and 3.02 pgml with 50, IOU. 250 and 500 ng allicin respectively (Fig. 27; p < 
0.001). On the contrary, healthy controls exhibited in between 1.33 — 3.12 pg/ml of 
RANKL (Fig. 28). Next, after dose response evaluation, an attempt was also made to 
re-check the data by co-culturing with the maximum dose of allicin (500 ngiml) 
selected in the study, and that, similar results were observed to the one's observed 
above in dose response experiments at the maximum dose (Fig. 28; p < 0.001). All 
data represent mean ± SE; p < 0.001 and n=8 in each study groups. 
3. Evaluation ofAllicin-induced percent suppression by computational analysis in 
the secretion of sR N.KL in culture supernatants of osteoporosis patients 
Computation of the data depicted in Fig. 27 exhibited that allicin suppressed the 
secretion of sRANKL by around 16.94%, 38.69%, 60.85% and 90.89% with 50, 100, 
250 and 500 ng allicin respectively (Fig. 29). The IC;o was computed out to he in 
between 100 -135 ng/ml. 
4. Dose response effect of Resveratrol and Curcumin on sRANKL levets in culture 
supernatants of healthy controls and osteoporosis patients 
Monocytes of study groups were co-cultured separately with varying concentrations 
of resveratrol and curcumin (0, 2. 5. 10, 15, 20 and 25 g'ml). In case of osteoporosis 
patients, sRANKL secretion was found to dose-dependently decrease from 35.16 
pg/rnl at through 29.11, 24.26, 15.16, 11.33, 9.16 and 8.89 pg;nl with 0, 2, 5, 10, 15, 
20 and 25 gg resveratrol respectively (Fig. 30; p < 0.001). On the contrary, healthy 
controls exhibited in between 1.3 — 3.2 pglmi of RANKL (Fig. 30). 
Thereafter, the effect of varying doses of curcumin on RANKL in 5 days monocyte 
cultures was also analyzed. Co-culturing of patients monocytes with curcumin 
exhibited a dose-dependent down-regulation of sRANKL, which was of the order of 
32.65, 27.81, 22.45. 17.29, 13.07. 9.44 and 9.23 pg/ml with 0, 2, 5, 10, 15, 20 and 25 
µe%ml of curcumin respectively (Fig. 31). All data represent mean ± SE; p < 0.001 
and n=8 in each study groups. ICso  was computed out to be -- 9 tg/ml. 
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Next, computational analysis of the data revealed that curcumin down regulated the 
secretion of sRANKL by around 15%, 314% 46%, 60%, 70% and 73% with 2, 5, 10, 
15, 20 and 25 pig curcumin respectively (Fig. 32) 
5. Generation of Human Osteoclust Precursors from Peripheral Blooa Mononuclear 
Cells (PBMCsJ 
Peripheral blood mononuclear cells (PBMCs) were used directly for the generation of 
osteoclast precursors after centrifugation with Ficoll-Hypaque. After the 3 day culture 
duration in osteoclastogenic medium (o-MEM culture medium supplemented with 
10% FCS, 100 U/ml penicillin, 100 pg'ml streptomycin, 50 ng/ml M-CSF and 25 
ng/ml RANKL), multinucleated osteoclast precursors were observed to appear and the 
number increased after 5 days of culture, as revealed by Tartrate Resistant Acid 
Phosphatase (TRAP) staining (Figs. 33, 34). However, there was negligible 
appearance of osteoclast precursors after 24 h (I day) of culture (Fig. 33). The 
number of multinucleated preosteoclasts, arising from PBMCs isolated from the blood 
of normal healthy individual (data not shown) and osteoporosis patients (Figs. 33, 
34), were counted by TRAP staining. Interestingly, we observed an individual 
variation in osteoclast generation from different donors as depicted by different 
number of multinucleated cells in Figs. 33 and 34. 
G Effect of Al(icin, Resverutrol and Curcumin on the Generation of Human 
Osteoclasis 
Interestingly, we observed that co-culturing of PBMCs from osteoporosis patients 
(n=30) with Resveratrol (25 pg'ml) or Curcumin (25 pg/ml) or Allicin (500 ng/m[) in 
osteoclastogenic medium for 3 days resulted in an appreciable amount of reduction in 
appearance of multinucleated osteoclast precursors (Figs. 35, 36, 37, 38, 39, 40, 41, 
42 and 43). Hence, this reflects the potential of allicin. resveratrol and curcumin to 
exert regulatory effect in osteoclast generation and differentiation. The above doses of 
allicin, resveratrol and curcumin were selected after performing dose response 
experiment, where TRAP assay revealed a linear suppression in the formation of 
multinucleated cells was observed. The above data shows nearly 20-30 % suppression 
in appearance of multinucleated cells in cultures separately resveratrol (25 pig/ml) or 
curcumin (25 ,g/ml) respectively reserving relative to control devoid of any 
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supplement. Interestingly, around 35-40 % suppression in appearance of 
multinucleated cells was observed in cultures receiving 500 ng/ml of allicin relative to 
control cultures devoid of any allicin (Figs. 35-43). 
Effect of :Natural Antioxidant, Epigallocatechin gallate (EGCG), on the Generation 
of Human Osteoclast. 
Interestingly, we observed that co-culturing of PBMCs with EGCG (20 }►g'ml) in 
osteoclastogenic medium for culture duration of 5 days leads to appreciable amount of 
reduction in appearance of multinucleated osteoclast precursors (Fig.43 a, 43 b). 
Hence, this data gives an idea of potential of EGCG to exert regulatory effect in 
osteoclast generation and differentiation. 
7. Time course kinetics of multinucleated cell suppression by natural antioxidants 
Monocytes from osteoporosis patients (n=6) were separately co-cultured with allicin 
(500 ng/ml), resveratrol (25 pg/ml) and curcumin (25 pgIml) for varying time periods 
i.e., for 0 hour, 24 hours, 72 hours and 120 hours. Control cultures devoid of any 
supplements exhibited multinucleated cells to the order of 4, 5, 73 and 101 at 0 hour. 
24 hours, 72 hours and 120 hours of culture period respectively (Fig. 44). On the 
contrary, cultures receiving allicin (500 ng/ml), resveratrol (25 pyml) or curcumin 
(25 µg/ml) exhibited a linear increase in the suppression of multinucleated cells with 
increase in time period of culture (Fig. 44). Thus, in comparison to control as 
mentioned above, allicin showed suppression to the order of 0, 2. 16 and 20 
multinucleated cells at 0 hour, 24 hours, 72 hours and 120 hours of culture (Figure 
44). Similarly, resveratrol exhibited suppression to the order of 1, 3, 22 and 24, while 
curcumin exhibited suppression to the order of 1. 3, 27 and 27 multinucleated cells at 
0 hour, 24 hours, 72 hours and 120 hours of cultures respectively (Fig. 44). 
8 (a) Determination of OPN by ELISA in sera of healthy controls and patients with 
osteoporosis. 
The presence of human OPN was probed both in sera of healthy controls (n=10) and 
osteoporosis patients (n= l 0). As evident from Fig. 45, sera of healthy controls showed 
negligible levels of osteopontin (range: 2.07 ng-'ml to 3.24 ng'ml). On the contrary, 
1: 
sera of osteoporosis patients exhibited appreciable levels of OPN, which was in the 
range of 15.98 ng/ml to 28.35 ngiml (Fig. 46; p < 0.001). Thus, in comparison to 
healthy controls, around an 8-fold OPN levels were recorded in osteoporosis patients. 
(b) Determination of OP.Y by ELISA in nronocyte culture supernatants of healthy 
eontrolc and osteoporosis patients. 
No or negligible levels of OPN were observed in 24 hours culture supernatants of 
monocvtes obtained from healthy controls (range: 1.09 ng/ml to 2.36 ng/ml; n=6) 
(Figs. 47, 4R). However, an appreciable levels amount of OPN was detected in 24 
hours culture supernatants of monocytes obtained from osteoporosis patients (range: 
16.23 ng/ml to 21.29 ng/ml; n=8; p < 0.001). Thus, in 24 hours monocyte culture 
supernatants, around 12 Bold levels of OPN was detected in osteoporosis patients in 
comparison to healthy controls. 
(c) Modulation Study of OPN by enrplot•ing positive modulator Calcitonin (Cl), in 
3 days mmnocyte cultures of patients with osteoporosis. 
Monocytes from osteoporosis patients (n-6) were cultured for 3 days in 
osteoclastogenic medium with and without I ngtml of CT. Cultures devoid of any CT 
exhibited OPN levels in the range of 15.67 ng/ml to 22.17 ng/ml (Fig. 49; p <0.001). 
However, in comparison to the above cultures devoid of CT, those culture wells 
receiving Ing/ml of CT exhibited an augmentation/increase by around 1.4-folds in 
OPN levels (range: 21.11 ng/ml to 33.45 ng/ml) (Fig. 49; p < 0.001). This 
substantiates that CT was a positive modulator of OPN. 
(d) Effect of Resveratrol alone as well as combination of Resverarrol and CT on 
OPiV 1evely in 3 days inonocyte cultures in osteoclastogenic ,nediu,n. 
Here again, monocytes from osteoporosis patients (n-6) were cultured for 3 days in 
osteoclastogenic medium along with either resveratrol (20 µg/ml) alone or with a 
combination of resveratrol (20 pg/ml) + CT (1 ng/ml). 
As evident from Fig. 50, an appreciably down-regulated/suppressed levels of OPN 
was recorded in monocyte cultures receiving resveratrol (20 µgiml)., which was in the 
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range of 4.13 ng/ml to 6.99 ng/ml (p < 0.001). Furthermore, cultures receiving a 
combination of resvcratrol and CT as said above, suppressed OPN levels which were 
in the range of 9.43 ngiml to 10.55 ng/ml (Fig. 50; p < 0.001). Comparison of this 
data with the one's obtained in Fig. 49, where CT was found to up-regulate OPN, here 
in Fig. 50, the results clearly shows that the positive modulatory effect of CT on OPN 
was appreciably neutralized by resveratrol, thereby exerting a remarkable negative 
modulatory effect on OPN. 
(e) Effect of Curcumin alone as well as a ntirntre of Curcuntin and CT on OPN 
levels in 3 days utonocyte cultures in osteoelastogenic mediuur. 
Momcytes from osteoporosis patients (n-6) were cultured for 3 days as has been 
described with resveratrol previously. Here, cultures separately received curcumin (20 
µg%mf) or a mixture of curcumin (20 ug/ml) and CT (i ng/mi). 
As evident from Fig. 51, cultures receiving curcumin alone exhibited an appreciable 
suppression in OPN levels (range: 8.88 ng/ml to 10.41ng/ml; p < 0.001) but this 
suppression was slightly lesser than those observed with resveratrol in Fig. 50. Next, 
cultures receiving a combination of curcumin (20 pglml) + CT (I nglml) exhibited 
similar results (Fig. 51) as was observed previously with combination of resveratrol + 
CT in Fig. 50. Thus, the results here in Fig. 51 clearly show that curcumin was a 
potent negative modulator of OPN but to a slightly lesser degree than resveratrol. 
(0 Effect of Allicin Jranr garlic as well as a mixture of Allicin and CT on OP,Y 
levels in 3 days monocyte cultures in osteoclastogenic medium. 
Next, we probed the effect of the third natural antioxidant, namely allicin, in the 
present study on OPN levels. Therefore, monocytes from osteoporosis patients (n-6) 
were cultured exactly similar to the manner as discussed above for resveratrol and 
curcumin. In this study, cultures separately received allicin (500 ng/ml) and a 
combination of allicin (500 ng(ml) and CT (I ng/ml). Thus, as evident from Fig. 52, 
allicin (500 ng/ml) was found to suppress OPN to a appreciably high magnitude, 
wherein, the range of suppression of OPN in various patients was in between 3.89 
ng/ml and 5.98 ng/ml (Fig. 52; p < 0.001) in comparison to cultures devoid of any 
allicin (Fig. 49). Furthermore, culturing of monoeytes with a combination of allicin 
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(500 ne'ml) and CI (I ng/ml) again showed remarkable suppression of OPN and that 
the positive modulator CT had no substantial effect in presence of the negative 
modulator i.e., allicin (Fig. 52). Next, upon comparison of the data depicted in Figs. 
49-52. it was observed that allicin proved to he the most potent suppressor of OPN 
followed by resveratrol, and in turn, followed by curcumin. 
(g Effect of Denosumab (Peoliaa on OPN levels in 3 days mmnoeyte cultures in 
osteoclastogetric medium. 
Next, the effect of known negative modulator, namely Denosumab (Prolia) of OPN 
and osteoclasts was probed. As evident from Fig. 53, monocyte cultures of 
osteoporosis patients (n=6) receiving denosumab (Prolix) (1 ng/ml) for 3 days in 
osteoclastogenic medium exhibited a remarkably suppressed, down-regulated levels 
of OPN (range: 3.99 ng/ml to 5.23 ng/ml; p < 0.001) in comparison to cultures devoid 
of any supplements (Fig. 49). Upon comparative analysis of the data obtained in Figs. 
49-53, it was observed that the degree of suppression% down-regulation of OPN was 
nearly similar/ same with natural antioxidant allicin and monoclonal antibody namely 
denosumab (Prolia). 
10. A study on Bone .Harker by Quantitative 'Real time RT-PCR: 
Next, an attempt was made for characterization of monocytes at the gene level from 
osteoporosis patients and compared to those or healthy individuals with respect to 
bone markers like TNF-a. 
(a) Expression of TNF-a mRNA 
As described in methods, PBMCs were isolated from the blood of normal healthy 
individuals and osteoporosis patients, and in turn, were subjected to adherent 
monocytes isolation. Monocytes from osteoporosis patients were then subjected to 
TNF-a niRNA evaluation by real-time RT-PCR- Thereafter, they were compared with 
the values of TNF-u mRNA copy number recorded in monocytes from healthy 
subjects. As is evident from Fig. 54, in comparison to healthy subjects' monocytes, 
those from osteoporosis patients revealed the presence of high basal levels of TNF-a 
raRNA copy number which was to the order of 8.33E+08 (p < 0.001). These data, 
therefore, revealed significantly high basal levels of TNF-a mRNA in the monocytes 
of osteoporosis patients. All values are mean ± SE of six experiments in each study 
group. 
(b) Expression of OPG nrRNA. 
Furthermore, mononuclear cells from the study group were subjected to OPG mRNA 
evaluation by real-time RT-PCR. In case of osteoporosis patients, the data exhibited 
higher basal levels of OPG mRNA copy number which was — 8.9 logs (p < 0.001) 
than the healthy subjects level (Fig. 55). This indicated higher basal level expression 
orOPG mRNA in osteoporosis patients' PBMCs. 
(c) Dose response effect of Allicin from garlic, Resveratroi and Curen,nin on 
human housekeeping gene RI S. 
Because of well established health benefits of garlic, resveratrol and curcumin since 
ancient times, we chose here to study their actions on monocytes isolated from 
PBMCs of osteoporosis patients (n=6). Allicin or resveratrol and curcumin failed to 
show any adverse effect on the human housekeeping gene R18. As evident from Fig. 
56-58 that neither allicin (0-500 ngiml) nor resveratrol (0-20 µg/ml), nor curcumin (0-
20 pg/ml) at any of their respective concentrations when these were used to co-culture 
the monocytes, had any significant effect on the expression of human housekeeping 
gene RI 8  as revealed by quantitative real-lime RT-PCR (Fig. 56-58). 
(d) Effect of varying doses of Allicin, Resverarro! and Curcanrin on TTVF-a 
expression. 
We first started with allicin to investigate its action upon TNF-a mRNA gene 
expression. Adherent monocytes from PBMCs of osteoporosis patients and healthy 
subjects were co-cultured with varying concentrations of allicin (0-500 ng,'ml) for 24 
hours. Cultures devoid of allicin i.e., at 0 ng served as control, Monocytes were then 
subjected to TNF-a mRNA evaluation by real-time RT-PCR. It is evident from Fig. 
59, the expression of TNF-u mRNA was dose-dependent showing significant down 
regulation in its copy number in case of osteoporosis patients from 8.33E+08 in 
untreated monocytes through 0.64 logs, - 4.1 logs, — 5.0 logs to — 6.1 logs when 
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monocytes were treated with 50. 100, 250. and 500 ng ml allicin respectively. 
However, no significant variation was observed in case of healthy individuals (n=6) 
(Fig. 59). The data, thus prove allicin as a potent suppressor of augmented TNF-a 
mRNA levels in osteoporosis whereby it can be used as a potent anti bone-resorptive 
agent in this kind of bone pathogenesis. Data represent mean = SE of six experiments 
in each study group i.e., n=6 and p < 0.001 in each case. 
Thereafter, it was also attempted to probe the effect of varying concentrations of 
resveratrol (0-20 µg ml) and curcumin (0-20 µg ml) on the expression of TNF-u 
mRNA in 24 hours cultures of PBMCs isolated from osteoporosis patients and healthy 
subjects. As is evident in Fig. 60, monocytes when subjected to TNF-a mRNA 
evaluation by real- time RT-PCR showed dose-dependence on resveratrol and 
curcumin respectively in all study groups. In case of osteoporosis patients, significant 
down regulation of TNF-u mRNA copy number of as much as 0.35 logs, 3.6 logs, -
5.1 logs, 5.5 logs and 5.8 logs was observed in monocytes treated with 2, 5. 10, 15 
and 20 µgml of resveratrol respectively when compared to untreated monocytes. 
On the contrary, no significant change in gene expression was observed in case of 
healthy subjects n=6) at any of the concentrations of resveratrol used. Similar 
observations were observed with curcumin in both healthy and patients' cultures (Fig. 
60). The data, thus points to resveratrol and curcumin especially at 15 and 20 tg/ml 
doses, as effective natural immunoregulator that can be used against the pathogenesis 
of bone loss in osteoporosis. All values are mean } SE of six experiments (n=6) (p < 
0.001). 
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Figure 1 
Fig. 1: Oxidative Stress Study in Serum by Determining the GPx Activity in 
healthy controls (n=30) and osteoporosis patients (n=30). The data represents 
mean f S.E.M.; p<0.001. 
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Figure 2 
Fig. 2: Oxidative Stress Study in Monocyte Cultures by Determining the GPx 
Activity in Healthy Controls (n=200) and Osteoporosis Patients (n=20). The data 
represents mean ± S.E.M.; p<0.001. 
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Figure 3 
Fig. 3: Determination of Intramonocyte Glutathioue JGSHJ (pg/ml) levels in 24 
hr monocyte cultures of healthy controls (n=20) and osteoporosis patients (n=20). 
The data represents mean ± S.E.M.; p<0.001. 
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Figure 4 
Fig. 4: Dose response effect of Curcumin (0 to 25 µg/ml) on (;Px activity in 24 hr 
monocyte cultures of healthy controls (n=20). The data represents mean f 
i.E.M.; p<O.001. (Black bars = Resveratrol; Blue bars = curcumin). 
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Figure 5 
Fig. 5: Dose response effect of Curcumin (0-25 µg/ml) on GPx activity in 24 hr 
monocyte culture supernatants of osteoporosis patients' (n=20). The data 
represents mean ± S.E.M.; p<0.001. 
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Figure 6 
Fig. 6: Dose response effect of Resveratrol (0-25 ttg/m]) on GPs activity in 24 hr 
monocpte culture supernatants of osteoporosis patients (n=20). The data 
represents mean ± S.F.M.; p<a.00l. 
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Figure 7 
Fig. 7: Dose response effect of allicin (0-500 ng/ml) on intramonocyte GSH in 24 
hr monocyte cultures of healthy (n=20) and osteoporosis patients (n=20). The 
data represents mean ± S.E.M.; p<0.001. (Black bars = healthy; Blue bars = 
patients). 
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Figure 8 
Fig. 8: Dose response effect of Resveratrol (0-25 tg/ml) and Curcumin (0-25 
pg/ml) on intramonocste (S11 levels in 24 hr monoevte cultures of osteoporosis 
patients. The data represents mean ± S.E.M.; p<0.001. (Black bars = controls 
which did not receive any supplements; Red bars = patients culture receiving 
resv'eratrol; and blue bars = patients culture receiving curcumin). 
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Figure 9 
Fig. 9: Dose response effect of Resveratrol (0-25 µg/ml) and Curcumin (0-25 
pg/mI) on intramonocyte GSH levels in 24 hr monocyte cultures of healthy 
controls. The data represents mean f S.E.M.; p<0.001. (Black bars =resveratrol; 
Blue bars = Curcumin). 
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Figure 10 
Fig. 10: Modulation of intramonocyte GSH levels in 24 hr monocyte cultures of 
Osteoporotic Patients (n=20). The supplements used for modulation were NAC 
(10 mM), SNSO (100 teWml), SN50/M (100 µglml), Allicin (500 ng/ml), 
Resveratrol (25 pg/ml), Curcumin (25 pg/ml) and (-) represents cultures devoid 
of ant treatment. The data represents mean S.E.M.; p<0.001. 
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Figure 11 
Fig. 11: Modulation of intramonocytc CSH levels in 24 hr monocyte cultures of 
Healthy Control (n=20). The supplements used for modulation were NAC (10 
mM), SN50 (100 µg/ml), SN50/M (100 pg/ml), Allicin (500 ng/ml), Resveratrol 
(25 µg/ml), Curcumin (25 g/ml) and (-) represents cultures devoid of ant 
treatment. The data represents mean ± S.F.M.; p<0.001. 
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Figure 12 
Fig. E2; Determination of serum Malondialdehyde (MDA) Levels, nglml (n=20 
for each study group). The data represents mean t S.E.M.; p<0.001. 
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Figure 13 
Fig. 13: Determination of MDA levels in 24 hr culture supernatants of monocytes 
of healthy controls (n=20) and osteoporosis patients (n=20). The data represents 
mean t S.E.M.; p<0.001. 
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Figure 14 
Fig. 14: Dose response effect of Allicin on MDA levels in 24 he mouocyte culture 
supernatants of Osteoporosis Patients (n=20). The data represents mean t 
S.E.M.; p<0.001. 
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Figure 15 
Fig. 15: Dose response effect of Resveratrol on MDA levels in 24 hr monocyte 
culture supernatants of osteoporotic patients (n=20). The data represents mean f 
S.E.M.; p<0.001. 
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Fig. 16: Dose response effect of Resveratrol on MDA levels in 24 hr monucyte 
culture supernatants of Healthy Controls (n=20). The data represents mean f 
S.E.M.; p<0.00t. 
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Figure 17 
Fig. 17: Dose response effect of Curcumin on MBA levels in 24 hr monocyte 
culture supernatants of Osteoporosis Patients (n=20). The data represents mean 
± S.E.M.; p<0.001. 
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Figure 18 
Fig. 18: Dose response effect of Curcumin on M1)A levels in 24 hr monoc'•te 
culture supernatants of Healthy Control (n=20). The data represents mean f 
S. E. ti1.; p<0.001. 
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Figure 19 
Fig. 19: Levels of IL-1 Beta in serum and 24 hr monucyte culture supernatants of 
healthy controls (n=9) and osteoporosis patients (0=8). The data represents mean 
± S.E.M.; p<0.001. 
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Figure 20 
Fig. 20: Dose-response effect of allicin (0-500 ng/ml) on expression of lblP in 24 
hr monocyte culture supernatants of Osteoporosis Patients (n=S). The data 
represents mean ± S.E.M_; p<OA01. 
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Figure 21 
Fig. 21; Dose-response effect of allicin (0-500 ng/ml) on expression of IL-1p in 24 
hr munucyte culture supernatants of Healthy Controls (n=8). The data 
represents mean f S.F..M.; p<0.001. 
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Figure 22 
Fig. 22: Dose-response effect of Resveratrol (0-25 pg/mI) on expression of IL-I 
in 24 hr monocyte culture supernatants of Osteoporosis Patients (n=8). The data 
represents mean ± S.E.M.; p<0.001. 
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Figure 23 
Fig. 23: Dose-response effect of Resveratrol (0-25 pg/ml) on expression of IL-ID 
in 24 hr monocyte culture supernatants of Healthy Controls (n=8). The data 
represents meant S.E.M.; p<0.001. 
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200 
Fig. 24: Dose-response effect of Curcumin (0-25 pg/ml) on expression of 1L-1 in 
24 hr monocyte culture supernatants of Osteoporosis Patients (n=8). The data 
represents mean t S.E.M.; p0.60l. 
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Figure 25 
Fig. 25: Dose-response effect of Curcumin (0-25 pg/mI) on expression of IL-1p in 
24 hr monocyte culture supernatants of Healthy Controls (n=8). The data 
represents mean ± S.E.M.; p<0.001. 
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Figure 26 
Fig. 26: Determination of Human RANKL levels in 24 hr monocyte culture 
supernatants of healthy controls (n=8) and osteoporosis patients (n=8) by 
ELISA. The data represents mean f S.E.M.;pcU.001. 
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Figure 27 
Fig. 27: Dose response effect of Allicin (0-500 ngtml) on human RANKL in five 
days monocyte culture supernatants of Osteoporosis patient (o=S). The data 
represents meant S.E.M.; pd1.001. 
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Figure 28 
Fig. 28: ELISA for determining the level of Human RANKL in five days 
monocyte culture supernatants of various Healthy Controls (n=8) and patient 
(n-8) that were co-cultured with 500 ng/ml of allicin. The data represents mean 
± S.E.M.; p<0.001. 
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Figure 29 
Fig. 29: Determination of varying doses of Allicin-induced percent inhibition of 
RANKL by computational analysis. pc00)1. 
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Figure 30 
Fig. 30: ELISA for determining the level of Human RANKL in five days 
monocyte culture supernatants of various healthy (n=8) and patient (n=8) that 
were co-cultured with varying doses (0 - 25 pg/ml) of Resveratrol. The data 
represents mean t S.E.M.; p<0.001. (Black bars = healthy controls; blue bars = 
patients). 
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Figure 31 
Fig. 31: Dose response effect of Curcumin (0-25 pglml) on human RANKL in five 
days monocyte culture supernatants of Osteoporosis patient (n=8). The data 
represents meant S.E.M.; p<0.001. 
144 
100 
. 30 
60 
40 
q20 
0 	2 	5 	10 	15 	20 	25 
C1FfIro1ii (ug m)) 
Figure 32 
Fig. 32: Determination of Curcumin-induced percent inhibition of RANK!. by 
computational analysis. 
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Figure 33 
Fig. 33: Generation of multinucleated cells in 24 his (I day) and 72 hrs (3 days) 
monocyte cultures of individual osteoporotic patients' (patient numbers 1 to 10) 
under Osteoclastogenic medium. p41.001; (Black bars = 72 his i.e. 3 days 
culture; blue bars = 24 hr i. e. 01 day culture). 
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Figure 34 
Fig. 34. Generation of multinucleated cells in 120 his (5 days) monocyte 
cultures of individual osteoporotie patients' (patient numbers t to 10) under 
Osteoclastogenic medium_p<O.001. 
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Figure 35 
Fig. 35; Effect of allicin (500 ng/ml) on the generation of multinucleated cells in 
72 hrs (3 days) monocyte cultures of individual osteoporotie patients' (patient 
numbers 1 to 10). pN.001; (Black bars = without allicin; blue bars = with 
allicin). 
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Figure 36 
Fig. 36: Effect of allicin (500 ug/ml) on the generation of multinucleated cells in 
72 his (3 days) monoeyte cultures of individual osteopurotic patients' (patient 
numhen 11 to 20). p<0.001; (Black bars = without allicin; blue bars = with 
allicin). 
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Figure 37 
Fig. 37: Effect of allkin (500 ng/ml) on the generation of multinucleated cells in 
72 hra (3 days) monocvte cultures of individual osteoporotie patients' (patient 
numbers 21 to 30). p<0.001; (Black bars = without allicin; blue bars = with 
allicin). 
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Figure 38 
Fig. 38: Effect of Resveratrol (2S µg/ml) on the generation of multinucleated cells 
in 72 hrs (3 days) monocyte cultures of individual osteoporotlic patients' (patient 
numbers I to 10). pcO.001; (Black bars = without resveratrol; blue ban = with 
resveratrol). 
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Figure 39 
Fig. 39; Effect of Resveratrol (25 pglml) on the generation of multinucltiated cells 
in 72 his (3 days) monocyte cultures of individual osteoporotic patients' (patient 
numbers II to 20). pcO.001; (Black bars = without resveratrol; blue bars = with 
resveratrol). 
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Figure 40 
Fig. 40; Effect of Resveratrol (25 pg/ml) un the generation of multinucleated cells 
in 72 hrs (3 days) monocyte cultures of individual osteoporotic patients' (patient 
numbers 21 to 30). p<0.001; (Black bars = without resveratrol; blue ban = with 
resveratrol)_ 
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Figure 41 
Fig. 41: Effect of Curcumin (25 p g/ml) on the generation of multinucleated cells 
in 72 hrs (3 days) monocyte cultures of individual osteoporotic patients' (patient 
numbers 1 to 10). p<0.001; (Black bars = without curcumin; blue bars = with 
curcumin). 
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Figure 42 
Fig. 42: Effect of Curcumin (25 pglml) on the generation of multinucleated cells 
in 72 hrs (3 days) m000cyte cultures of individual osteoporotic patients' (patient 
numbers 11 to 20). p<0.001; (Black bars = without curcumin; blue bars = with 
curcumin). 
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Figure 43 
Fig. 43: Effect of Curcumin (25 g/ml) on the generation of multinucleated cells in 
72 hrs (3 days) monocyte cultures of individual osteoporotic patients' (patient 
numbers 21 to 30). p<0.001; (Black ban = without curcumin; blue bars = with 
curcumin). 
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After 72 h (3 days) of Culture of PBMCs In 
Osteoclastogenic Medium 
100 
80 
U 
0 
V
Y 
~ 60 Y 
7 
C: 
40 
20 
E 
z 
0 
1 	2 	3 	4 	5 	6 	7 	8 	9 	10 
Osteoporoac PaaentNUmber 
Figure 43a 
Fig. 43a: Individual variation in ostcoclast generation in 72 hr monocyte cultures 
from different donors. Human osteoclasts were generated from peripheral blood 
mononuclear cells (PBMCs) as described under Methodology. The results from 
10 patient donors are presented as quantification of TRAP-positive 
multinucleated cell number. The effect of EGCG (20 pgfml) is shown in black 
bars; p<0.001. 
157 
ECC(_ 	■v.oth ECCC 
8 	9 	10 1 	2 	3 
500 
400 
U 
3 
200 c3 
C 
0 100 
E 2 z 
0 
4 	5 	6 	7 
Osteoporetic Patient Number 
After 120 h (5 days) of Culture of PBMCs in 
Osteoclastogenic Medium 
Figure 43b 
Fig. 43b: Individual variation in osteoclast generation in 120 hrs monocyte 
cultures from different donors. Human osteoclasts were generated from 
peripheral blood mononuclear cells (PBMCs) as described under Methodology. 
The results from 10 patient donors are presented as quantification of TRAP-
positive multinucleated cell number. The effect of EGCG (20 µg/ml) is shown in 
black bars; p<0.001. 
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Figure 44 
Fig. 44: Time course kinetic of multiinucleated cells generation in 72 he monocyte 
cultures of osteoporosis patients (n-6) and their suppression in the presence of 
allicin (500 ng/ml), resveratrol (25 pg/ml) and curcumin (25 pglml); 
p<O.t101.(Black bar without supplements; Blue bar— With allicin (5110 nglml), 
Red bar—With Resveratrol (25 jig/ml) and Violet bar— With Curcumin (25 
µg/ml). 
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Fig. 45: OPN levels (nglml) determined by ELISA in normal healthy sera (n=10); 
x0.001. 
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Figure 46 
Fig. 46: OPN levels (aglml) determined by ELISA in individual osteoporotic 
patients' sera (n=10); p<0.001. 
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Figure 47 
Fig. 47: ELISA for determining OPN levels (ug/ml) in 72 hr monocyte culture 
supernatant of normal healthy samples (n6); p<0.p01. 
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Figure 4A 
Fig. 48: ELISA for determining OPN levels (nglml) in 72 hr monocyte culture 
supernatant of osteoporotic patients (u6); p<O.001, 
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Figure 49 
Fig. 49: ELISA for determining OPN levels (ng/ml) in the absence and presence 
of calcitonin (1 ng/ml) in 72 hr monocyte culture supernatants of osteoporosis 
patients (n=6); p<O.001; Ihlack bars = cultures devoid of calcitonin; blue bars = 
cultures receiving 1 ng/ml calcitonin. 
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Figure 50 
Fig. 50: Determination of OPN levels (ng/ml) by ELISA in 72 hr monocyte 
culture supernatants of osteoporosis patients (n=6) that were co-cultured 
separately (a) in the presence of 25 pg/mt of Resveralrol and (b) with a mixture 
of 25 pg/ml Resveratrol + 1 ng/ml calcitonin. p<0.001; (Black ban = cultures 
receiving resveratrol only; blue bars = cultures receiving with a mixture of 25 
pig/ml Resveratrol + I ng/ml calcitonin). 
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Figure 51 
Fig. 51: Determination of OPN levels (ng/ml) by ELISA in 72 hr monocyte 
culture supernatants of osteoporosis patients (n6) that were co-cultured 
separately (a) in the presence of 25 pg/ml of Curcumin and (b) with a mixture 
of 25 pg/ml Curcumin + I ng/ml calcitonin. p<0.001; (Black bars = cultures 
receiving Curcumin only; blue bars = cultures receiving with a mixture of 25 
pg/ml Curcumin + l ng/mI calcitonin). 
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Figure 52 
Fig. 52: Determination of OPN levels (ng/ml) by ELISA in 72 hr monocyte 
culture supernatants of osteoporosis patients (n=6) that were co-cultured 
separately (a) in the presence of 500 ng/ml of Allicin and (b) with a mixture of 
5% ng/ml of Allicin + 1 ng/ml calcitonin. p<O.IIOI; (Black bars = cultures 
receiving allicin only; blue ban = cultures receiving with a mixture of 500 ng/ml 
of Allicin + I ug/ml calcitonin). 
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Figure 53 
Fig. 53: Determination of that were Effect of) on OPN levels (ng/ml) by ELISA in 
72 hr monocyte cultures of osteoporotic patients (n=!) that were cc-^_!t-  ^c-' ••'t• 
Denosumab (Prolia) (1 nglml); p<U.001. 
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Figure 54 
Fig. 54: Real Time RT-PCR for TNF-alpha mRNA copies number expression in 
24 hr monocyte cultures of healthy (n6) and osteoporosis patients (n=6). 
p<0.001. 
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Figure 55 
Fig. 55: Real Time RT-PCR for OPG mRNA expression in 24 hr monocyte 
cultures of healthy (n=6) and osteoporosis patients (n6).p<0.001. 
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Figure 56 
Fig. 56: Dose Response effect of Allicin (0-500 ng/ml) on the Expression of 
Human House Keeping Gene R18 in 24 hr monocyte cultures of osteoporosis 
patients (n=6) by 'real time' RT-PCR.. pa0A01. 
171 
1.00E+10 
1.00E+08 
1.00E+0L: 
1.00E+04 
1.00E+02 
a 
1.00E+00 
0 	 2 	 5 	 10 	 15 	 20 
ResveratroI (µ*/m4 
Figure 57 
Fig. 57: Dose Response Effect of Resveratrol (0-20 ug/mi) on the Expression of 
Human House Keeping Gene R18 mRNA in 24 hr monocyte cultures of 
osteoporosis patients (n=6) by `real time' RT-PCR.. p<0.001. 
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Figure 58 
Fig. 58: Dose Response Effect of Curcumin (0-20 µg/mI) on the Expression of 
Human House Keeping Gene R18 mRNA in 24 hr monocyte cultures of 
osteoporosis patients (n=6) by 'real time' RT-PCR.. p<0A01. 
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Figure 59 
Fig. 59: Dose Response Effect of Alliein (0-500 ng/ml) on the expression of TNF-
alpha mRNA in 24 hr cultures of monocytes of osteoporosis patients (n=6) by 
`real time' RT-PCR. p<O.00L (Black ban = health; blue bars = patient). 
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Figure 60 
Fig. 60: Dose Response Effect of Resveratrol (0-20 pglml) on the expression of 
TNF-alpha mRNA in 24 hr cultures of monocytes of osteoporosis patients (n=6) 
by 'real time' KT-PCR..p<0.00I. (Black bars = healthy; blue bars — patient). 
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Figure 61 
Fig. 61: Dose Response Effect of Curcumin (0-20 pg/ml) on the expression of 
TNF-alpha mRNA in 24 hr cultures of monncvtcs of osteoporosis patients (n=6) 
by `real time' RT-PCR.. p41.001. (Black bars =healthy; blue bars = patient). 
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DISCUSSION 
Osteoporosis is a chronic, progressive disease of the skeleton characterized by 
bone fragility due to a reduction in bone mass and possible alterations in hone 
architecture which lead to a propensity for fractures with minimum trauma [Kang ei 
aL, 2014]. Bone formation is related to osteoblastic proliferation, ALP activity, and 
osteocalcin and collage synthesis. Bone resorption is associated with osteoclast 
formation and differentiation, and TRAP [Kang er al., 2014]. Oxidative stress is 
caused by an imbalance between the generation of reactive oxygen species (ROS) and 
the activity of antioxidant defense. Severe oxidative stress has been implicated in 
many chronic and degenerative diseases, including osteoporosis, cancer, ageing, and 
neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and 
amyotrophic lateral sclerosis [Kang et al., 2014]. Several medications such as CT, 
calcium products, estrogen, bisphosphonates. ipriflavone and anabolic steroids have 
been reported to be effective for curing osteoporosis [Kang et at, 2014 and references 
within]. However, these medications may have serious side effects, may not improve 
bone quality, or may not reduce susceptibility to fracture [Kang et al, 2014 and 
references within]. Recently, oriental traditional medicines have been re-evaluated by 
clinicians because these medicines have fewer side effects and are more suitable for 
long-term use compared with chemically synthesized medicines [Kang et al., 2014 
and references within]. Some natural flavonoids with potent antioxidant activity 
including scopoletin, resveratrol, and baiealein have found to exert anti-osteoporotic 
activities through suppressing osteoclast formation and TRAP [Kang et al., 2014]. 
Accordingly, natural antioxidants have become a topic of increasing interest as they 
could provide a safe, economical and valuable tool in combating such diseases. 
Low bone mass and micro architectural deterioration of bone tissue, increasing 
susceptibility to fracture is one of the main characteristics of osteoporosis 
[fleinemann, 2000]. Although osteoporosis is often described as a silent disease 
because it is typically asymptomatic until a fracture occurs, the disease negatively and 
significantly impacts morbidity and mortality as it can lead to severe pain, deformity, 
disability, and death [Heinemann, 2000; Salkeid et. al., 2000]. Osteoporosis is an 
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under recognized disorder in men whereas a highly recognized and predominant 
phenomenon in post menopausal women [Ebeling, 2008; Adler, 2011; Burge et al., 
2007]. When compared to females, reports show that males often develop fractures 
around a decade later in life [Adler, 2011] and that, are less likely to survive with a 
high mortality rate after hip fracture [Bass et al., 2007; Jiang et al., 2005]. Besides 
from bone fractures because osteoporosis, a variety of hone parameters across 
different types of hip osteoartluitis and their relationship to osteoporotic fracture risk 
have also been widely studied [Castaiio-Betancoutt et al., 2013]. 
TNF-a - which belongs to class of inflammatory autocrine cytokine, have been 
shown to inhibit osteogenic differentiation of MSCs and bone formation in estrogen 
deficiency-induced osteoporosis. Unfortunately, till date, the precise or exact 
mechanism responsible for it remains poorly understood. Furthermore, reports 
indicate that microRNAs (miRNAs) have been shown to regulate MSC differentiation 
[Yang et al., 2013. Next, in an another other experiment carried out recently by Yang 
et at, 2013, has identified a novel mechanism whereby TNF-a, suppressing the 
functional axis of a key miRNA (miR-21) contributes to estrogen deficiency-induced 
osteoporosis. Moreover, in the same study, workers have reportedly screened 
differentially expressed miRNAs in MSCs derived from estrogen deficiency-induced 
osteoporosis and found miR-21 was significantly down regulated. miR-21 was 
suppressed by TNF-a during the osteogenesis of MSCs. Furthermore, miR-21 was 
confirmed to promote the osteoblast differentiation of MSCs by repressing Spryl, 
which can negatively regulate the osteogenic differentiation of MSCs. Up regulating 
miR-21 partially rescued TNF-u-impaired osteogenesis of MSCs. Whereas, it was 
observed that blocking of TNF-a ameliorated the inflammatory environment and 
significantly enhanced bone formation with increased miR-21 expression and 
suppressed Spry] expression in ovadectomized (OVX) mice. Also, their results 
revealed a novel function for miR-21 and suggested that suppressed miR-21 may 
contribute to impaired bone formation by elevated TNF-a in estrogen deficiency-
induced osteoporosis [Yang et al., 2013]. A wide spectrum of studies have reported 
increased production of TNF by cultures of mononuclear cells derived from 
osteoporosis patients, an effect reversed by estrogen replacement [Shevde e1 al., 
2000]. 
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ROS may play a role in bone loss in osteoporosis patients by generating a 
more oxidized hone microenvironment [Almeida and O'Brien, 2013]. Globally, 
osteoporosis is known since the origin of human civilization, but complete 
understanding about its management still remains poorly understood till date. 
Augmented generation of ROS in vivo due to a wide spectrum of in-vivo-related 
reasons, leads to the activation and up-regulation of hone markers like pro-
inflammatory cytokine TNF-u and it's super family member OPG as well as OPN and 
CT at both the protein and gene i. e. mRNA levels. This in turn results in accelerated 
osteoclast differentiation, thereby resulting to loss of bone mass, including 
osteoporosis, arthritis, orthopedic implant loosening, etc. Thus, if ROS production in 
vivo is regulated by natural antioxidants, then the above-mentioned bone markers 
associated with chronic bone conditions may be easily regulated. 
Therefore, in view of the above, we probed here the management and/or 
regulation of ROS and TNF-u activation in osteoporosis patient monocytes by 
employing various natural antioxidants like allicin from garlic, resveratrol, curcumin 
and EGCG from green tea. The mechanisms of cellular activation as well as TNF-u 
and ROS enhancement would definitely help in better understanding the pathogenesis 
of osteoporosis. 
It has been well established that the autocrine cytokine TNF-a is implicated in 
the pathophysiology of bone metabolism, where_the presence of elevated levels of 
TNF in the bone marrow of ovx animals and in the conditioned media of peripheral 
blood cells of postmenopausal women as well as osteoporosis patient is well 
documented [Pacifici, 2010]. Interestingly, ROS are also involved in the 
etiopathology and progression of osteoporosis as reported earlier, and that, radicals 
generated in cells of osteoporosis patient stimulate TNF-a. causing accelerated bone 
loss. 
In the present study, we employed various natural antioxidants like allicin 
from garlic as well as resveratrol and curcumin and also to a lesser extent, EGCG 
from green tea, whose exact mechanism underlying their antioxidant activity still 
remains poorly understood. Allicin-induced enhancement of GPx activity has been 
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reported [Perchellet et at.. 1986; Bryk et al., 2002]. To the best of our understanding, 
we show for the first time that allicin, resveratrol and curcumin exerts potent anti-
inflammatory and free radicals scavenging effects on osteoporosis patient 
mononuclear cells. 
Doses of allicin higher than I00 tM and those of EGCG higher than 23 µg/ml 
have proven to be toxic [Ankri et a1., 1997; Hasan et at, 2006; Kawai et a/.. 2005], 
thus, doses below the above mentioned doses were selected in the present study. 
Therefore, prior to all investigations, cell viability and potential cyaotoxicity were 
determined for the doses employed in this study using trypan blue and MTT assay 
where viability of -98-99% was observed with the lower doses selected in the present 
study. Moreover, our laboratory has previously demonstrated that the doses employed 
in the present study for allicin or EGCG had no effect on human housekeeping genes 
namely R18, thereby demonstrating that the effect of allicin or EGCG, was not 
mediated by cellular death, but rather by specific inhibition of expression and 
secretion of pro-inflammatory molecules [Hasan et al, 2006; Singh el al.. 2002; 
Fatima et al., 2012]. Hence, data has not been shown here. Similarly, after performing 
dose response effects of resveratrol and curcumin, it was found that cells remained 
viable to the extent of -98-99% at 20-25 µg/ml of resveratrol and curcumin 
respectively as revealed by trypan blue and !MfTT assay, and that both these natural 
antioxidants had no adverse effect on human housekeeping gene RI S. 
The real time RT-PCR results indicate an appreciable / high degree of down-
regulation in endogenous TNF-u mRNA expression by allicin, resvcratrol and 
curcumin in osteoporosis patient monocyles cultured under osteoclastogenic medium. 
Our results regarding TNF-a m RNA and OPG mRNA expressions in osteoporosis 
patients as well as regulation by the above antioxidants are in accordance to similar 
pattern observed by other workers with different antioxidants than ours [Nazrun etal., 
2012]. Furthermore, TNF-u generation in monocytes is regulated at multiple 
intracellular levels, beginning with transcription [Raabe et at, 1998]. Elevated 
expression of TNF-a mRNA and activation of a relevant transcription Factor, NF-KB, 
have been reported in monocytic cells derived from osteoporosis patient. In 
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accordance to earlier finding, in the present study, we also report here the up 
regulation of'INF-a mRNA expression as well as activation of NF-KB in human 
monocytes derived from osteoporosis patient patients. The induction of TNF-a 
expression was observed to be mediated through activation of NF-KB, as evidenced 
by the suppression of TNF-a tuRNA in the presence of SN50, an inhibitor of NF-tcB. 
On the contrary, the control SN50JM, an inactive analogue of SN50, failed to show 
any such effect. It has been well established that 'INF-u induced nuclear translocation 
ofNF-r.B was inhibited by SN50 peptide as demonstrated in EMSA [Lin et al., 1995]. 
Therefore, in light of the above view, the data in the present study 
demonstrated that this effect involved inhibition of the NF-KB pathway induced by 
various natural antioxidants namely allicin, resveratrol and curcumin, probably by 
inhibiting the degradation of hdBa. The NFKB heterodimer is retained in the 
cytoplasm in an inactive form through association with one of the IKBS inhibitory 
proteins. As a consequence of stimulation by TNF-a, the IKBa gets phosphorylated by 
a specific kinase complex (IKK) leading to its ubiquitination, and subsequent 
proteolysis by the 28S proteosome [Lang et al., 2004: Li and Verma, 2002]. The 
degradation of IxB releases active NF-KB, which translocates to the nucleus and 
regulates gene expression by binding to KB binding sites or by interacting with other 
transcriptional factors [Brown et al., 1995]. Since a number of genes involved in 
inflammatory responses are regulated by NF-xB pathway, thus a high magnitude 
downregulation of the NF-KB pathway by allicin and or resveratrol and curcumin 
would predictably reduce the elaboration of NF-KB-mediated TNF-a mRNA 
expression. 
Next, it's a well established fact that olutathione directly reacts with ROS, and 
GPx catalyzes the removal of hydrogen peroxide [Mesiter and Anderson, 1983]. 
Down-regulation or decrease in GPx activity indicates impairment of hydrogen 
peroxide-neutralizing mechanisms [Rukmini et al., 2004]. Here, in the present study, 
it was observed that in osteoporosis patient monocytes that were untreated with allicin 
or resveratrol or curcumin, there was an appreciably suppressed GPx activity, thereby 
in turn, correlating with earlier reports that substantial amounts of ROS are being 
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generated in hone cells of osteoporosis patient due to lowering of antioxidant defences 
in such type of cells. Augmentation / enhancement of GPx activity in osteoporosis 
patient monocyte cultures after addition of NAC, a precursor of in vivo antioxidant 
glutathione. indicates reversal of impaired neutralizing mechanisms. Interestingly. 
here slightly augmented GPx activity was observed when allicin or resveratrol or 
curcumin was co-cultured instead of NAC, indicating allicin as well as resveratrol and 
curcumin to be an effective natural antioxidant combating ROS, generated as a 
consequence of cellular activation in osteoporosis patient monocytes. Thus, our data 
exhibited amelioration in GPx activity by allicin, resveratrol and curcumin, which in 
turn, correlated inversely with the down regulation of TNF-a mRNA expression and 
ROS in monocytes of osteoporosis patient. 
Next, in our study, peripheral blood mononuclear cells (PBMCs) were used 
directly for the generation of osteoclast precursors under osteoclastogenic medium. 
The multinucleated osteoclast precursors were observed to appear on day 3 and the 
number increased after 5 days of culture, as revealed by Tartrate Resistant Acid 
Phosphatase (TRAP) staining. However. after 24 h (I day) of culture, appearance of 
osteoclast precursors was negligible. The number of multinucleated preosteoclasts, 
arising from PBMCs isolated from the blood of normal healthy individual (data not 
shown) and osteoporotic patients were counted by TRAP staining, where individual 
variation in osteoclast generation from different donors were observed. 
Interestingly, we observed that co-culturing of PBMCs with resveratrol (25 
pgiml) or curcumin (25 pg ml) or allicin (500 ng/ml) in osteoclastogenic medium for 
3 and 5 days resulted in an appreciable amount of reduction in appearance of 
multinucleated osteoclast precursors, thereby reflecting the potential of these natural 
antioxidants to exert regulatory effect in osteoclast generation and differentiation. 
Nearly 30% suppression in appearance of multinucleated cells was observed in 
cultures receiving 20 pg/ml of resveratrol or curcumin relative to control cultures 
devoid of any supplements as said above. Interestingly, around 40% suppression in 
appearance of multinucleated cells was observed in cultures receiving 500 ng!ml of 
allicin relative to control cultures devoid of any supplement i. e. allicin. 
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Our data shows around 12-fold augmented OPN levels in culture supernatants 
of monocytes fi-om osteoporotic patients in comparison to healthy controls. To the 
best of our knowledge, we show for the first time the natural antioxidants (allicin, 
resveratrol and curcumin) — induced down-regulation! suppressed levels of OPN, and 
that too, to an appreciable magnitude. Even, modulation with positive modulator 
namely CT failed to minimize the negative modulatory effects of allicin, resveratrol 
or curcumin on OPN. Out of these three natural antioxidants, allicin proved to be the 
most potent suppressor / down-regulator of OPN followed by resveratrol followed by 
curcumin. 
One of the most striking findings was that allicin followed by resveratrol was 
equally good as Denosumab (Prolia), which has recently been employed in the 
treatment of osteoporosis, in suppressing OPN levels. Denosumab (Prolia®) [Rizzoli 
et al.. 2010] offers a new approach in the treatment of osteoporosis [Dubois et al., 
201I]. At present, it is being clinically used for the treatment of osteoporosis and 
cancer-related bone disorders in Japan, Europe, United States and many other 
countries [Yasuda, 2013]. It decreases bone resorption by inhibiting osteoclast 
formation, function and survival [Dubois et al., 2011]. Denosumab is a fully human 
monoclonal 1g02 antibody that binds RANKL with high affinity and specificity, 
preventing interaction with RANK on the osteoclast membrane [Yasuda, 2013]. In 
other words we can say that it is a fully human anti- RANKL monoclonal antibody or 
a RANKL neutralizing antibody [Yasuda, 201 3]. It is a strong inhibitor of RANKL. It 
blocks the interaction of RANKL with RANK [Schmiedel et al., 2012]. Thus, it 
mimics the endogenous effects of osteoprotegerin (OPG) [Yasuda, 2013]. By 
attaching to and blocking RANKL, denosumab inhibits osteoclast differentiation, 
activation and survival [Dubois et a)., 2011]. This favors bone formation over bone 
resorption. increasing bone mass and reducing the risk of fractures [Cummings et al., 
2009]. It also reduces the release of RANKL-induced immunomodulatory factors by 
acute myeloid leukemia (AML) cells and their immunomodulatory effects [Schmiedel 
or al., 2012]. In addition, Denosumab prevents inhibitory RANK signaling into NK 
cells, which results in enhanced NK cell antitumor reactivity [Schmiedel et al., 2012]. 
It has been developed and shown to be effective in tre-rtment of non-malignant and 
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malignant ostcolysis I Lacey et al., 2012J. It has also been demonstrated to prevent or 
delay skeletal-related events (SREs) in patients with solid tumors that have 
metastasized to bone [Dougall et al., 2014[. Denosumab is administered once every 6 
months as a 60-mg subcutaneous injection [Dubois et al., 2011]. It is very stable in 
the blood stream for several months after single subcutaneous injection [Yasuda, 
2013]. During treatment, calcium and vitamin D supplementation is important 
[Dubois et al., 2011]. Adverse Effects of Denosumab (ProliaF) have also been 
reported, where patients with hypocalcaemia and/or chronic kidney disease may 
develop symptomatic hypocalcaemia upon treatment with denosumah [Dubois et al., 
20111. Therefore, hypocalcaemia should be corrected before therapy and serum 
calcium concentration monitored [Dubois et al., 2011j. Because RANKL also has a 
function in the immune system, denosumab could adversely influence infections of 
the urinary and upper respiratory tracts I Dubois et al., 20111. 
Thus, in the present study, the suppressed levels of OPN which was induced 
by allicin as well as resveratrol and curcumin respectively may probably be by 
blocking RANKL by these natural antioxidants just like denoswnab, and in turn, 
inhibits osteoclast differentiation, activation and survival, and consequently, in turn, 
favors bone formation over bone resorption, increasing bone mass and reducing the 
risk of fractures. Recent report shows the effect of resveratrol in rats that improves 
bone repair by modulation of bone morphogenctic proteins and OPN gene expression 
[Casarin et at, 2014]. 
Next, our data revealed that allicin, resveratrol and curcumin appreciably 
down regulated / suppressed the secretion of sRANKL. With allicin, it was observed 
that sRANKL dose-dependently decreased from 33.16 pgimi at 0 ng/ml by around 
16.94%, 38.69%, 60.55% and 90.89% with 50, 100, 250 and 500 ng allicin 
respectively, where the IC50 was computed out to he in between 100-135 ng/ml. 
Similarly, analysis of the data exhibited that resveratrol down regulated / suppressed 
the secretion of sRANKL from 35.16 pg/ml at through 29.11, 24.26, 15.16, 11.33, 
9.16 and 8.89 pg/mI with 0, 2, 5, 10, 15 20 and 25 pg resveratrol respectively. The 
IC so  was computed out to be around 8 pglmt of Resveratrol. Furthermore, 
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computational analysis of the data revealed that curcumin down regulated the 
secretion of sRANKL by around 1500.  31%. 46°c. 60%, 70% and 73% with 2, 5. 10, 
15 20 and 25 µg curcumin, and that, the IC50 was found to be around 9 µg/ml of 
Curcurnin. Therefore. the present study provides for the first time evidences that 
natural antioxidants namely allicin from garlic as well as resveratrol and curcumin 
inhibited RANKL mediated signaling events that lead to osteoclast differentiation and 
function in monocyte cultures. Incubation of osteoclast progenitor cells with allicin or 
resveratrol or curcumin inhibited TRAP activity and TNF-alpha mRNA expression in 
a dose dependent manner. 
The findings in the present study are novel and contribute to define a 
mechanism for the altered bone turnover in osteoporosis patients that, which in turn, 
may protect patients from early bone loss or lead to increased bone mass. Bone mass 
is tightly regulated by osteoclastic and osteoblastic bone remodeling. The contribution 
of natural antioxidants like allicin from garlic as well as resveratrol and curcumin to 
bone remodeling in vivo is poorly understood. The findings of the present study are 
indicative/suggestive that allicin. resveratrol and curcumin are inhibiting 
osteoclastogenesis, likely by preventing the formation of pre-osteoclast cells capable 
of fusing into multinucleated osteoclasts. ROS including superoxide anion and 
hydrogen peroxide (H2O,) have been recognized as major intermediaries in the 
formation and activation of osteoclasts in vitro and in vivo [Wittrant et al., 2008: Suda 
et al., 1993; Garrett et al., 1990; Lee et al., 2005]. RANKL-mediated ROS production 
serves to regulate RANKL signaling pathways required for osteoclast differentiation 
[Koh et al., 2006; Ha et al., 2004; \ 'ittrant et al., 2008]. Furthermore, in RAW264.7 
and BMM precursor cells. RANKL increases ROS. whereas expression of catalase in 
BM%1 cells blocks RANKL-induced ROS production and inhibits the formation of 
TRACP+osteoclasts [Wittrant cat al., 2008: Lee et al., 2005]. and that, such effects 
were reported to be correlated with the decreased formation of multinucleated 
osteoclast-like cells in the TRACP assays and likely contributed to the inability of 
these cells to differentiate in response to RANKL. 
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'Pherefore, in summary, our data regarding regulation of TNF-a, sRANKL, 
OPN, GPx activities, ostcoclast formation and differentiation, etc by allicin from 
garlic as well as resveratrol and curcumin could provide a valuable tool in probing the 
control molecular mechanism of osteoporosis, and in turn, such natural antioxidants 
may serve as adjuncts in the management of osteoporosis. 
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CONCLUSION 
In conclusion, it can be inferred from the present study that: 
1. Appreciable degree of suppression in GPx activity in both sera as well as in 
monocyte cultures of osteoporosis patients was observed, and that, the 
intramonocyte GSH levels were also found to be significantly down-regulated 
in osteoporosis patients. 
2. Allicin from garlic as well as resveratrol and curcumin dose-dependently 
ameliorated/up-regulated the suppressed GPx activity as well as GSH levels in 
osteoporosis patients. 
3. Activation of monocvtes of osteoporosis patients which was mediated by 
reactive oxygen species (ROS) resulted in the induction of 
enhanced&augmented basal levels of TNF-a and IL-l. Furthermore, allicin, 
resveratrol and curcumin efficiently caused down-regulation in TNF-alpha and 
IL- (beta in both sera as well as in monocyte cultures of osteoporosis patients. 
4. Appreciably high levels expression of TNF-a and OPG in monocytes of 
osteoporosis patients was observed. 
5. 25 pg//ml of Resveratrol, 25 kg'ml of Curcumin and 500 ng'ml of allicin 
exhibited no toxic effect on the cell viability as it showed no effect on human 
housekeeping gene RI 8. 
6. All the three natural antioxidants namely allicin, resveratrol and curcumin 
were found to dose-dependently down-regulate the expression of TNF-alpha 
mRNA in monocytes of osteoporosis patients. 
7. All the three natural antioxidants namely allicin., resveratrol and curcumin that 
were separately co-cultured with PBMCs in osteoclastogenic medium for 3 
and 5 days resulted in an appreciable amount of suppression/down-
regulation/reduction in appearance of multinucleated osteoclast precursors, 
thereby reflecting upon the beneficial potential of allicin, resueratro1 and 
curcumin to exert regulatory effect in osteoclast generation and differentiation. 
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8. Osteoporosis patient's cultures exhibited high magnitude of augmented levels 
of sRANKL and osteopontin levels in comparison to healthy controls. 
9. The natural antioxidants namely allicin, resveratrol and curcumin dose- 
dependently suppressed i down-regulated / decreased sRANKL and 
Osteopontin secretions in cultures of osteoporosis patients. 
10. All the natural antioxidants selected in this study exhibited potential 
antioxidant as well as anti-bone resorptive properties as suggested from results 
observed from down-regulation of bone markers like sRANKL, osteopontin, 
TNF and IL-lb. 
11. Modulation with positive modulator namely calcitonin failed to minimize the 
potent negative modulatory effects of allicin, resveratrol or curcumin on 
osteopontin. 
12. Out of these three natural antioxidants, allicin proved to be the most potent 
suppressoridown-regulator of OPN and sRANKL, followed by resveratrol and 
in turn, followed by curcumin. 
13. One of the most striking findings was that allicin followed by resveratrol was 
equally good as Denosumab (Prolia), which has recently been employed in the 
treatment of osteoporosis, in suppressing Osteopontin levels. 
Thus, in summary, based on the results, it is hoped that the present study 
would be of immense help in the better understanding of osteoporosis management by 
employing natural antioxidants. 
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Abstract: 
Osteoporosis has been shown to be associated tutth elevated 
levels of TNF-a and int racellular reactive oxygen species (ROS). ROS 
is actively related to production of LYE-o, which in turn, leads to 
activation of bone markers, thereby resulting in accelerated osteoclast 
differentiation leading to osteoporosis. (-)-Cpigalloeatechin-3-gallate 
(EGCG), one of the most potent polyphenol, an active ingredient of 
green tea (Camellia sinensis), has earlier been reported to have potent 
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antioxidant and free radical scoaenging properties along with strong 
ininunoniodulatoy activity. EGCG is found to suppress osteoclasts 
differentiati.ort. EGCG is also found to exert inununornodulutory and 
antioxidatiue effects on inonoeytes of osteoporotic patients. Secreted 
T,'VF-a were found to be suppressed using varied doses of EGCG. 
EGCG, dose dependently found to enhance the glutathione peroxidase 
(GPx) activity. Therefore, EGCG has the potential to be used as an 
adjunct in the cheinopreuention and treatment of osteoporosis. 
Key words: Epigallocatechin-3-gallate (EGCG), Glutathione 
peroxidase (GPx), Reactive oxygen species (ROS), TNF- a 
Introduction 
Bone is the primary site of haematopoiesis. The complex 
interplay between the bone organ system and the immune 
system is continuously emerging with the advancement of 
research (Bab and Einhorn, 1994; Horowitz and Jilka, 1992; 
Wein et al., 2005). Osteoporosis is a disease of bones that leads 
to an increased risk of fracture (Alldredge et al., 2009), where 
the bone mineral density (BMD) is reduced, bone micro 
architecture deteriorates, and the amount and variety of 
proteins in bone is altered. Osteoporosis is defined by the World 
Health Organization (WHO) as a bone mineral density that is 
2.5 standard deviations or more below the mean peak bone 
mass (WHO, 1994). The underlying mechanism in all cases of 
osteoporosis is an imbalance between bone resorption and bone 
formation (Frost and Thomas, 1963). Bone is resorbed by 
osteoclast cells, after which new bone is deposited by osteoblast 
cells (Raisz, 2005). Osteoclasts having the unique property of 
dissolving bone are the cells of hematopoietic origin, whose 
inhibition leads to treatment of diseases of bone loss such as 
osteoporosis. 
' Corresponding author: nxi7@hotinail.com 
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There are various peculiar characteristics of osteoclasts, such 
as tartrate- resistant acid phosphatase (TRAP) staining, 
multinuclearity, formation of actin ring structure and a polar 
cell body during resorption, and contraction in response to 
calcitonin. Osteoclasts express a number of molecular markers, 
such as calcitonin receptor, RANK (receptor of RANKL, 
receptor activator of NFKB ligand), c-fms (receptor of M-CSF, 
macrophage-colony stimulating factor), cathepsin K, c-src, fosL1 
and the vitronectin receptor (integrin av63) (Nijweidi et al., 
1986; Susa et al., 2004: Netter. 1987). 
The activation of osteoclasts is regulated by various 
molecular signals, of which RANKL is one of best studied. This 
molecule is produced by osteoblasts and other cells (e.g. 
lymphocytes), and stimulates. Osteoprotegerin (OPG) binds 
RANKL before it has an opportunity to bind to RANK, and 
hence suppresses its ability to increase bone resorption. 
RANKL. RANK and OPG are closely related to tumor necrosis 
factor and its receptors (Raisz, 2005). Therefore, the 
OPG/RANKL/RANK cytokine system is essential for osteoclast 
biology. Various studies suggest that human metabolic diseases 
such as osteoporosis are related to alterations of this system 
(Hofbauer et al., 2004). Furthermore, local production of 
eicosanoids and interleukins is thought to participate in the 
regulation of bone turnover, and excess or reduced production of 
these mediators may underlie the development of osteoporosis 
(Raisz, 2005). 
Tea [Ca,nellia sinensis (Theaceae)] is second only to 
water in terms of worldwide popularity as a beverage. Green 
tea is chemically characterized by the presence of large 
amounts of polyphenolic compounds known as catechins. which 
includes epicatechin (EC), epicatechin-3-gallate (ECG), and 
EGCG account for 30-40% of the dry weight of green tea 
(Lambert and Yang. 2003; Yang et al.. 2006). The compound (-)-
epigallocatechin-3-gallate (EGCG) is the most abundant and 
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biologically active catechin contained in green tea (Lambert and 
Yang, 2003). It is devoid in black tea (Lorenz et al., 2009). 
EGCG has been shown to be 25 to 100 times more potent than 
vitamins C and E in terms of antioxidant activity (Doss et al., 
2005). Although catechins have been shown to reduce bone 
resorption, the mechanisms of action of EGCG on bone 
metabolism have not been well studied (Delaisse et al., 1986). 
The protective action of green tea polyphenols (GTPs) against 
bone loss in ovariectomized (OVX) rats through their 
antioxidant capacities to scavenge reactive oxygen species 
(ROS) has been documented IShao et al., 2011]. 
Recent evidence showed that EGCG could increase the 
formation of mineralized bone nodules by human osteoblast-
like. SaOS-2 cells (Vail et al., 2007), enhance osteogenesis in a 
bone marrow mesenchymal stem cell line (Chen et al., 2005), 
and induce apoptotic cell death of osteoclasts differentiated 
from RAW 264.7 cells in vitro (Yun et al., 2007). EGCG may 
improve asteoporotic condition by inhibiting progressive bone 
loss due to both increased osteoclastic bone resorption and a 
decrease in osteoblastic bone formation. EGCG is also reported 
to suppress osteoclast differentiation and ameliorate 
experimental arthritis in mice over the short term (Ivlorinobu et 
al., 2008). Furthermore, EGCG inhibits matrix 
metalloproteinases (NLNIPs) expression and activity, which 
plays an important role in degeneration of the matrix 
associated with bone and cartilage. Regulation of osteoclast 
activity is essential in the treatment of bone-disease, including 
osteoporosis and rheumatoid arthritis (Oka et al., 2012). 
Recently. it has been reported that EGCG at a low 
concentration can slightly enhance the osteogenic effect in vivo, 
whereas at a higher concentration it can prevent the osteogenic 
differentiation of human alveolar bone-derived cells (hABCs) 
both in nitro and in uivo(MTah et al.. 2014). EGCG can also be 
used as a proosteogenic agent for the stem-cell-based therapy of 
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osteoporosis (Jin et al.. 201.1). The inhibitory effect of EGCG to 
osteoclastogenesis is reported to be associated with a down 
regulation of RANKL/RANK signal, and increased apoptosis of 
preosteoclasts (Zhao et al., 2014). 
Thus, in the present study, attempts have been made to 
probe the effects of natural antioxidant EGCG on bone markers 
and osteoclast generation in cultures of PBMIC's from patients 
with osteoporosis. Dietary supplementation in anti-bone 
resorptive therapy is relevant as a safe and economic option, 
where EGCG has been proposed as an effective herbal 
therapeutic, as it is a strong anti-oxidant and anti-
inflammatory agent having beneficial effects on bone 
metabolism. Thus, it is hoped that this cost-effective strategy 
would be of immense help in the better understanding of 
osteoporosis management. In order for clarity, the overall cost-
effective schematic strategy to combat osteoporosis with natural 
antioxidants like EGCG is summarized below. 
Schematic strategy: 
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2. Materials and methods 
2.1. Materials 
The study has prior institutional ethical clearance. Blood from 
patients with osteoporosis (n=30.40) was obtained from those 
admitted to the orthopedic wards and from the corresponding 
out patient section of J.N. Medical College Hospital, A.M.U., 
Aligarh. Blood donated by healthy normal volunteers (n=30-40) 
served as controls. EGCG was from Sigma—Aldrich (St. Louis, 
MO, USA). Ficoll-Paque was from Pharmacia (LKB 
Biotechnology Piscataway, NJ). RANKL and M-CSF were from 
I & D Systems, USA. All other chemicals were of the highest 
purity grade available. 
2.2. Isolation of peripheral blood mononuclear cells (PBMC) 
from blood of normal and osteoporosis patients 
Blood samples were drawn from appreciable number of patients 
(n=30-40) with osteoporosis as well as normal healthy 
volunteers which served as controls (n=30-40) for isolation of 
peripheral blood mononuclear cells (PBMC), using a Ficoll-
Hypaque density gradient method as described by us previously 
(Hasan et al., 2006; Hasan et al.. 2007; Islam et al.. 2004). 
2.3. Culture Conditions for Oat eoclastogenesls 
The culture conditions for osteoclastogenesis have been 
described elsewhere (Faust et al., 1999; Buckley et al., 2005). 
This has also been employed in our earlier communication 
elsewhere. The isolated PBMCs were centrifuged at 400g for 30 
minutes at 21°C.The resulting buffy layer was removed with a 
Pasteur pipette. Then the remaining cells were washed twice in 
PBS. These isolated mononuclear cells were cultured at a 
density of 2x106 cellslem2 in 10 cm Petri dishes in u-MEM 
culture medium supplemented with 10% FCS, 100Uhnl 
penicillin, 100 pg/ml streptomycin, Songhnl M-CSF and 
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25ng/m1 RANKL (Osteoclastogenic medium) at 37°C in a 
humidified 5% CO2 atmosphere. After 24 It of culture, the non-
adherent cell fraction was discarded. The adherent population 
was washed with PBS. Thereafter, trypsin was added to the 
culture and incubated at 37°C for approximately 6 min. 
Subsequently, cells were scrapped off and reseeded. The culture 
duration was 1, 3 and 5 days and the cells were subjected to 
phenotypic characterization by TRAP staining and were 
identified as committed multinucleated preosteoclasts (pOCs). 
2. 4. Tartrate Resistant Acid Ph.osphatase (TRAP) Staining and 
Quantification of TRAP-positive Muhinucleated Cell Number 
TRAP staining of adherent cultures was done with a kit 
(Sigma—Aldrich, USA) on a 96-well culture plate, exactly 
according to manufacturer's instruction. This has also been 
employed in our earlier communication elsewhere. The stained 
cells developed red color of different intensity. The number of 
TRAP-positive multinucleated (>2 nuclei per cell) preosteoclasts 
cells was measured using the I x 1-mm grid placed in the 
ocular of the microscope. Five sites were measured in a well of a 
96-well plate, and a mean value was calculated. 
2.5. Dose Response Effect of Rpigallocalech.in gallate (EGCG)-a 
green tea polyphenol and natural antioxidant, on generation of 
osteoclasts from PBMCs 
To investigate the effect of natural antioxidants like 
epigallocatechin-3-gallate (EGCG) on osteoclast generation 
from PBMCs, varying doses of EGCG (0-25 pg/ml) were added 
to the PBMC cultures seeded at a cell density of 2x117 cells/cm' 
in a 96-well plate in a osteoclastogenic medium as described 
above and incubated for 24 h (1 day), 72 It (3 day) and 120 h (5 
days) at 37°C in a humidified atmosphere of 5% COs. 
Thereafter, the cells were analysed with TRAP staining. 
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2.6. Isolation of total RNA /messenger RNA 
As per manufacturer's specifications (Qiagen, Valencia , CA), 
total RNA or messenger RNA (mRNA) was isolated from cells of 
normal healthy controls as well as cells from patient with 
osteoporosis as described by us previously (Hasan et al., 2006; 
Hasan et al., 2007; Islam et al., 2004). 
2.7. Quantitative real-time RT-PCR and expression of sTNF-
alplut in culture supernatants 
Quantitative real-time RT-PCR with internal fluorescent 
hybridization probes was employed to quantify host TNF-a gene 
transcription as described by us previously (Hasan et al., 2006; 
Hasan et al., 2007; Islam et al., 2004). This technique affords a 
sensitive and specific quantification of individual RNA 
transcripts (Islam et al., 2004). Human R18 housekeeping gene 
was employed to normalize gene expression. TaqMan PCR 
primers and probes as well as target-specific RT primer for each 
assay were designed as described by us elsewhere (Hasan et al., 
2006; Hasan et al.. 2007; Islam et al., 2004).The primer and 
probe sequences used have been previously reported by us as 
well as elsewhere (Islam et al., 2004; Holland et al., 1991). To 
assure lack of DNA contamination in the RNA samples, in some 
experiments, a duplicate tube of sample with no RT enzyme 
was included as control. DNA contamination remained 
negligible. In each sample, host 18S ribosomal RNA was used 
as internal control. Expression of TNF- a mRNA was corrected 
to internal control (host 18S rRNA) in the same sample and was 
expressed as copies of TNF-a in 1010 copies of R18 (equivalent to 
1 x 10'; monocytes). 
The expression of sTNF-alpha in culture supernatants of 
PBIVMC's from patients with osteoporosis that were co-cultured 
with and without FGCG (20 pg/ml) as described above was 
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evaluated as described by us earlier (Hasan et al., 2006; Hasan 
et al., 2007; Islam et at, 2004). 
2.8. Glutathione peroxidase assay 
The activity of glutathione peroxidase (GPx) was measured as 
described elsewhere (Holland et al.. 1991). Briefly, culture cells 
from patient with osteoporosis as described above were co-
cultured with or without EGCG (20 µg/ml) for 5 days in 
osteoclastogenic medium. Thereafter, cells were scrapped and 
centrifuged as described earlier (Hasan et al., 2006), and the 
supernatants were subjected to GPx activity determination. 
The GPx activity was quantified inlOO tl of each sample, with 
continuous photometric monitoring of oxidized glutathione 
(GSSG) at 37°C. The conversion of NADPH to NADP was 
evaluated using UV absorbance at 340 nm (Flohe and Gunzler, 
1984). GPx activity was calculated after subtraction of the 
blank value, as µmol of NADPH oxidized/min/mg protein (U/mg 
protein). 
2.9. Statistical analysis 
Results were analyzed by use of paired t test and expressed as 
means 1 S.E. of ten experiments. P < 0.05 was considered 
statistically significant 
3. Results; 
3.1. Generation of Human Osteoclast Precursors front. 
Peripheral Blood Mononuclear Cells (PBMCs) and Suppresice 
Effect of Epigallocatechin gallate (EGCG) on the Generation of 
Human Osteoclasts 
Peripheral blood mononuclear cells (PBMCs) were used directly 
for the generation of osteoclast precursors after centrifugation 
with Ficoll-Hypaque. Multinucleated osteoclast precursors were 
observed to appear after the 3 day culture duration in 
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osteoclastogenic medium (a-MEM culture medium 
supplemented with 10% FCS, 100U/ml penicillin, 100 llglml 
streptomycin, 50ng/ml M-CSF and 25ng/ml RA-NKL) (Fig. 1). 
Interestingly, in comparison to the data of 3 days culture, the 
tartarate resistant acid phosphatase (TRAP) staining exhibited 
the number of multinucleated cells to increase appreciably after 
5 days of culture (Figs. 2). However, the first two days of 
culture showed no detectable appearance of osteoclast 
precursors (data not shown). The number of multinucleated 
preosteoclasts, arising from PBMCs isolated from the blood of 
normal healthy individual (data not shown) and osteoporotic 
patients (n=30) (Fig, 1 and 2) were counted by TRAP staining, 
Individual variation in osteoclast generation from different 
donors was observed (individual data not shown and instead 
mean values are shown). Next, co-culturing of PBMCs with 
EGCG (20 pg/ml) in osteoclastogenic medium for 5 and 3 days 
exhibited an appreciable suppression in the range of around 
56% to 37% in appearance of multinucleated osteoclast 
precursors (Figs. 1 and 2). Hence, this shows the potential of 
EGCG to exert regulatory effect in osteoclast generation and 
differentiation. 
3.2. Dose Response Effect of Epigallocotechin gallote (EGCG) on 
the Generation of Human Osteoclasts 
The above dose of EGCG was selected after performing dose 
response experiment, where TRAP assay revealed a linear 
suppression in the formation of multinucleated cells was 
observed (Fig. 3). Nearly 20-25% suppression in appearance of 
multinucleated cells was observed in cultures receiving 20 and 
25 pg/ml of EGCG relative to control cultures devoid of any 
EGCG (Fig- 3). 
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3.3. Effect of EGCG on T \'F- a gene expression 
The expression of TNF- a was determined at both the protein 
and mRNA levels. PBMC's from normal healthy and patients 
with osteoporosis (n=20) were co-cultured for 24 h with 20 
lig/ml EGCG. Cultures devoid of EGCG served as controls. 
Culture supernatants were subjected to evaluation of sTNF- a 
expression at the protein level by ELISA. As evident from Fig. 
1A, EGCG (20pg/ml) down regulated the expression of sTNF- a 
by around 66.97% (P<0.001) relative to cultures devoid of any 
EGCG. Similar observations were recorded at the mRNA level. 
The suppressive effect of EGCG (20 pg/ml) on the amplification 
of TNF-a gene was found to be of appreciable magnitude, as 
was revealed by real-time RT-PCR, where in comparison to 
control, a down regulation of TNF- a mRNA copy numbers by 
4.1-logs (P < 0.001) was recorded with 20 tlg/iiil of EGCG (Fig. 
4B). Our previous study on cultures from normal healthy 
donors with or without EGCG did not show any significant 
TNF-a or any effect of EGCG (30). Thus. EGCG potently 
inhibits the pro-inflammatory cytokine TNF-a in PBMC 
cultures of patients with osteoporosis. 
3.-1. Gliitathlone peroxidase a.ctiuity 
GPx activity was determined in PBMC's culture of patient with 
osteoporosis, which were co-cultured for a days with or without 
20 pg/ml of EGCG. Normal healthy cells devoid of EGCG served 
as controls. As evident from Fig. 4C, GPx activity was found to 
be suppressed by 52.61 % (P < 0.001; n=20) in cultures of 
patient's cells relative to normal healthy cells. Interestingly, in 
comparison to patient's cells, co-culturing with EGCG (20 
pg/ml) revealed amelioration in the GPx activity by - 40.3% (P 
< 0.001) (Fig. 5). Thus, EGCG proved to be a potent enhancer of 
GPx activity in culture cells of patient with osteoporosis. 
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4. Discussion: 
Globally, osteoporosis is known since the origin of human 
civilization, but complete understanding about its management 
still remains poorly understood till date. Augmented generation 
of ROS in vivo due to a wide spectrum of in-vivo-related 
reasons, leads to the activation and up-regulation of bone 
markers like pro-inflammatory cytokine TNF-a and its super 
family member OPG as well as osteopontin and calcitonin at 
both the protein and gene i. e. mRNA levels. This in turn 
results in accelerated osteoclast differentiation, thereby 
resulting to loss of bone mass, including osteoporosis, arthritis, 
orthopaedic implant loosening, etc. 
Thus, if ROS production in vivo is regulated by natural 
antioxidants like EGCG from green tea, neem extract, turmeric, 
allicin from garlic, etc., then the above-mentioned bone markers 
associated with chronic bone conditions may probably be easily 
regulated. We have previously shown the effect of EGCC in 
other diseases (Islam et al., 2000; Yang et at., 2014). Several 
studies have reported increased production of TNF by cultures 
of mononuclear cells derived from osteoporotic and 
postmenopausal women, an effect reversed by estrogen 
replacement (Alldredge et al., 2009; Islam et al., 2004), and 
that, ROS may play a role in bone loss by generating a more 
oxidized bone microenvironment (Buckley et at., 2005; Holland 
et al., 1991). 
We probed here the management and/or regulation of 
ROS and TNF-a activation in PBh2C's from patients with 
osteoporosis that were cultured under osteoclastogenic medium. 
Probing the adjuncts for down regulation of augmented TNF-a 
and ROS in patients with osteoporosis would definitely help in 
better understanding the pathogenesis of osteoporosis. 
TNF-a is implicated in the pathophysiology of bone 
metabolism. The presence of elevated levels of TNF in the bone 
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marrow of ovx animals and in the conditioned media of 
peripheral blood cells of postmenopausal and osteoporosis 
subjects is well documented (Vein et al.. 2005, Alldredge et al.. 
2009: «'HO, 1994). Moreover, ROS are also involved in the 
etiopathology and progression of osteoporosis. Radicals 
generated in cells of postmenopausal and osteoporosis patients 
stimulate TNF-u. causing accelerated bone loss. 
EGCG- a green tea polyphenol as well as a natural 
antioxidant was employed in the present study whose exact 
mechanism underlying its antioxidant activity still remains 
poorly understood. EGCG-induced enhancement of GPx activity 
has been reported 
Augmented expression of TNF-a mRNA has been 
reported in monocytic cells derived from patients with 
osteoporosis (Raisz, 2005). Consistent with these finding, we 
also report the up regulation of TNF-a mRNA expression in 
PBMC's from patients with osteoporosis that were cultured 
under osteoclastogenic medium. 
The most striking finding of the present study shows 
that EGCG exerts potent anti-inflammatory, antioxidant and 
anti-osteoclast effects on PBMC's from patients with 
osteoporosis that were cultured under osteoclastogenic medium. 
Since higher doses of EGCG (>23 pM) have proven toxic, thus 
lower doses (0-20 pN1) were employed in the present study. The 
results indicate an appreciable suppression in endogenous 
'FNF-ct mRNA expression by - 4.1 logs with 20 pg/ml of EGCG 
in mononuclear cells of patients with osteoporosis. 
Glutathione directly reacts with ROS, and GPx catalyzes 
the removal of hydrogen peroxide (Flohe and Gunzler, 1984). 
Lowering in GPx activity infers impairment of hydrogen 
peroxide-neutralizing mechanisms (Flohe and Gunzler, 1984). 
Here, we observed a suppression in GPx activity in PBMC's 
from patients with osteoporosis that were cultured under 
osteoclastogenic medium, thereby correlating with earlier 
EUROPEAN ACADEMIC RESEAR('H - Vol. 11. Issue 3 / .June 2011 
3617 
Wasil Hasan. Saba Ahmad, Hamida Thakur. biazhar Abbas. Abbas All \landi and 
Naimul Islam- In vitro regulation of osteoclast generation: A cost-effective 
strategy to combat osteoporosis with natural antioxidants and polyphenols 
like EGCG 
reports that substantial amounts of ROS are being generated in 
bone cells due to lowering of antioxidant defenses. Amelioration 
of GPx activity was observed in PBMC's from patients with 
osteoporosis that were co-cultured with EGCG under 
osteoclastogenic medium. This indicates EGCG-induced 
reversal of impaired neutralizing mechanisms in PBMC's from 
patients with osteoporosis that were cultured under 
osteoclastogenic medium. Thus, our study shows ameliorated 
GPx activity by EGCG, which correlated inversely with the 
down regulation of TNF-ci mRNA expression and ROS in 
culture cells of patients with osteoporosis. 
In summary, dietary supplementation in anti-bone 
resorptive therapy is relevant as a safe and economic option, 
where EGCG may act as an effective herbal therapeutic, as it is 
a strong anti-oxidant, anti-inflammatory and anti-osteoclast 
agent having beneficial effects on bone metabolism. EGCG, a 
green tea polyphenol has been reported to exert potent anti-
oxidant and anti-inflammatory effects by inhibiting signaling 
and gene expression (Yang et al., 2014). Thus, it is hoped that 
the present study may help in the better understanding of the 
management of osteoporosis. 
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Fig. 1. 72 hrs cultures: Human osteoclasts were generated from peripheral 
blood mononuclear cells (PBAICs) in 72 hrs cultures as described in methods. 
The results from :30 patient donors (mean value) are presented as 
quantification of TRAP-positive multinucleated cell number. The effect of 
EGCG (20 lg/ml) is shown in black bars. (P<0.001 in all cases) 
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Fig. 2. 120 hrs cultures: Human osteoclasts were generated from peripheral 
blood mononuclear cells (PBMICs) in 120 hrs cultures as described in methods. 
The results from 30 patient donors (mean value) are presented as 
quantification of TRAP-positive multinucleated cell number. The effect of 
EGCG (20 pg/ml) is shown in black bars. (P<0.001 in all cases) 
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Fig. 3. Dose response effect of EGCG (0-25 pg/ml) on multinucleated cells in 
120 hr cultures of PBAMC's from patients with osteoporosis (n=30). The cells 
were cultured under osteoclastogenic medium as described in methods 
(P<0.00 1). 
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Fig. 4A. Expression of soluble TNF-a by ELISA in 24 hr cultures of 
PBRIC's from patients with osteoporosis (n=20) that were untreated 
and treated with 20 µg/ml of EGCG under osteoclastogenic medium 
(P<0.001). 
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Fig. 4B. Modulation of TNF-a mRNA expression by Real Time RI-PCR in 24 
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methods. 
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of PBMC's isolated from patients with osteoporosis (n=20; P<0.0o1)_ The cells 
were cultured under osteoclastogenic medium as described in methods. GPx 
activity is expressed as Ulmg protein. 
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Epigallocatechin-3-gallate (EGCG), A Polyphenol and 
Natural Anti-Oxidant, Down Regulates Multinucleated 
Osteoclasts 
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Abbas, Abbas Ali Mandi" and Najmul Islam 
Department of Biochemistry, Faculty of Medicine, Jawaharlal Nehru Medical College, Aligarh 
Muslim University, Aligarh, India 
'Department of Orthopaedic Surgery, Faculty of Medicine, Jawaharlal Nehru Medical College, 
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Osteoporosis has been shown to be associated with reactive oxygen species (ROS) which in 
turn is actively related to production of bone markers promoting osteoclast differentiation 
thereby leading to osteoporosis. Most of the in vitro modulation/regulation of osteoclost 
differention is on cell lines or dentine slices but there are only fewer studies on 
modulation/regulation of osteoclast differentiation in in vitro cultures of human PBMC's 
from patients with osteoporosis. We report that epigallocatechin-3-gallate (EGCG), one of 
the most potent polyphenol, an active ingredient of green tea (Camellia sinensis), as well 
as an natural antioxidant coupled with strong immunomodulatory activity appreciably 
suppresses osteoclasts differentiation in cultures of human PBMC's from osteoporosis 
patients. Therefore, EGCG may have the potential to be used in the treatment/prevention 
of osteoporosis by suppressing/preventing the generation of multinucleated osteoclasts. 
Key words: Osteoporosis, Epigallocotechin-3-gallate (EGCG), Glutathione peroxidase (GPx), 
Reactive oxygen species (ROS) and TNF- a. 
INTRODUCTION 
Bone is a vital, dynamic and complex 
connective 	tissue 	having 	multiple 
functions 	in 	vertebrates, 	including 
protection of vital organs and the 
environment and niches required for 
haematopoiesis, 	mechanical 	and 
structural support for muscles and joints, 
and a mineral reservoir that is essential 
for calcium homeostasis, and of growth 
factors stored in the matrix [Lacey et al., 
2012; Rouhi, 2012; Boyce and Xing, 2008; 
Marcus et al., 20081. 
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The 	structure-function 	relationships 
observed in bone under normal 
physiological conditions, coupled with its 
role in maintaining mineral homeostasis, 
strongly suggest that it is an organ of 
optimum structural design (Rouhi, 20121. 
In maintaining the structure—function 
relationship, bone tissue is constantly 
being broken down and rebuilt in a 
process called remodeling [Rucci, 20081. 
Bone has the potential to adapt its 
architecture, shape, and mechanical 
properties via a continuous process 
termed adaptation in response to altered 
loading conditions [Burr et al., 2002; 
Forwood and Turner, 1995; Hsieh and 
Turner, 2001). The regulation of bone 
mass in mammals is governed by a 
complex interplay between bone-forming 
cells termed osteoblasts (OBs) and bone-
resorbing cells termed osteoclasts (OCs), 
and is guided physiologically by a diverse 
set of hormones, cytokines and growth 
factors. The balance between these 
processes changes over time, causing an 
elevated risk of fractures with age [Lacey 
et al., 2012]. With age, remodeling tends 
to result in a negative bone balance due 
to decrease in the number of osteoblasts, 
in that at each remodeling site slightly less 
bone is deposited than is resorbed. This 
negative balance leads to osteopenia and 
osteoporosis (OP), thus predisposing the 
bone to fracture during even minimal 
trauma [D'ippolito et al., 1999; Marcus et 
al., 20081. 
Tea is the most consumed beverage 
worldwide next to water. Tea is a 
flavonoid-rich beverage and contributes 
substantially to the intake of dietary 
catechins. Tea also contains some 
flavonols, particularly quercetin and 
kaempferol [McKay and Blumberg, 2007]. 
About 20% of the consumed tea is green 
tea, which is primarily consumed in China 
and Japan and contains mostly 
nonoxidized 	Polyphenols, 	more 
particularly catechins [Graham, 1992; 
Mukhtar and Ahmad, 2000). After 
harvesting, the leaves of the bush are 
steamed and dried to produce green tea 
leaves. In green tea leaves, the following 
polyphenolic compounds are found: (-)-
epigallocatechin-3-gallate (EGCG), a major 
component; (-)-epicatechin (EC); (-)-
epigallocatechin (EGC) and (-)-epicatechin-
3-gallate (ECG). 
Epigallocatechin gallate (EGCG) is also 
known as epigallocatechin-3-gallate. It is 
the ester of Epigallocatechin and Gallic 
acid, and is a type of catechin. EGCG is the 
most abundant catechin in tea and is a 
potent antioxidant that 	may 	have 
therapeutic applications in the treatment 
of many disorders. EGCG accounts for 
more than 50% of the total of catechins 
[Nagal et ol., 2006]. EGCG, a green tea 
polyphenol has been reported to exert 
potent anti-oxidant and anti-inflammatory 
effects by inhibiting signaling and gene 
expression (Yang et al., 20141. 
EGCG has the physiological role in the 
induction of osteoclast cell death 
(Nakagawa et al., 2002; Yun et al., 2007) 
and mineralization of osteoblasts [Takita 
et of., 2002; Vali et at., 2007). EGCG is 
found to reduce the generation of TRAP 
positive multinucleated cells, bone 
resorption activity, and osteoclast-specific 
gene expression without affecting cell 
viability [Morinobu et al., 2008). EGCG 
down-regulated expression of nuclear 
factor of activated T cells cl (NF-ATc1), 
but not of NF-KB, c-Fos, and c-Jun, 
suggesting that down regulation of NF-
ATc1 is one of the molecular bases of 
EGCG action [Morinobu et al., 2008). 
EGCG is found to suppress osteoclast 
differentiation 	and 	ameliorated 
experimental arthritis in mice over the 
short term (Morinobu et al., 2008). The 
inhibitory effect of EGCG to 
osteoclastogenesis has been reported to 
be associated with a down regulation of 
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RANKL/RANK signal, and increased 
apoptosis of preosteoclasts [Zhao et a!, 
2014]. Mah eta/ has reported EGCG at a 
low concentration can slightly enhance 
the asteogenic effect in vivo, whereas at a 
Nigher concentration it can prevent the 
osteogenic differentiation of human 
alveolar bone-derived cells (hABCs) both 
in vitro and in vivo (Mah etol., 2014]. 
j o a on '
I 
iii ~~ 
L 
on 
Catechize (3%) Epicatechin (1'I%) 
i l os off _l 
Em on 
On LLu 	J un 
Ciallocatechin f9'%b) 	Epigallaeatechin (ii o/) 
01 0S 
ou zee 
i -- --0 -r- 	-  c 	.on _ _os 
oa 	o 	Y au 	of S fl 
OH 011 
Epicatechin gallate (11%) Gallocatechin gatlate (11%) 
oil 
.ly 	) OE  
on 
~. -i	on 
on 
Epigallocatechin gallate (4"70 ) 
Molecular structures of C. sinenesis polyphenols. Green tea extract contains 85% 
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Most of the ostcoclast differentiation 
studies have been done mostly on cell 
lines or dentine slices and less on human 
PBMCs from osteoporosis patients. Thus, 
we have carried out preliminary study to 
check whether natural antioxidant EGCG 
causes osteoclast differentiation or not in 
in vitro cultures of human PBMCs from 
osteoporosis patients. 
MATERIAL AND METHODS 
Isolation 	of 	Peripheral 	Blood 
Mononuclear Cells (PBMC) from blood of 
Normal and Osteoporosis patients 
Blood samples were drawn from 
appreciable number of patients (n=30-40) 
with osteoporosis as well as normal 
healthy volunteers which served as 
controls (n~30-40) for isolation of 
peripheral blood mononuclear cells 
(PBMCL using a Ficoll-Hypaque density 
gradient method as described by us 
previously (Hasan et of., 2006; Hasan at 
of., 2007; Islam at al., 2004). 
Culture Conditions for Osteoclostogenesis 
The isolated PBMC5 were centrifuged at 
400g for 30 minutes at 21'C. Thereafter, 
the buffy layer was removed and washed 
twice in PBS. These isolated mononuclear 
cells were plated at a density of 2x10° 
cells/cm' in 10 cm Petri dishes in a-MEM 
culture medium supplemented with 10% 
FCS, 1000/ml penicillin, 100 pg/ml 
streptomycin, 50ng(ml M-CSF and 
2Sng/ml 	RANKL 	(Osteoclastogenic 
medium) at 37°C in a humidified 5% CO2 
atmosphere. The cells were then cultured 
for 24 hr, and the non-adherent cell 
fraction was subsequntly discarded. The 
adherent population was washed with 
PBS. Thereafter, trypsin was added to the 
culture and incubated at 37°C for 
approximately 6 min. Subsequently, cells 
were scrapped off and reseeded. The 
culture duration was 5 days and the cells 
were 	subjected 	to 	phenotypic 
characterization by TRAP staining and 
were 	identified 	as 	committed 
multinucleated preosteoclasts (pOCs) 
Susa eta!,, 20041. 
Tartrate Resistant Acid Phosphatase 
(TRAP) Staining and Quantification of 
TRAP-positive 	Mu/tinuclaated 	Cell 
Number 
TRAP staining of adherent cultures was 
done with a kit from Sigma on a 96-well 
culture plate, exactly according to 
manufacturer's instruction. The stained 
cells developed red color of different 
intensity. The number of TRAP positive 
multinucleated (>2 nuclei per cell) 
preosteoclast cells was measured using 
the 1 • 1-mm grid placed in the ocular of 
the microscope. Five sites were measured 
in a well of a 96-well plate, and a mean 
value was calculated. 
Effect of Eplyallocatechin gallate (EGCG) 
on the generation of Qs1eaciasts from 
PBMCs 
To investigate the effect of natural 
antioxidants 	like 	epigallocatechin-3- 
gallate (EGCG) on osteoclast generation 
from PBMCs, 15 1g/ml of EGOS was 
added to the PBMC cultures seeded at a 
cell density of 2x10s cells/cm' in a 96-well 
plate in a osteoclastogenic medium as 
described above and incubated for 24 h (1 
day), 72 h (3 day) and 120 IT (5 days) at 
37°C in a humidified atmosphere of 5% 
CO, Thereafter, the cells were analysed 
with TRAP staining. 
RESULTS 
Generation of Human Osteoclost 
Precursors from Peripheral Blood 
Mononuclear Cells (PSMCs) 
Peripheral blood mononuclear cells 
(PBMCs) were used directly for the 
generation of osteoclast precursors after 
centrifugation with Ficoll-Hypaque. The 
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results show that after the 3 day culture 
duration in osteoclastogenic medium (a-
MEM culture medium supplemented with 
10% FCS, 1000/ml penicillin, 100 pg/ml 
streptomycin, 50ng/ml M-CSF and 
25ng/ml 	RANKL), 	multinucleated 
osteoclast precursors begin to appear and 
the number increased after the 5 day of 
culture which were characterized by 
Tartrate Resistant Acid Phosphatase 
(TRAP) staining (Fig. 1, 2, 3, 4, 5, 6). It may 
be pointed out that there was no 
appearance of osteoclast precursors after 
24 h (1 day) of culture (data not shown). 
The 	number 	of 	multinucleated 
preosteoclasts, arising from PBMCs 
isolated tram the blood of normal healthy 
individual (data not shown) and 
osteoporotic patients (shown in Fig. 1, 2, 
3, 4, 5, 6), were counted by TRAP staining. 
Interestingly, we observed an individual 
variation in osteoclast generation from 
different donors as depicted by different 
number of multinucleated cells in Fig 1,2, 
3. 
Effect of Natural Antioxidant, 
Epigallocatechin gallate (EGCG), on the 
Generation of Human Osteoclasts 
Interestingly, we observed that co-
culturing of PBMCs with EGCG (15 .tg/ml) 
in osteoclastogenic medium for culture 
duration of 5 days leads to appreciable 
amount of reduction in appearance of 
multinucleated osteoclast precursors (Fig. 
1, 2, 3, 4, 5, 6). Hence, this data gives an 
idea of potential of EGCG to exert 
regulatory effect in osteoclast generation 
and differentiation. More deep studies are 
underway in our laboratory and would be 
communicated elsewhere. 
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Fig. 1 Patient No. 1 to 10: Individual variation in osteodast generation from different 
donors. Human osteoclasts were generated from peripheral blood mononuclear cells 
(PBMCs) as described under Methodology. The results from 10 patient donors are 
presented as quantification of TRAP-positive multinucleated cell number. The effect of 
EGCG (15 .tg/ml) is shown in black bars. The results are shown as means ± SEM. 
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Fig. 2 Patient No. 11 to 20: Individual variation in osteoclast generation from different 
donors. Human osteoclasts were generated from peripheral blood mononuclear cells 
(PBMCs) as described under Methodology. The results from 10 patient donors are 
presented as quantification of TRAP-positive multinucleated cell number. The effect of 
EGCG (15 pg/ml) is shown in black bars. The results are shown as means ± SEM. 
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Fig. 3 Patient No. 21 to 30: Individual variation in osteoclast generation from different 
donors. Human osteoclasts were generated from peripheral blood mononuclear cells 
(PBMCs) as described under Methodology. The results from 10 patient donors are 
presented as quantification of TRAP-positive multinucleated cell number. The effect of 
EGCG (15 pg/ml) is shown in black bars. The results are shown as means ± SEM. 
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Fig. 4 Patient No. 1 to 10: Individual variation in osteoclast generation from different 
donors. Human osteoclasts were generated from peripheral blood mononuclear cells 
(PBMCs) as described under Methodology. The results from 10 patient donors are 
presented as quantification of TRAP-positive multinucleated cell number. The effect of 
EGCG 115 µg/ml is shown in black bars. The results are shown as means ± SEM. 
After 120 h (5 days) of Culture of PBMCs in 
Osteoclastogenic Medium 
0 	Witw1EGCG •WMEGGG 
11 	12 	13 	Ills 	16 	11 	is 	19 	20 
nsieopum6c Patent Number 
Fig. 5 Patient No. 11 to 20, Individual variation in osteoclast generation from different 
donors. Human osteoclasts were generated from peripheral blood mononuclear cells 
(PBMCs) as described under Methodology. The results from 10 patient donors are 
presented as quantification of TRAP-positive multinucleated cell number. The effect of 
EGCG (15 pg/mll is shown in black bars. The results are shown as means ± SEM. 
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Fig. 6 Patient No. 21 to 30: Individual variation in osteodast generation from different donors. Human 
osteodasts were generated from peripheral blood mononuclear cells (PBMCs) as described under 
Methodology. The results from 10 patient donors are presented as quantification of TRAP positive 
multinucleated cell number. The effect of EGCG (15 µg/ml) is shown in black bars. The results are shown as 
means t SEM. 
DISCUSSION 
The global prevalence of osteoporosis is 
probably as old as the origin of human 
civilization, but unfortunately till date, 
complete understanding about the 
management of osteoporosis in humans 
still 	remains 	poorly 	understood. 
Accelerated 	human 	osteoclast 
differentiation is responsible for most 
chronic conditions that lead to loss of 
bone mass, including osteoporosis and 
arthritis etc. 
It is well recognized that hormonal 
deficiency (estrogen) is a major 
contributory factor to postmenopausal 
osteoporosis. However, in non-
postmenopausal osteoporosis, various 
intrinsic factors and not hormonal 
deficiency contribute to osteoporosis. 
Bone molecular biology and physiology 
research, which leads to improved bone 
health of men and women, will reduce the 
risk of osteoporosis and other bone 
disorders later in life. Augmented 
generation of ROS in vivo due to a wide 
spectrum of in-vivo-related reasons, leads 
to the activation and up-regulation of 
bone markers like pro-inflammatory 
cytokine TNF-a and its super family 
member OPG leading to accelerated 
osteoclast 	differentiation, 	thereby 
resulting to loss of bone mass/ 
osteoporosis. 
Thus, if ROS production in vivo is 
regulated by natural antioxidants like 
EGCG from green tea then the bone 
markers associated with chronic bone 
conditions may probably be easily 
regulated. We have previously shown the 
effect of EGCG in other diseases [Fatima 
et al, 2012; Islam et al, 2000]. 
Several studies have reported increased 
production of TNF-a by cultures of 
mononuclear cells derived from 
osteoporotic 	and 	postmenopausal 
women, an effect reversed by estrogen 
replacement [Alldredge, et al, 2009; Islam 
et a!, 2004], and that, ROS may play a role 
in bone loss by generating a more oxidized 
bone microenvironment [Faust et al, 
1999; Buckley et al, 2005]. 
In this preliminary study, we have 
successfully proved here the EGCG-
induced suppression of multinucleated 
osteoclasts in PBMC's from patients with 
osteoporosis that were cultured under 
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osteoclastogenic medium. Probing the 
adjuncts for down regulation of 
augmented osteoclasts probably due to 
ROS in patients with osteoporosis would 
definitely help in better understanding the 
pathogenesis of osteoporosis. 
Thus, it is hoped that the present study 
could be of immense help in the better 
understanding 	of 	osteoporosis/ 
postmenopausal osteoporosis 
management. 
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Abstract: 
Osteoclasts and osteoblasts dictate skeletal mass, structure, 
and strength via their respective roles in resorbing and forming bone. 
Bone remodeling is a spatially coordinated lifelong process whereby 
old bone is removed by osteoclasts and replaced by bone-forming 
osteoblasts. The refilling of resorption cavities is incomplete in many 
pathological states, which leads to a net loss of bone ►Hass with each 
remodeling cycle (Hasan W et al, 2014). Postnlertopausal osteoporosis 
and other conditions are associated with an increased rate of borne 
remodeling, which leads to accelerated borne loss and increased risk of 
fracture. Osteosyn thesis of the bone matrix is achieved by osteoblasts 
and coordinated within this con►ple.r machinery of bone remodeling 
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with resorption of extracellular bone matrix performed by osteoclasts. 
Bone resorption is dependent on a cytokine known as RANKL (receptor 
activator of nuclear factor hB ligand), a TNF family member that is 
essential for osteoclast formation, activity, and survival in normal and 
pathological states of bone remodeling. (Kohli SS and Kohli VS, 2011; 
Kearns AE et al., 2008). The catabolic effects of RANKL are prevented 
by osteoprotegerin (OPG), a TNF receptor family member that binds 
RANKL and thereby prevents activation of its single cognate receptor 
called RANK. Osteoclast activity is likely to depend, at least in part, on 
the relative balance of RANKL and OPG. This review highlights the 
complex interplay of the RANKL-RANK/OPG axis and their 
management in bone health. 
Key words: RANKL, RANK, OPG, osteoclastogenesis, TNF-a, 
estrogen, T cells, NF-kB, osteoporosis. 
Osteoporosis is a degenerative bone disease in elderly men and 
women characterized by low bone mineral density, increased 
fragility and deterioration of bone tissue leading to high 
fracture risk. In recent years, it has become a major health 
hazard afflicting more than 200 million people worldwide, and 
it is thought to be one of the highest incidence of diseases in 
aged people (Hamdy RC, 2002).This metabolic bone disease, 
over a life time results in fractures in 40% of aging women 
and 15% of aging men. (Riggs BL et al, 2002). Usually, 
osteoporosis is thought to be an age-adjusted symptom, and 
hypogonadism is the most well- established cause of 
osteoporosis (NIH Consensus Statement 2000) 
Maintenance of bone mass is continuously controlled in 
adults by osteoblasts, which form new bone, and osteoclasts, 
which is the primary multinucleated bone-resorbing cell 
involved in bone remodeling (Park CK et al, 2007). Imbalance 
between bone formation and bone resorption is the key 
pathophysiological event in many metabolic bone disorders in 
adult humans, including osteoporosis, which results in bone 
loss (Fazzalari NL, 2008; Kearns AE et al, 2008). To resorb 
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bone effectively, osteoclasts attach themselves firmly to the 
bone surface using specialized actin-rich podosonies. which they 
use to form tightly sealed roughly circular extensions of their 
cytoplasm with the underlying bone matrix. Within these 
sealed zones called as resorption lacuna, they form ruffled 
membranes that increase the surface area of the cell membrane 
for secretion protons, proteases. superoxides. hydrochloric acid 
and the proteolytic enzyme cathepsin K onto the bone surface 
through ruffled borders (Shen CL et al., 2009, Yavropoulou NIP 
& Yovos JG, 2008). They thereby simultaneously dissolve the 
mineral and degrade the matrix of bone, while protecting 
neighboring cells from harm by this sealing mechanism. (Boyce 
BF and Xing L., 2007). Other main characteristics of osteoclasts 
are: multinuclearity, formation of actin ring structure, a polar 
cell body during resorption, vitronectin receptor (integrin av63) 
and contraction in response to calcitonin.(Susa \I et al, 2004). 
Differentiation of osteoclasts is characterized by acquisition of 
mature phenotypic markers such as the calcitonin receptor 
(CTR), tartrate resistant acid phosphatase (TRaCP), receptor 
activator of NFKB ligand (RANKL), and ability to resorb bone. 
Resorption involves synthesis of cysteine proteinases, such as 
Cathepsin K, and matrix metalloproteinases (MMPs) (Wittrant 
Y et al., 2008). The completion of resorption is associated with 
apoptosis of osteoclasts. followed by a reversal phase during 
which additional cells including preosteoblasts move to the 
bone surface. Osteoblasts orchestrate the formation of new bone 
matrix and regulate its mineralization. The return of the bone 
surface to its quiescent state involves the apoptosis of 
osteoblasts, their incorporation into the bone as osteocytes, or 
their transformation into bone surface-lining cells. Osteocytes, 
which mature to differentiate into active osteoblasts, also 
release diffusible chemical signals that regulate the resorptive 
potential in their local surroundings (You L et al., 2008, Kearns 
AE et al., 2008). 
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RANK 
 
Receptor activator of nuclear factor kappa B (RANK), a member 
of the TNF receptor superfamily, is a type E transmembrane 
protein containing four cysteine-rich pseudorepeat domains in 
the extracellular region, a hallmark of the TNF-R family. The 
mouse and human RANK contain 625 and 616 aa residues, 
respectively, the latter having a signal peptide (28 aa), an N-
terminal extracellular domain (184 aa), a transmembrane 
spanning domain (21 aa), and a large C-terminal cytoplasmic 
tail (383 aa). In the human genome, RANK is present on 
chromosome 18g22.1. The extracellular part of TNF-R-like 
receptors forms elongated structures by a scaffold of disulfide 
bridges, which fit into the inverted bell/ groove of the ligand 
trimer in a 3:3 complex (Locksley RAI et al., 2001). This has 
recently been demonstrated to be true for the interaction 
between RANKL and RANK (Lam et al., 2001). Although 
RANK is ubiquitously expressed in human tissues, its cell 
surface expression is limited to CD4+ T cell line MP-1, foreskin 
fibroblasts, OC precursors, and certain Hodgkin lymphomas 
(Hsu et a1., 1999; Flumara et al., 2001). RANK knockout mice 
lack peripheral lymph nodes and have defective T and B cell 
maturation (Li J et al., 2000). RANK is also expressed in 
several cancer cell lines where it seems to play a central role in 
tumor cell migration and invasion (Santini D et al, 2011). 
RANKL 
Human RANKL [also called TNF-related activation-induced 
cytokine (TRANCE)! osteoprotegerin ligand (OPGL) /osteoclast 
differentiation factor (ODF)], a cytokine independently 
discovered by four different groups (Wong BR et al., 1997; 
Yasuda 11 et al.,1998; Lacey DL et al., 1998), is a member of the 
TNF ligand superfamily. It is a cytokine family that also 
includes TNF- a, TNF- a CD40 ligand, Fas ligand, CD30 ligand, 
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TWEAK, and TRAIL (Locksley RM et al., 2001). Like other 
members of the TNF-like family of cytokines, RANKL is a type 
II transmembrane protein, with a large extracellular receptor-
binding domain, a membrane-anchoring domain, and a 
connecting stalk. The RANKL gene is present on human 
chromosome 13q14 and on mouse chromosome 14. The shape of 
the ligand is that of an inverted bell, which at the base 
interacts with the receptors in 3:3 symmetric complexes. The 
trimeric protein contains four unique surface loops that create 
the specificity in its interaction with the receptor RANK 
(Lerner UH, 2004). RANKL trimers exist either as membrane-
anchored proteins or in a soluble cleaved form , which is derived 
from the membrane form as a result of either proteolytic 
cleavage or alternative splicing, both being functionally active 
(Nakashima T et al., 2000). 
RANKL expression is stimulated in osteoblast/stromal 
cells by most of the factors that are known to stimulate 
osteoclast formation and activity. RANKL is a TNF family 
member that stimulates the fusion of pre-osteoclasts, (Lacey DL 
et al., 1998), the attachment of osteoclasts to bone (O'Brien EA 
et al., 2000), their subsequent activation (Burgess T et al., 
1999), and their survival (Lacey DL et al., 2000, Kostenuik PJ. 
2005). It is highly expressed in lymph nodes, thymus and lung. 
and at low levels in a variety of other tissues including spleen 
and bone marrow (Wady T et al., 2006). In inflamed joints 
RANKL is expressed by synovial cells and secreted by activated 
T cells, binds to RANK that is expressed on the dendritic cells, 
and such binding regulates the function and survival of these 
latter cells. (Schett G et al., 2005, Tat SK et al, 2009). It is also 
expressed by some malignant tumor cells that also express 
RANK, and thus it may play a role in inducing tumor cell 
proliferation by an autocrine mechanism or in a paracrine 
manner (Kim NS et al.. 2006). 
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OPG 
Osteoprotegerin (OPG); also known as osteoclastogenesis 
inhibitory factor (OCIF) or TNF receptor-like molecule (TR 1), 
is a secreted protein that regulates bone mass by inhibiting 
Osteoclast differentiation and activation (Simonet WS et al., 
1997; Yasuda H et al., 1998). OPG is synthesized in humans, 
rats, and mice as a 401-aa protein, which, after cleavage of 21-
aa signal peptide, results in a 380-aa mature protein. In 
humans, the OPG gene is located on chromosome 8q23-24. The 
as sequence of OPG displays several homologies to members of 
the TNF-R superfamily, including RANK. OPG contains four 
cysteine-rich domains in the N-terminal end, two homologous 
`death domains' (DDH) in the C-terminus, a heparin-binding 
site, and a cysteine residue required for homodimerisation but, 
in contrast to other members of the TNF-R superfamily, lacks a 
transmembrane spanning domain and a cytoplasmic tad. 
Secreted OPG acts as a 'decoy receptor' due to its affinity to 
both membrane-bound and soluble RANKL and prevents the 
activation of RANK. OPG mRNA has been detected in bone, 
cartilage, aorta, skin, lung, heart, kidney, liver, brain, and in 
several other tissues. At the cellular level, OPG is expressed in 
OBs. stromal cells, endothelial cells, aortic smooth-muscle cells, 
fibroblasts, dendritic cells, and lymphoid cell lines (Lerner UH, 
2004). 
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Figure 1: RANIVRANKIJOPG (receptor activator of nuclear factor kappa-
B)/receptor activator of nuclear factor kappa-B ligand/osteoprotegerin) 
pathway of osteoclastogenesis (Dufresne A. et al., 2012). 
OPG is a soluble decoy receptor that binds to RANKL and 
prevents RANKL from binding and activating receptor 
activator of nuclear factor-kB (RANK). This triad of proteins -
OPG/RANKL/RANK — has been shown in genetic and 
pharmacology studies to have a critical role in the regulation of 
osteoclasts and bone resorption (Figure 1). Genetic variations in 
the genes coding for RANK, RANKL and OPG are thought to 
play roles in the susceptibility to osteoclastogenesis (Asscoann 
G et al., 2010). Although other hormones and cytokines are able 
to influence osteoclasts in various ways. RANK/RANKL 
signaling is indispensable for the existence and activity of 
osteoclasts (Boyce BF and Xing L, 2007). 
OPG has also been an invaluable tool for understanding 
the bone remodelling process, because OPG rapidly reduces 
osteoclast numbers while having no direct effect on osteoblasts. 
OPG inhibits the formation (Martin TJ and Sims NA. 2005, 
Karsenty G and Wagner EF, 2002), attachment to bone, 
activation (Ma YL et al., 2003) and survival of osteoclasts. OPG 
rapidly decreases osteoclast numbers and increases osteoclast 
apoptosis within hours after injection (Lacey DL et al., 1998). 
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OPG is not incorporated into bone matrix and its effects on 
bone resorption are therefore fully reversible. Osteoclast 
numbers recover within days of stopping treatment as 
recombinant OPG is gradually cleared from the blood (Simonet 
WS et al., 1997, Lacey DL et al., 1998). Serum OPG has been 
reported to increase in conditions such as aging (Chen G et al., 
2006, Kapur RP et al., 2004) and postmenopausal osteoporosis 
(Hughes AE et al., 2000). In some observational studies, serum 
OPG levels showed negative correlation with bone resorption, 
positive correlation with BMD and reduced levels in patients 
with prevalent fractures. Thus, there are contradictory data, in 
general, that the upregulation of RANKL is associated with 
downregulation of OPG (Hofbauer LC and Schoppet M, 
2004).At this point, it is not possible to reconcile the many 
contradictory observations reported with serum analyses of 
OPG and RANKL (Kostenuik PJ, 2005). 
RANK/RANKLIOPG - Molecular triad 
RANKL, RANK, and OPG are three key molecules that 
regulate osteoclast recruitment and function. Macrophage 
colony-stimulating factor (M-CSF) and the receptor activator of 
nuclear factor KB (NF-KB) ligand (RANKL),a novel member of 
Tumour Necrosis Factor (TNF) family of cytokines, are 
produced as membrane-bound or secreted form in osteoblasts, 
are essential for osteoclast differentiation, function, and 
survival (Lacey DL et al, 2012; Kohli SS and Kohli VS, 2011; 
Shen CL et al,2009; Ando K et al 2008; Matsuo K & Irie N, 
2008). 
Proinflammatory cytokines like Tumor necrosis factor-
alpha (TNF), Interleukin-1 (IL-1&IL-6), RANKL are abundant 
in sites of inflammation and are known to promote osteoclast 
recruitment, differentiation, and activation, playing a pivotal 
role in induction of bone remodeling (Clowes JA et al, 2005; 
Gravallese EM et al, 2000: Takayanagi H et al, 2000). These 
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cytokines, primarily. TNF-a and IL-16, modulate this system 
primarily by stimulating M-CSF production .which further 
trigger the pool of preosteoclastic cells and by directly 
increasing RANKL expression, thus augmenting NF-xB : and 
inhibiting osteoblast survival. In addition, a number of other 
cytokines and hormones, such as TGF-6 (increased OPG 
production), PTH (increased RANKLldecreased OPG 
production), 1,25-dihydroxyvitamin D3 (increased RANKL 
production), glucocorticoids (increased RANKL/decreased OPG 
production) , and estrogen (increased OPG production) 
(Saika M et al.. 2001) exert their effects on osteoclastogenesis 
by regulating osteoblastic/stromal cell production of OPG and 
RANKL (Khosla S. 2001). However, other harmones like 
calcitonin acts directly on osteoclastic cells, and estrogen has 
been shown to induce apoptosis of osteoclasts as well as inhibit 
osteoclast differentiation by interfering with RANK signaling 
(Hughes AE et al., 2000, Khosla S. 2001). Moreover, TGF-6 can 
also stimulate RANK expression on preosteoclastic cells, and 
thus enhance osteoclastic sensitivity to RANKL (Yan T et al., 
2000). 
Binding of RANKL with its receptor. RANK, initiates 
signal transduction events by eliciting recruitment of the 
adaptor proteins, the TNF receptor-associated factor 2 
(TRAF2). TRAF5, and TRAFG (Park Ch et al, 2007).These 
further activate downstream signalling pathways and several 
transcription factors. Since TNF-alpha is abundant in inflamed 
bone sites and plays a major role in progression of the disease, 
it implies that TNF closely regulates RANKI RANKL-induced 
osteoclastogenesis. Stimulation of RANK results in strong NF-
kB activation (Lacey DL et al., 2012) Various TNF-receptor 
(TNFR) associated factor (TRAF) proteins associate with the 
cytoplasmic domain of RANK and relay RANK stimulation to 
NF-kB. TRAFs are cytoplasmic adaptor proteins that bind to 
the intracellular domains of various receptors of the TNFR 
superfamily. The TNFR superfamily member RANK contains 
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three putative TRAF-binding domains and each TRAF-binding 
domain has a different affinity for TRAF2, 5 and 6 (Walsh MC 
and Choi Y,2003; Darnay BG et al. (1998). RANK activation by 
RANKL is followed by its interaction with TNF receptor-
associated factors (TRAF) family members TRAF2, TRAF3, 
TRAF5, and TRAF6 (Wong BR et al.,1998; Darnay BG et al., 
1998) which in turn recruits NF-kB inducing kinase leading to 
the activation of NF-kB (Darnay BG et al., 1999). Among 
TRAFs, TRAF6 is the most important adaptor for RANK-
RANKL-induced osteoclastogenesis. The TRAF6 binding region 
in RANK was shown to be necessary for RANK-induced NF-kB 
activation and in vitro osteoclastogenesis (Darnay BG et al., 
1998), In particular, genetic experiments have shown that 
TRAF6 is required for osteoclast formation and osteoclast 
activation. Importantly, TRAF6 deficient mice develop severe 
osteopetrosis.TRAF6 and NF-kB play an indispensable role in 
OC differentiation as demonstrated by the osteopetrotic 
phenotype of TRAF6 and NF-kB knockouts. (Wada T et al 
2006). 
NF-kB is a dimer consisting of the NF-kb / Rel family 
proteins which include p50, p52, p65, c-Rel, and Rel-B. Mice 
lacking both the NF-kB p50 and p52 proteins are osteopetrotic 
The upstream subunits that mediate NF-kB activation, 
comprising the catalytic subunits IkB kinase a (IKKa) and 
IKKb and the non-catalytic subunit IKKg (also called NEMO), 
are also important for RANK—RANKL signaling and 
osteoclastagenesis (Wada.T et al., 2006) In the unstimulated 
cells, NF-k3 dimer in cytosol is present as an inactive form 
complexed with an inhibitory protein IkB, two major forms of 
which are IkB-a and IkB- 6 (Thompson et al., 1995). When 
stimulated by stimulatory cytokine, TNF- a, the NF-kB dimer 
dissociates from IkB and translocates to the nucleus, the 
process being called `activation of NF-kB'. The activated NF-kB 
dieter binds to the regulatory NF-kB elements in the target 
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genes and regulates their transcription (Hehlgans T & Pfeffer 
K, 2005: Yan-Hong Zhang et al, 2001). 
In addition to the local regulation of osteoclasts, one 
surprising finding was that RANKL is upregulated on T cells 
upon activation. It has, therefore, been speculated that RANK-
RANKL might be an important regulator of interactions 
between T and dendritic cells and might have a role in the 
regulation of the T-cell-dependent immune response (Wada T et 
al.. 2006; Tat SN et al, 2009). However, dendritic cells, where 
RANK was initially identified, appear normal in their function 
to induce T cell proliferation .These data indicate that RANKL 
has a crucial role in lymph node organogenesis and that 
RANKL has a role in monocyte function and in mediating 
inflammatory response (Seshasayee, D. et al, 2004). 
The central role of estrogen deficiency in the 
pathogenesis of osteoporosis in postmenopausal women has 
been clearly established. Postmenopausal osteoporosis and 
other conditions are associated with an increased rate of bone 
remodeling, which leads to accelerated bone loss and increased 
risk of fracture. Estrogen deficiency results in increased bone 
resorption over bone formation and net bone loss. Estrogen has 
been demonstrated to up-regulate gene expression and protein 
synthesis of OPG in human osteoblastic cells (Hofbauer LC et 
al., 1999; Michael H et al. 2005) in i'itro. It is logical from 
animal and in citro studies that the RANKL/OPG system is 
involved in the pathogenesis of postmenopausal osteoporosis 
(Kearns AE et al., 2008). There is general agreement that OPG 
levels increase after the menopause. (Michael H et al, 2005: 
Mezquita-Raya P et al.. 2005). Estrogens attenuate 
osteoclastogenesis and stimulate osteoclast apoptosis, but the 
molecular mechanism and contribution of these effects to the 
overall antiosteoporotic efficacy of estrogens remain 
controversial (Millan MM et al., 2010). Unpredictably, genetic 
inactivation of RANKL and RANK revealed surprising novel 
functions. Mice lacking RANKL or its receptor RANK had 
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impaired lobuloalveolar mammary structures during 
pregnancy, resulting in death of newborns. RANKL expression 
in mammary gland epithelial cells is induced in pregnancy in 
response to sex and/or pregnancy hormones and stimulates 
proliferation of mammary epithelial cells constitutively 
expressing RANK (Fata JE et al, 2000). Thus, RANKL and 
RANK, the master regulators of skeletal calcium release, are 
also essential for the sex and/or pregnancy hormone induced 
formation of the lactating mammary gland. The link between 
RANKL and RANK and sex and/or pregnancy hormones 
provides a rationale for hormonal regulation of bone 
metabolism and gender bias in osteoporosis. 
OPG is a secreted TNFR-related protein acts as a decoy 
receptor by blocking RANKL binding to its cellular receptor 
RANK. The binding of OPG to RANKL inhibits the binding 
between RANKL and RANK; this, inturn. prevents osteoclast 
precursors from differentiating and fusing to form mature 
osteoclasts. In normal mice, recombinant OPG blocks the pro-
resorptive effects of numerous hormones and cytokines, 
including IL-1 and TNF-a .OPG is also highly effective at 
preventing systemic bone loss in osteopenic mice that over 
express TNF-a. The ratio of RANKL: OPG may be the ultimate 
determinant of bone resorption (Hasan W et al., 2014; Lacey DL 
et al., 2012) This can be further substantiated by the fact that 
in transgenic mice in which the OPG gene was knocked out, 
severe osteoporosis quickly set in. Spontaneous fractures were 
observed in these animal models due to excess formation of 
RANKL-RANK complex (Kohli SS and Kohli VS, 2011). In 
many situations, bone resorption is stimulated by both 
increased RANKL and decreased OPG, which can amplify pro-
resorptive signals. Parathyroid hormone (PTH) is perhaps the 
best described mediator of this reciprocal regulation (Kostenuik 
PJ, 2005) The OPG-RANKL complex counterbalances the 
effect of the RANK-RANKL complex, thus playing the most 
important role in bone homeostasis. 
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Summary and future directions 
Discovery of the RANXIJRANK/OPG system represents the 
most important advance in osteoclast biology in the past 
decade. This system helps maintain skeletal homeostasis and is 
disrupted in most diseases that affect the skeleton by altered 
levels of RANKL, OPG. or both, which are expressed by 
osteoblasts and stromal cells or other cells. Osteoclasts not only 
respond to signals from osteoblasts and other cell types 
involved in immune responses, but they also regulate osteoblast 
functions. In addition, RANKL/RANK signaling and OPG play 
important roles in the development of other tissues (at least in 
mice) and appear to be involved in the growth of some 
malignant tumors. 
The RANKL-RANK system brought us a rapid progress 
in the understanding of the regulatory mechanism of osteoclast 
differentiation. The knowledge obtained from osteopetrotic 
mouse models is now being reconstituted in the context of the 
RANKL-stimulated signaling network. However, osteoclast 
differentiation is regulated not only by RANKL and OPG, 
instead is affected by various other hormones and cytokines. 
For example, RANKL induces its own inhibitor IFN-B and 
autoregulates RANKL signaling. Also, in healthy subjects, 
serum OPG correlated negatively with bone resorption markers 
and positively with bone formation markers. These 
relationships suggest that high OPG levels are associated with 
a favorable balance of bone formation over bone resorption. 
The identification of NFkB as the master transcription 
factor for osteoclastogenesis led us to realize the importance of 
RANK/RANKL signaling, crucial for osteoclast differentiation. 
Elucidation of the roles of RANI{L/ RANK and OPG in these 
various types of cells, their signalling pathways in normal and 
disease states is likely to lead to the development of novel 
strategies and new drugs designed to specifically influence the 
production of these cytokines or responses to them. Thus the 
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costimulatory signal-activated by RANK/RANKL/OPG axis will 
open a new era of asteoimmunology, providing an 
unprecedented therapeutic strategy for skeletal and immune 
disorders. 
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Excessive resorption by osteoclasts may 
lead to pathological destruction such as 
osteoporosis. Osteoclasts are bone-
specific multinucleated cells generated 
from hematopoietic monocyte precursor 
cells through differentiation processes 
primarily governed by two key cytckines 
receptor activator of nuclear factor kappa 
B ligand (RANKL) and macrophage colony-
stimulating factor (M-CSF) [Moon et al., 
2012]. 
Osteoprotegerin (OPG) 
It is also known as osteoclastogenesis 
inhibitory factor (OCIF) or tumor necrosis 
factor receptor super family member 
11B (TNFRSFI1B). It is a protein that in 
humans is encoded by the 
TNFRSF11B gene [Wada etal., 2006]. The 
initial cloning and characterization of OPG 
as a soluble, decoy receptor for RANKL 
belonging to the TNF receptor super 
family was the first step that eventually 
led to an unraveling of this system 
[Simonet at al., 1997; Khosla, 2001]. OPG 
is 	a 	basic glycoprotein comprising 
401 amino acid residues arranged into 7 
structural domains. It is found as either a 
60-kDa monomer or 120-kDa dieter linked 
by disulfide bonds [Schoppet eta., 2002). 
RANKL activity can be blocked by the 
soluble decoy receptor OPG, resulting in 
prevention of bone resorption [Simonet et 
al., 19973. Thus, OPG is the naturally 
occurring 	inhibitor 	of 	osteocl ast 
differentiation [Patil and Desai, 2014). 
OPG is produced by a lot of cell types, 
such as bone-marrow stromal cells and 
osteoblasts. OPG protects bone from 
excessive resorption by binding to RANKL 
with high affinity and preventing or 
blocking it from binding to RANK [Patil and 
Desai, 2014; Boyce and Xing, 20081. It 
blocks the fusion/differentiation stage of 
osteoclast precursors, rather than the 
proliferation stage, by binding to RANKL. 
Thus, the relative concentration of RANKL 
and CPG in bone is a major determinant 
of bone mass and strength [Boyce and 
Xing, 2008). 
Receptor activator of NF-KB ligand 
(RANKL) 
RANKL is the molecule which is blocked by 
OPG. It is also known as tumor necrosis 
factor ligand super family member 11 
(TNFSF11), TNF-related activation-induced 
cytokine (TRANCE), osteoprotegerin ligand 
(OPGL) and osteoclast differentiation 
factor (O(M) is a protein that in humans is 
encoded by the TNFSF11 gene [Wong at 
al., 1997; Anderson et al., 1997; Yasuda et 
al., 1998; Lacey et al., 19981. RANKL is one 
of 	the 	critical 	mediators 	of 
osteoclastogenesis [Bharti et al., 20041. 
RANKL is the most important locally 
produced 	 pro-osteoclastogenic 
factorjcytokine that, in combination with 
M-CSF. induces osteoclast formation in 
vitro [Wittrant as ol., 2004]. RANKL is 
expressed as a membrane-bound protein 
on the surface of osteoblasts, osteocytes 
and marrow stromal cells [Lacey or al., 
19981. In addition, activated T cells 
secrete RANKL as a soluble molecule 
[Kong et al., 1999]. Most osteotrapic 
factors such as IL-1, IL-11, PGE2 and 1,25-
IOH)zDs  induce osteoclast formation by 
binding to marrow stromal cells, which in 
turn express increased levels of soluble or 
membrane forms of RANKL [Wittrant et 
al., 2004). It was identified as the key 
mediator of osteoclastogenesis in both a 
membrane- bound form expressed on 
p reosteob lastic/strom al cells and T cells as 
well as a soluble form ISuda et al., 1999; 
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The discovery of the molecular triad receptor activator of nuclear factor-kappa 8 (RANK)/ 
RANK ligand (RANKL)/osteoprotegerin (OPG) axis in the mid 1990s for the regulation of 
bone resorption has led to major advances in our understanding of how bone modeling 
and remodeling are regulated (Patil and Desai, 2014; Boyce and Xing, 20081. This system 
has helped in elucidating a key signaling pathway between stromal cells and osteoclasts 
[Wittrant et al., 2004J.This system is the dominant and final mediator of 
osteoclostogenesis. OPG, RANKL and RANK are the members of the tumor necrosis factor 
super family of ligands and receptors. These three factors play a decisive role in regulating 
bone metabolism. This was demonstrated by the findings of extremes of skeletal 
phenotypes (osteoporosis vs. osteopetrosis) in mice with altered expression of these 
molecules (Khosla, 2001). These tumor necrosis factor super family members also have 
important functions outside bone (Boyce and Xing, 2007). 
Keywords: 
INTRODUCTION 
Bone homeostasis involves the constant 
remodeling and rebuilding of bone. While 
the bone formation side of the equation is 
carried out by the mesenchymal lineage- 
derived osteoblasts, the remodeling side 
of the homeostasis equation in bone is 
carried out by the hernatopoietic lineage 
osteoclast [Marcus etal., 2008]. 
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Excessive resorption by osteoclasts may 
lead to pathological destruction such as 
osteoporosis. Osteoclasts are bone-
specific multinucleated cells generated 
from hematopoietic monocyte precursor 
cells through differentiation processes 
primarily governed by two key cytckines 
receptor activator of nuclear factor kappa 
B ligand (RANKL) and macrophage colony-
stimulating factor (M-CSF) [Moon et al., 
2012). 
Osteoprotegerin (OPG) 
It is also known as osteoclastogenesis 
inhibitory factor (OCIF) or tumor necrosis 
factor receptor super family member 
11B (TNFRSF11B). It is a protein that in 
humans is encoded by the 
TNFRSF11B gene [Wada et al., 2006]. The 
initial cloning and characterization of OPG 
as a soluble, decoy receptor for RANKL 
belonging to the TNF receptor super 
family was the first step that eventually 
led to an unraveling of this system 
[Simonet et al., 1997; Khosla, 2001]. OPG 
is 	a 	basic glycoprotein comprising 
401 amino acid residues arranged into 7 
structural domains. It is found as either a 
60-kDa monomer or 120-kDa dimer linked 
bydisuIfide bonds [Schoppet etal., 2002]. 
RANKL activity can be blocked by the 
soluble decoy receptor OPG, resulting in 
prevention of bone resorption [Simonet et 
al., 1997]. Thus, OPG is the naturally 
occurring 	inhibitor 	of 	osteoclast 
differentiation [Patil and Desai, 2014]. 
OPG is produced by a lot of cell types, 
such as bone-marrow stromal cells and 
osteoblasts. OPG protects bone from 
excessive resorption by binding to RANKL 
with high affinity and preventing or 
blocking it from binding to RANK [Patil and 
Desai, 2014; Boyce and Xing, 2008]. It 
blocks the fusion/differentiation stage of 
osteoclast precursors, rather than the 
proliferation stage, by binding to RANKL. 
Thus, the relative concentration of RANKL 
and OPG in bone is a major determinant 
of bone mass and strength [Boyce and 
Xing, 2008]. 
Receptor activator of NF-KB ligand 
(RANKL) 
RANKL is the molecule which is blocked by 
OPG. It is also known as tumor necrosis 
factor ligand super family member 11 
(TNFSF11), TNF-related activation-induced 
cytokine (TRANCE), osteoprotegerin ligand 
(OPG L) and osteoclast differentiation 
factor (ODF) is a protein that in humans is 
encoded by the TNFSF11 gene [Wong et 
ol., 1997; Anderson et al., 1997; Yasuda et 
ol., 1998; Lacey et al., 1998). RANKL is one 
of 	the 	critical 	mediators 	of 
osteoclastogenesis [Bharti et at., 2004]. 
RANKL is the most important locally 
produced 	 pro-osteoclastogenic 
factor/cytokine that, in combination with 
M-CSF, induces osteoclast formation in 
vitro [Wittrant et al., 2004]. RANKL is 
expressed as a membrane-bound protein 
on the surface of osteoblasts, osteocytes 
and marrow stromal cells [Lacey et al., 
1998]. In addition, activated T cells 
secrete RANKL as a soluble molecule 
[Kong et al., 1999]. Most osteotropic 
factors such as IL-1, IL-11, PGE2 and 1,25-
(OH)zD3 induce osteoclast formation by 
binding to marrow stromal cells, which in 
turn express increased levels of soluble or 
membrane forms of RANKL [Wittrant et 
al., 2004]. It was identified as the key 
mediator of osteoclastogenesis in both a 
membrane- bound form expressed on 
preosteoblastic/stromal cells and T cells as 
well as a soluble form [Suda et al., 1999; 
Wong et al., 1999; Khosla, 2001; Theill et 
al., 20021. Under physiologic conditions, 
osteoblasts produce CSF-1 and the 
differentiation-inducing factor, RANKL 
[Yoshida et al., 1990; Amano et al., 1998; 
Lacey et al., 1998; Yasuda et al., 1998]. 
Osteoclastic activity is triggered via the 
osteoblasts' 	surface-bound 	RANKL 
(39) 
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activating the osteoclasts surface- 
bound RANK. 	The 	RANKL/RANK 
interaction is needed for differentiation 
and maturation of osteoclast precursor 
cells to activate osteoclasts and for the 
survival of mature osteoclasts [Patil and 
Desai, 20141. The binding of RANKL to the 
RANK receptor activates NF-KB signaling 
leading to the formation of mature 
multinucleated osteoclasts [Wada et al., 
2006). The activity of RANKL is balanced 
by the level of expression of its inhibitor 
osteoprotegerin OPG. It is the local ratio 
of RANKL to OPG that ultimately 
determines if osteoclast formation will 
occur by regulating the amount of 
available RANKL. Therefore, RANKL/OPG 
ratio is an important determinant of bone 
mass and skeletal integrity [Boyce and 
Xing, 	2007]. 	RANKL 	induces 
osteoclastogenesis through the activation 
of NF-KB [Bharti et al., 2004). 
Osteoblasts 
~: RANKL 
OPG( 
Y Z 
Osteoclast precursor TRAM 6 
V 
NF-KB 
i 
NF-KB 
c-Fos 
NFATc1 
Osteoclastogenic 
genes 
Figure 1. The Signaling Pathway for normal osteoclastogenesis [Boyce and Xing, 2007]. 
OPG can reduce the production 
of osteoclasts by 	inhibiting 	the 
differentiation of osteoclast precursors 
into osteoclasts and also regulates the 
resorption of osteoclasts in vitro and in 
vivo. Thus, in this, way, OPG protects the 
skeleton from excessive bone resorption 
by binding to RANKL and preventing it 
from binding to its receptor, RANK 
[Raisz, 2005; Boyce and Xing, 2007]. By 
binding RANKI.. OPG inhibits NF-KB 
which is a central and rapid acting 
(40) 
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leading NF-KB activation [Boyle et al., 
2003]. NF-KB increases c-Fos expression 
and c-Fos interacts with NFATc1 to trigger 
the transcription of Qsteoclastogenic 
genes leading to the osteoclast 
differentiation IJilka, 2003; Raisz, 2005; 
Boyce and Xing, 20071. JNK1- activated c-
Jun signaling in cooperation with NFAT is a 
key to RANKL-regulated osteoclast 
differentiation [Ikeda et al., 2004]. 
Stimulation of p38 results in the 
downstream 	activation 	of 	the 
microphthalmia/microphthalmia 
transcription factor (mi/Mitf). This factor 
controls the expression of the genes 
encoding TRAP and CTSK, indicating the 
importance of p38 signaling cascades 
[Boyle et a1., 2003]. RANKL-induced 
NFATc1 is a downstream event of NF-KB 
signal pathway (Moon et al., 2012). 
RANKL/RANK 	signaling 	regulates 
osteoclast formation, activation and 
survival in normal bone modeling and 
remodeling and in a variety of pathologic 
conditions characterized by increased 
bone turnover. RANKL/RANK signaling is 
also required for lymph node formation 
and mammary gland lactation hyperplasia 
[Boyce and Xing, 2007]. RANK has been 
shown to interact with TRAF6 [Junko et 
al., 2002; Darnay et al., 1998; Darnay et 
al., 1999; Galibert et al., 1998; Kim et al., 
1999], TRAF5 (Darnay et al., 1998; Darnay 
et al., 1999; Galibert et al., 19981, TRAF1 
[Galibert et al., 1998; Kim et al., 1999], 
TRAF 2 [Darnay et al., 1998; Darnay et al., 
1999; Galibert et al., 1998; Kim et ol., 
1999] and TRAF3 [Galibert et al., 1998; 
RANKL to its receptor RANK leads to 
recruitment of the adaptor protein TNF 	CONCLUSION 
receptor-associated factor 6 (TRAF6) to 	Thus, as illustrated above, the molecular 
the cytoplasmic domain of RANK, thereby 	triad OPG/RANKL/RANK axis plays a very 
resulting in the activation of distinct 	dynamic role in the bone metabolism. 
signaling cascades mediated by MAPK, 
including 1NK, p38 MAP kinase (p38), and 	ACKNOWLEDGEMENTS 
extracellular signal-regulated kinase (ERK), 
transcription factor for immune-related 
genes, and a key regulator of 
inflammation, innate immunity, and cell 
survival and differentiation [Krakauer, 
2008]. OPG levels are influenced by 
voltage-dependent calcium channels Cav 
1.2. OPG also protects arteries from 
medial calcification [Boyce and Xing, 
2007]. Space shuttle flight STS-l08 in 
2001 tested the effects of OPG on mice in 
microgravity, finding that it did prevent 
increase in resorption and maintained 
mineralization [Bateman and Countryman, 
2002]. OPG production is stimulated in 
vivo by the female sex hormone estrogen 
as well as the osteoporosis drug, strontium 
ranelate [Khosla, 2001]. 
Receptor Activator of Nuclear Factor K B 
(RANK) 
RANK is stimulated by RANKL. RANK is also 
called osteoclast differentiation factor 
receptor (ODFR), TNF receptor super 
family member 11A (TNFRSFIIA) and 
TNF-related activation induced cytokine 
receptor (TRANCE-R) [Wada et ol., 2006]. 
RANK is also expressed on dendritic 
cells and facilitates immune signaling. 
RANKL then binds to its receptor RANK, 
present at the surface of osteoclast 
precursors and mature osteoclasts, 
inducing osteoclast formation and 
activation [Nakagawa et al., 1998; Khosla, 
20011. The interaction between RANK and 
RANKL plays a critical role in promoting 
osteoclast differentiation and activation 
lead.ng to bone resorption. The binding of 	Kim et al., 1999]. 
(41) 
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